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“The History of Medicine  
• 2000 B.C. – Here, eat this root  
• 1000 A.D. – That root is heathen. Here, say this prayer.  
• 1850 A.D. – That prayer is superstition. Here, drink this potion.  
• 1920 A.D. – That potion is snake oil. Here, swallow this pill.  
• 1945 A.D. – That pill is ineffective. Here, take this penicillin.  
• 1955 A.D. – Oops....bugs mutated. Here, take this tetracycline.  
• 1960-1999 A.D. – 39 more "oops"...Here, take this more powerful antibiotic.  
• 2000 A.D. – The bugs have won! Here, eat this root.”  
— Anonymous  
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ABSTRACT 
 
Introduction: Resistance to antibiotics and chemotherapy is a major health problem in 
Portugal and also globally. Nowadays, a significant proportion of clinical Gram-
negative isolates are multi-drug resistant (MDR) and whenever studied, the MDR 
phenotype has been shown to be mediated by over-expressed efflux pumps (EPs). The 
over-expression of bacterial EPs is known to result from their exposure to one antibiotic 
that in some manner renders the bacterium with an MDR phenotype. Nevertheless, the 
process by which the development of an MDR phenotype that occurs during the period 
the patient is being treated with an antibiotic has yet to be completly demonstrated in 
the laboratory. Moreover, the degree of resistance of the Gram-negative clinical isolate 
is often-times many fold greater than the constant concentration used in therapy and 
reached in the patient plasma.  
Among Enterobacteriaceae, the major EP belongs to the RND superfamily which is 
mainly driven by energy coming from the proton motive force (PMF). Environmental 
factors such as Calcium (Ca2+), pH or glucose (energy source) have major influence in 
the mechanisms of retention or efflux of compounds by the cell. However, because the 
cell envelope is the first bacterial cell component to face changes in the environmental 
conditions such as hydrostatic pressure, osmolarity or antibiotic pressure, it is essential 
to have an over-view of all the processes involved in the acquisition of resistance. 
Therefore it is worthy to understand how such environmental conditions influence the 
outer-membrane composition of the cell and its mechanism of efflux. 
The first part of this dissertation focuses on the effect of such environmental conditions, 
on the composition of the outer membrane and the cellular responses It was, then, 
studied the role of antibiotic-promoted stress via step-wise increasing concentrations of 
antibiotic or serial passages of the bacterial strain in the same concentration of 
antibiotic, simulating what happens in the patient when she/he is submitted to long 
periods of antibiotic therapy.  
Efflux modulators can be used in therapy together with antibiotics for improvement of 
antibiotic action. Their use starts to be widely accepted as a new approach for the 
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 therapy of multi-drug resistance. Therefore, the second part of this dissertation focuses 
on the purification and characterization of compounds purified from the plant 
Carpobrotus edulis whose methanolic extract had been previously shown to inhibit 
MDR EPs of bacteria. Because it was previously shown by others the relationship 
between EP in bacteria and cancer cells, the purified compounds were also studied for 
their inhibitory activity on one of the major efflux pump transporters of cancer cells (P-
gp).  
Methods: Methods of protein extraction and electrophoresis were employed to 
assess the composition of the outer membrane after the bacterial cells face two 
different kind of growth media: solid and liquid. The effect of the antibiotic 
pressure on the EP expression was studied by growing different bacterial strains 
under increasing concentration of antibiotic or maintaining them in the same 
concentration for longer periods of time. The progeny strains were then tested for 
their response to the antibiotics in the presence of EPI and for their EP expression 
by real time reverse transcription PCR (rtRT-PCR). The effect of efflux pump 
modulators such as CCCP, PAβN, verapamil, phenothiazines, and the modulating 
effects of calcium, pH and energy source were studied by the semi-automated 
ethidium bromide (EB) method that follows the accumulation or efflux of EB, on a 
real time manner, by the bacterial cells under the conditions applied to the media.  
The assessment of C. edulis compounds for in vitro activity against wild type 
bacterial strains and their counterpart strains that over-produce given EPs was 
conducted by determination of the minimum inhibitory concentration (MIC) of the 
purified compounds as well as for other antibiotics of reference for each strain in 
the presence of the compounds to be tested. The activity of the compounds as efflux 
modulators were also tested by the semi-automated EB method, already mentioned. 
The compounds were also assessed for their capacity to increase the killing activity 
of macrophages infected with bacterial strains: ex vivo activity. Finally, the purified 
compounds were tested for their antiproliferative effect on cancer cell lines and 
their capacity to inhibit the P-gp responsible for the multi-drug resistance in those 
cell lines.   
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Results: During this study it was observed that in liquid medium a greater 
expression of a 55kDa protein takes place as opposed to Salmonella strains grown 
in solid medium. The simulation of the response of bacteria to the therapy with 
antibiotics through the two different adaptation processes showed that the bacterial 
response is dependent upon the method of adaptation to the antibiotic used.  
The results of this dissertation also suggest that efflux and accumulation of EB by 
E. coli strains are dependent on pH and energy that influence the performance of 
the AcrAB pump. This EP is dependent upon protons present in the periplasm for 
its activation. The efflux response is independent of the pH of growth of the 
bacteria whereas it is dependent on the pH of the assay, suggesting that bacteria are 
able to adapt to different environmental conditions such as pH and presence of 
noxious agents. Due to its capacity for binding protons, CCCP was used at different 
pH, in order to understand the role of protons and PMF on the efflux. The use of 
CCCP together with variations in the pH helped to identify the main types of efflux 
transporters that respond to the different environmental conditions. However, PAβN 
modulates efflux of ethidium bromide by competing with it for the site of extrusion 
of the pump (a KM was determined). 
Oleanolic acid, β-amyrin, uvaol, catechin, epicatechin, MGDG and procyanidin B5 
were the compounds isolated from the plant C. edulis. It was observed that the 
activity of some of these compounds was differed according to the mechanisms of 
resistance that characterizes the different strains against which their activity was 
studied. This is in agreement with the results obtained for the response of the 
bacterial cell adapted through different mechanisms to the use of efflux modulators. 
The results suggest that the triterpene uvaol was the most active compound as an 
efflux modulator in bacteria and cancer cells.  It also has significant activity against 
intracellular Staphylococcus aureus. 
Conclusion: A 55kDa protein was previously described as a virulence factor. The same 
protein had less expression when the bacteria were grown in presence of a 
phenothiazine, a compound described as an efflux modulator. Consequently, the action 
of these compounds as adjuvants may be due to their capacity to reduce the virulence of 
the strain. Therefore the results obtained for bacteria grown in solid and liquid media 
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 are of extreme importance because they can be an evidence for the reasons by which 
these compounds are described as helper compounds. They can also indicate why 
infections by the same organism but through different food sources have different 
degrees of infection and virulence on the patient. 
Adaptation caused by serial passages in the same concentration of antibiotic suggests 
the presence of “mutator” genes that allows the cell to survive under stress conditions 
and reduce energy consumption that would otherwise be higher with the over-
expression of efflux systems as occurs when bacteria is exposed to step-wise increasing 
concentrations of antibiotic. 
The results of this dissertation also suggest that the AcrAB mediated efflux is dependent 
upon protons present in the periplasm for their activation. Hence, when E. coli faces 
stress conditions caused by a noxious agent, its extrusion would be preferentially 
performed by an ABC type transporter at pH greater than 7. The efflux response is 
independent on the pH of growth of the bacteria but dependent on the pH of the assay 
suggesting that bacteria are able to adapt to different conditions such as environmental 
pH that it has to face during the infection process in the human body. Energy dependent 
efflux mechanisms vary upon the pH and the conjunction of pH and glucose is an 
important tool in the study and understanding of the physiology and mechanisms of 
efflux. Efflux pumps belonging to the ABC superfamily have an important role in efflux 
at pH 8; however, PMF is essential for RND family mediated efflux as per the results 
obtained at pH 5. The use of compounds that interfere with the PMF or directly affect 
the efflux systems has also a relevant role in the study of the efflux mechanisms and 
their physiology.   
Based on the results obtained with compounds purified from C. edulis, this plant is a 
promising source for search of more effective antibacterial, antimycobacterial and 
anticancer compounds. It is worthy to mention that the extremely easy availability of 
this plant in the coast of Portugal makes it an outstanding raw material for large scale 
production of its constituents which is essential for the development of any products to 
be used in practical medicine. 
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RESUMO 
 
Introdução: A resistência aos antibióticos é um grave problema de saúde quer em 
Portugal quer a nível mundial. Nos dias de hoje, uma grande percentagem dos isolados 
clínicos de bactérias Gram-negativas é multi-resistente (MR) e, sempre que estudado, o 
fenótipo MR é mediado pela sobre-expressão de bombas de efluxo (BE). A sobre-
expressão de bombas de efluxo em bactérias resulta da exposição destas a um 
antibiótico que, por vários processos, lhes confere um fenótipo MR. Contudo, o 
processo pelo qual a estirpe bacteriana desenvolve resistência durante a terapia com 
determinado antibiótico, ainda não foi completamente demonstrado em laboratório. 
Frequentemente, o grau de resistência dos isolados clínicos é muitas vezes superior à 
dose constante de antibiótico usada na terapia e atingida no plasma do paciente. 
Entre as Enterobacteriaceae, a principal BE pertence à família RND, na qual a energia 
necessária ao efluxo provém da força proto-motriz (PMF). Factores do meio envolvente, 
tais como, cálcio, pH ou glucose (fonte de energia), têm extrema influência nos 
mecanismos de retenção ou efluxo de compostos pela célula. Contudo, uma vez que o 
invólucro celular é o primeiro componente bacteriano a enfrentar alterações das 
condições do meio onde a bactéria se encontra, tais como alteração da pressão 
hidrostática, osmolaridade ou pressão antibiótica, é essencial compreender a 
generalidade dos processos envolvidos na aquisição de resistência. Assim, é urgente 
compreender como é que as condições do meio influenciam a composição da membrana 
celular e os seus mecanismos de efluxo. 
A primeira parte desta dissertação estuda o efeito dessas condições na composição da 
membrana externa e nas respostas celulares. Foi então estudado o efeito do stress 
provocado quer por aumentos crescentes na concentração de antibiótico, quer por 
passagens sucessivas da estirpe bacteriana em concentrações constantes de antibiótico, 
simulando o que acontece no paciente quando submetido a longos períodos de terapia 
com antibiótico. 
Moduladores do efluxo podem ser usados em terapia, conjuntamente com os 
antibióticos, de modo a aumentar o seu efeito terapêutico. A sua utilização começa a ser 
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 aceite como uma nova abordagem terapêutica contra a multi-resistência. Deste modo a 
segunda parte desta tese foca a purificação e caracterização de compostos isolados da 
planta Carpobrotus edulis, cujo extracto metanólico mostrou, anteriormente, inibir BE 
bacterianas. Uma vez que foi já demonstrado existir uma relação entre BE de bactérias e 
de células cancerígenas, foi também estudado o efeito inibitório dos compostos 
purificados num dos transportadores com mais relevância em multi-resistência em 
células cancerígenas (P-gp). 
Métodos: Foram utilizados métodos de extracção de proteínas e electroforese para 
estudar a composição da membrana externa de células bacterianas cujo crescimento 
ocorreu em dois meios diferentes: sólido e líquido. O efeito da pressão antibiótica na 
expressão de BEs foi estudada através do crescimento de estirpes bacterianas em 
concentrações crescentes de antibiótico ou mantendo-as em concentrações de 
antibiótico constantes por longos períodos de tempo. No final das sucessivas passagens 
foi estudada a resposta celular a diferentes antibióticos na presença de moduladores de 
efluxo bem como os níveis de expressão de BEs por RT-PCR em tempo real. O efeito 
de moduladores de efluxo tais como CCCP, PAβN, verapamil ou fenotiazinas e os 
efeitos do cálcio, pH e fontes de energia foram estudados pelo método semi-automático 
que segue a acumulação ou efluxo de brometo de etidium pelas células bacterianas, em 
tempo real, nas condições aplicadas ao meio do ensaio experimental.  
O estudo das actividades in vitro dos compostos isolados de C. edulis em relação a 
estirpes de referência e outras multi-resistentes, que sobre-expressam determinadas BE, 
foi realizado por determinação das concentrações mínimas inibitórias dos compostos, 
bem como de outros antibióticos, aos quais as estirpes eram resistentes, na presença do 
composto. O método semi-automático atrás referido foi também utilizado no estudo 
destes compostos como moduladores de efluxo. A influência destes compostos na morte 
de estirpes bacterianas fagocitadas por macrófagos foi também estudada: ensaios ex 
vivo. Por fim, foi estudada a actividade antiproliferativa dos compostos isolados em 
linhas celulares cancerígenas bom como a sua capacidade de inibição da P-gp 
responsável pela multi-resistência nessas linhas celulares. 
Resultados: Durante este estudo foi observado que em meio líquido há maior expressão 
de uma proteína com 55kDa em oposição ao que acontece quando a bactéria cresce em 
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meio sólido. A simulação da resposta bacteriana durante a terapia pelos dois processos 
descritos, mostrou que a resposta bacteriana é dependente do processo de adaptação 
seguido. 
Os resultados desta dissertação sugerem, também, que o efluxo e a acumulação de EB 
por células de E. coli são dependentes do pH e de energia, os quais influenciam o 
desempenho da bomba de efluxo AcrAB. Esta BE depende da concentração 
periplasmática de protões para a sua activação. O efluxo é independente do pH do meio 
onde as células bacterianas cresceram, contudo, é dependente do pH do ensaio, o que 
sugere que a bactéria é capaz de se adaptar a diferentes condições do meio tais como pH 
ou agentes prejudiciais à sua sobrevivência. Devido à sua capacidade quelante, o 
composto CCCP foi usado a diferentes pH com o objectivo de compreender o papel da 
concentração protónica e da PMF no efluxo. O uso de CCCP juntamente com variações 
no pH, possibilitou a identificação dos principais tipos de sistemas de efluxo que 
respondem às diferentes condições do meio. Contudo, o composto PAβN interfere com 
o efluxo de EB, por competição com este, pelo sítio activo da bomba de efluxo (um KM 
para esta competição foi determinado). 
Os compostos isolados da planta C. edulis foram: ácido oleanólico, β-amirina, uvaol, 
catequina, epicatequina, MGDG e procianidina B5. Foi observado que estes compostos 
tinham diferentes actividades consoante o mecanismo de resistência característico de 
cada uma das estirpes em que a sua actividade foi estudada. Este facto está de acordo 
com os resultados obtidos para a resposta celular de bactérias, cuja multi-resistência foi 
obtida por diferentes mecanismos, perante o uso de moduladores. Os resultados obtidos 
sugerem que, de entre os compostos isolados, o composto uvaol foi o mais activo como 
modulador da actividade de efluxo, quer em células bacterianas quer em células 
cancerígenas. Também demonstrou uma actividade significativa contra Staphylococcus 
aureus intracelular.  
Conclusão: Uma proteína de 55kDa foi anteriormente descrita como factor de 
virulência. A mesma proteína encontrava-se menos expressa em bactérias cultivadas na 
presença de uma fenotiazina, um composto descrito como modulador de efluxo. Deste 
modo a acção destes compostos como adjuvantes terapêuticos pode dever-se à sua 
capacidade de reduzir a virulência de determinada estirpe. Deste modo, os resultados 
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 obtidos, quando células bacterianas cresceram em meios líquido e sólido, são 
extremamente importantes pois podem indicar o motivo pelo qual infecções pelo 
mesmo organismo, mas por via de diferentes origens alimentares, apresentam diferentes 
graus de infecção e virulência para o paciente. 
A adaptação induzida por passagens sucessivas em meio com a mesma concentração de 
antibiótico sugere a presença de genes “mutantes” cuja actividade possibilita a 
sobrevivência celular em condições de “stress”, reduzindo o consumo de energia. De 
outro modo este seria mais elevado devido à sobre-expressão dos sistemas de efluxo, tal 
como acontece quando a bactéria é sujeita a passagens em concentrações crescentes de 
antibiótico. Os resultados desta dissertação também sugerem que a activação do efluxo, 
mediado pela bomba de efluxo AcrAB, é dependente da concentração protónica no 
periplasma. Assim, quando células de E. coli experimentam condições adversas 
causadas por agentes tóxicos, o efluxo é efectuado preferencialmente por 
transportadores do tipo ABC se o pH for maior que 7. O facto de o efluxo ser uma 
resposta independente do pH a que a estirpe cresceu, mas dependente do pH do meio em 
que o ensaio está a decorrer, sugere que a bactéria é capaz de se adaptar a diferentes pH 
do meio, tais como os que encontra durante o processo de infecção. Os mecanismos de 
efluxo dependentes de energia também variam com o pH. Deste modo a conjugação 
destes dois factores é muito importante para o estudo e compreensão da fisiologia e dos 
mecanismos de efluxo. As BEs que pertencem à família ABC têm uma função 
importante a pH 8, contudo a PMF é fundamental para o efluxo por via dos 
transportadores da família RND, como observado nos ensaios a pH 5. O uso de 
compostos que interferem com a PMF ou afectam directamente os sistemas de efluxo 
tem também um papel relevante no estudo dos mecanismos de efluxo e sua fisiologia. 
Os resultados obtidos com os compostos purificados da planta C. edulis, sugerem que 
esta planta contem compostos promissores com actividade antibacteriana e 
anticancerígena. É importante salientar que a abundância desta planta na orla marítima 
de Portugal faz com que a produção em larga escala dos seus constituintes seja fácil, o 
que é um factor essencial no desenvolvimento de quaisquer produtos a usar na prática 
clínica. 
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I. INTRODUCTION 
 
 
Introduction  
1. Chemotherapeutics and resistance  
1.1  The new Era of the antibiotics  
 
Antibacterial agents are derived either from natural sources (the antibiotics) or from 
total chemical synthesis. Antibiotics that are sufficiently nontoxic to the host are used as 
chemotherapeutic agents. Some antibacterial agents act as bactericidal, destroying 
bacteria, while others are bacteriostatic, inhibiting the growth of bacteria without 
destruction (1;2). 
Since 1928, when Alexander Fleming discovered penicillin (3), and mainly after its 
commercialization in 1941 (4), the number of antibiotics used in medicine had increased 
as fast as it could not be imagined at that time. The discovery of penicillin was 
considered as a miracle of science by many people, and, in fact, it saved thousands of 
lives. After the success of penicillin other antibiotics, mainly β-lactams, were 
developed: streptomycin (discovered in 1944 (5)), tetracycline (derived from 
aureomycin (6) and patented in 1955 (7)) or chloramphenicol (first isolated in 1947 (8)). 
Within a few years resistance to an antibiotic was observed in the laboratory as well as 
clinically (3). A few years later the first cases of multi-drug resistance (MDR) were 
published (9). Due to mono-resistance and multi-drug resistance the need for additional 
effective antibiotics was evident and resulted in the creation of new antimicrobials 
derived from the few natural antibiotics known at that time. The “golden age of 
antibiotics” was born! However, it is amazing that, after thirty years of success in the 
search for new antibacterials, only three classes of antibiotics have entered the market 
since 1970 (10). 
Nowadays, the wide range of antibiotics is grouped into different classes according to 
their mode of action, spectrum of activity or similarities in the chemical structure. The 
latter classification is the most common.  
In general, antibiotics are grouped as (8): 
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• Aminoglycosides: such as amikacin, gentamicin, kanamycin or streptomycin. 
This class of antibiotics derived from bacteria (order of Actinomycetales) 
interferes with protein synthesis by binding to the 30S component of the 
bacterial ribosome; 
• Antimycobacterial agents: This group includes a wide range of antibacterials 
used against Mycobacterium spp. (tuberculosis, leprosy, etc) and includes, for 
example, rifamycin, isoniazid, pyrazinamide, ethambutol, streptomycin, amino 
salicylic acid, sulphones; 
• Cephalosporins and related β-lactams: Cephalosporins are synthetic 
compounds derived for the natural antibiotic cephalosporin C. As the 
penicillins, members of this group inhibit bacterial cell wall synthesis. The 
first generation cephalosporins are active against Gram-positive bacteria but 
are not active against methicillin-resistant staphylococci. The second 
generation is highly resistant to β-lactamases and is active against Gram-
negative bacteria. Third and fourth generations are broad range antibiotics 
because they are active against many Gram-positive and Gram-negative 
bacteria. 
• Chloramphenicol: The first broad spectrum antibiotic whose activity is 
mainly bacteriostatic by interfering with protein synthesis.  
• Glycopeptides: An example of this group is vancomycin that interferes with 
the cell wall synthesis. It is active against Gram-positive cocci. 
• Macrolides: Large group of antibiotics that have a common macrocyclic 
lactone ring to which one or more sugars are attached. These antibiotics can be 
bacteriostatic or bactericidal, depending on the organism, and interfere with 
the protein synthesis. An example of this group is erythromycin. 
• Penicillins: This group inhibits the cell wall synthesis and its action is, in 
general, bactericidal. Although penicillin is still in use, derivatives of this 
antibiotic, such as ampicillin, have been more widely used. 
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• Quinolones: Quinolones are synthetic antibiotics structurally related to 
nalidixic acid. Modifications of the structure of nalidixic acid yielded 
fluoroquinolones which include, for example, ciprofloxacin, ofloxacin or 
norfloxacin. 
• Sulfonamides: They are usually bacteriostatic and interfere with the folic acid 
synthesis. Its use was greatly reduced because of the development of 
resistance. An example of a sulfonamide is the Prontosil. 
• Tetracyclines: The compounds of this group are usually bacteriostatic and 
their mechanism of action is similar to that of aminoglycosides. Tetracyclines 
have a broad spectrum of activity. The increase of resistant strains and the 
adverse effects have reduced their use. However, they are the most commonly 
used antibiotics in animal husbandry.  
The problem of resistance has been detected for all the classes of antibiotics described 
above (8). Development of antibiotic resistance results from the selection of bacterial 
populations whose antibiotic target has mutated during the time the population has been 
exposed to the antibiotic (antibiotic pressure). The frequency of resistance of a bacterial 
species to a given antibiotic is a product of antibiotic misuse and ineffective therapy. In 
economically disadvantaged countries, inadequate access to drugs contributes heavily to 
the frequency of antibiotic resistance (11). The problem of antibiotic resistance and its 
causes, are of extreme importance with respect to infections such as tuberculosis, and 
are the major motive for the work conducted in this thesis. 
Antibiotic resistance is not restricted to bacteria. It is found in all infectious non-
bacterial agents as well as in cells of an animal that is treated with a chemotherapeutic 
agent. Chemotherapeutically treated cancer that becomes refractory to the agent used for 
therapy and to any other chemotherapeutic agent, is an example of resistance that has 
been extensively described in the literature (12-15). A general overview of cancer, its 
therapy and resistance mechanisms will be discussed later on this thesis. 
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1.2  Fight against resistance  
 
It is widely accepted that the problem of drug resistance, even in prokaryotic or 
eukaryotic cells, does not yet have solution (16-19). 
Although, predictably, new resistance will emerge with time, there are ways to frustrate 
this possibility. Quality in education of health workers, easier access to a wide range of 
effective antibiotics, in economically disadvantaged countries, coupled to education of 
the patient population, the selection of appropriate therapy and patient compliance are 
the most important points according to this question.  
Albeit, new drugs do not give the ultimate answer to this question, the discovery of new 
families of antibiotics, with new characteristics, still has high prospects. 
On the other hand, to find new compounds that are able to potentiate or restore the 
decreased activity of existing antibiotics is, nowadays, commonly accepted as one of the 
best approaches to fight against multi-drug resistance (20-22). 
The concept of adjuvant therapy has emerged (discussed in chapter 6 of this 
Introduction). In order to achieve practical benefits from this strategy, many studies 
have been performed leading to a better understanding of the mechanisms of resistance 
acquired by bacteria.  
  
1.3  Mechanisms of resistance  
 
As already mentioned, the understanding of the resistance mechanisms is one of the first 
steps leading to a possible solution against multi-drug resistance. Bacteria develop 
resistance against certain antibiotics or groups of antibiotics by several mechanisms. For 
the bacterial cells, these mechanisms can be intrinsic or acquired: 
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• Intrinsic resistance: some bacteria have low permeability to different classes 
of antibiotics/compounds (23). For example, Gram-negative bacteria and 
mycobacteria have thick and highly hydrophobic outer membranes, which act 
as a permeability barriers to hydrophilic compounds, such as macrolides (ex. 
erythromycin) (24). 
• Acquired resistance: through mutation, acquisition of new genetic material 
(plasmids encoding for resistance mechanisms; foreign genetic elements; etc. 
(25;26)) affords survival under antibiotic pressure (19) - Figure 1. 
 
 
Figure 1 - Schematic representation of cell mechanisms of resistance.  
Some mechanisms can lead to resistance through different approaches, as for example the different ways 
by which the uptake of the antibiotic can be decreased or even forbidden. These differences are described 
in the text. Adapted from (27). 
The most typical mechanisms of resistance, as presented by Figure 1, are: 
• Modification of the antibiotic target / site of action, so that the antibiotic 
cannot bind to it and render it inactive (resistance to macrolides, vancomycin, 
β-lactams, fluoroquinolones and aminoglycosides) (28);  
• Enzymatic inactivation of the antibiotic by secretions of enzymes that 
degrade the antibiotic (ex. β-lactamases) or modify the antibiotic so that it is 
ineffective (ex. the resistance to chloramphenicol (CHL) - In resistant strains, 
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CHL is acetylated at the C3 hydroxyl group, by a cytoplasmic enzyme, CHL 
acetyltransferase. CHL acetyltransferase enzymes can be plasmid or 
chromosomally encoded.) (29);  
• Overproduction of the target such that the amount of antibiotic is not 
compatible with the amount of target (30) (ex. Resistance to vancomycin in 
staphylococci. The strain over-expresses the targets sites of vancomycin far 
from the key places for the cell survival, cell wall synthesis, so that it acts at 
that place without block the critical target sites) (31);  
• The target to be inhibited is part of a multi-chemical pathway that has 
alternative pathways which lead to the needed product (Bypass of inhibitory 
steps) (ex. Sulfonamide resistance mediated by different plasmid encoded 
enzymes with the same activity as the antibiotic target but structurally different 
and not affected by the antibiotic) (32);  
• Developing mechanisms that do not allow the accumulation of the antibiotic 
within the cell, preventing it from reaching the necessary concentration to be 
active (19): 
 
? Decreasing the permeability of the cell wall to an antibiotic. For 
instance by decreasing the expression of porins (for example 
OmpF and OmpX which are involved in the control of the 
penetration of antibiotics such as β-lactams and fluoroquinolones 
through the enterobacterial outer membrane (33)) or reducing the 
internal size of the pore through mutation of some amino acids 
(34);  
? Increasing efflux activity, which by extrusion of the antibiotic 
decreases its cellular concentration (19;35;36). Ex. resistance of 
Escherichia coli to tetracycline (8;35;37).  
The combination of these two last systems leads to high level of resistance mainly in 
Gram-negative bacteria (38).  
With respect to eukaryotic cells and, especially cancer, the main mechanisms of 
resistance are yet to be completely understood. However, overproduction and 
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modification of enzymatic targets, over-expressed efflux mechanisms, ability of the 
cells to avoid apoptosis, are well studied mechanisms (39). Resistance to anticancer 
drugs also results from other factors including individual variation among patients and 
somatic cell genetic differences in tumors, even those from the same tissue of origin. 
Frequently, resistance is intrinsic to the cancer, but with prolonged or ineffective 
therapy, acquired resistance is common. The most frequent cause for acquisition of 
resistance to a broad range of anticancer drugs is the over-expression of one or more 
energy-dependent transporters – efflux mechanisms. However, insensitivity to drug-
induced apoptosis and induction of drug-detoxifying mechanisms probably play an 
important role in acquired anticancer drug resistance (12;15;39-41). 
The next two chapters will focus on the mechanisms of resistance that are related with 
the bacterial cell envelope. 
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2. Cell envelope and resistance 
 
The structure and ensuing characteristics of the cell envelope have an important role in 
the resistance of bacterial cells to antibiotics. The cell envelope of Gram-negative and 
Gram-positive bacteria, mycobacteria and the plasma membrane of eukaryotic cells will 
be described in this chapter.  
 
 
Figure 2 – Schematic representation of the cell envelope of a bacterial cell.  
The thickness and composition of the cell wall change between the Gram-positive and Gram-negative 
cells. Source: http://www.scq.ubc.ca/ 
 
2.1  Cell envelope 
 
The cytoplasm of prokaryotes and eukaryotes is surrounded by a unit - the plasma 
membrane (PM). The plasma membrane is itself, a very important organelle of the cell 
that controls input and output of compounds. With respect to bacteria, an additional 
membrane is external to the plasma membrane and provides supplementary properties 
that contribute to its survival in the environment it normally inhabits. This outer 
membrane (OM) differs between Gram-negative and Gram-positive bacteria; the former 
having a more complex structure than that of the latter. Whereas intrinsic or acquired 
resistance of eukaryotes is determined by the characteristics of its plasma membrane, 
intrinsic and acquired resistance of prokaryotes is due to the structure of the cell wall 
and properties of the plasma membrane. 
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The cell envelope consists of different structures:  
1) Plasma membrane  
Electron microscopic examinations of cell membranes have led to the 
development of a lipid bilayer model of the PM. The bi-molecular leaflet of 
phospholipids is arranged as shown by Figure 3.  
 
 
Figure 3 - General structure of the cell membrane.  
Source: http://cellbiology.med.unsw.edu.au/units/images/cell_membrane.png 
 
In general, membranes are highly conserved structures, similar for all living 
things (with exception of the virus). The bi-layer structure of the PM is stabilized 
by hydrophobic interactions - Wandervals forces, ionized groups of amino acids, 
lipid interactions. Membranes are very organized but asymmetric organelles, due 
to the difference of environments in both of their sides. Even if well organized 
organelles, membranes are dynamic in order to an easily adaptation to possible 
changes of the environmental conditions (42). Lipids and proteins are its main 
composition.  
Attached to the surface and cytoplasmic side as well as within the leaflet layer of 
the PM are proteins. The majority of membrane proteins are responsible for 
structural functions, the moving of small molecules across the membrane 
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(transporters, ATPases, kinases, etc) or involved in energy generation (ATP 
synthase, enzymes involved in final steps of glycolysis, etc).  
The lipids form a bilayer, with their hydrophilic portion facing the aqueous 
environment, and the hydrophobic parts clustering together inside the membrane. 
The majority of the lipid contents are phospholipids. The phospholipid bi-
molecular leaflet with its functional transport units, bestow a semi-permeable 
barrier-like characteristic to the PM, allowing some molecules to enter under 
control and others are kept outside in a selective interaction manner (23). The 
fluidity of the lipid bilayer affects its permeability in an inversely proportional 
way. About 50% of the bacterial species also contain hopanoids (Figure 4), 
molecules with similar structure to sterols found in eukaryotic membranes that 
help to the stabilization of the membrane. 
 
Figure 4 - Chemical structure of Hopanoid. 
Hopanoid is a sterol molecule found in eukaryotic membranes that helps in its stabilization. 
 
 
2) Cell wall  
The cell wall is located outside the plasma membrane and protects the cell from 
osmotic lysis. It does not exist in all organisms. Some bacteria have cell walls 
containing peptidoglycan.  
 
The structure of the cell envelope of Gram-negative and Gram-positive bacteria, as well 
as of mycobacteria, is different and provides them special characteristics and different 
levels of intrinsic resistance. The organization of their bacterial envelope is represented 
in Figure 5. 
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A  
 
B 
 
Figure 5 - Organization of the bacterial cell envelope.  
A – Gram-negative and Gram-positive bacteria. Source: (43); B – Mycobacteria. Source: (44). LAM, 
lipoarabinomannans; LM, lipomannans; PIM, phosphatidylinositol mannosides  
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2.1.1  Gram-positive 
 
In Gram-positive bacteria, the cytoplasmic membrane, that immediately surrounds the 
inside of the cell, is a thin structure with about 8 nm thick (Figure 5A). This structure is 
followed by a cell wall (15-80 nm thick), consisting of several layers of peptidoglycan 
complexed with teichoic acids. Some cell wall components protect against phagocytic 
engulfment or digestion. Examples of Gram-positive bacteria are the species belonging 
to the Staphylococcus genus. Staphylococcus aureus is an opportunistic pathogen and 
the major causative agent of numerous hospital and community acquired infections. The 
genome of S. aureus strains had been already sequenced (45) and became possible to 
identify many components of its cell envelope that interfere with its virulence, with its 
intrinsic resistance and components that are responsible to the acquisition of multi-drug 
resistance (discuss bellow on this section) (45;46).  
 
2.1.2 Gram-negative 
 
The cytoplasmic membrane is relatively fluid in order to allow the proper functioning of 
the cell membrane components (so then also permeable) and so, many bacteria 
developed other structures to protect themselves. Those include peptidoglycan cell wall, 
an outer membrane or layers of lipopolysaccharides (LPS) in which the lipid A 
possesses endotoxin activity (47).  
The LPS, which are organized in several structures, according to the species, are, 
probably, the explanation of the unusual slow influx of lipophilic solutes through the 
outer membrane (23). The external membrane provides a very impermeable barrier and, 
so, bacteria developed other mechanisms that provide the influx of nutrients from the 
external medium. These uptake is done through proteins, called porins, which allow the 
influx of nutrients by providing non-specific and specific channels across the membrane 
(47). The hydrophobic (lipid) pathway, which is based on the interaction between the 
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membrane lipids is other option (38). The most important function for the outer 
membrane, in Gram-negative bacteria, is to serve as a selective permeation barrier (23). 
The need of a response to environmental changes could lead to modifications in the LPS 
structure or in the porin constitution (23;38;48). This LPS structure will be described 
below, in detail, as well as its contribution to the intrinsic and emerging of resistance to 
antibiotics among bacteria. Escherichia spp. or Salmonella spp. are examples of bacteria 
with this kind of cell envelope (Figure 5A).  
 
2.1.3  Mycobacteria 
 
Mycobacterium is an example of how important is the constitution and organization of 
the cell envelope in the permeability of the cell and how it can influence resistance to 
antibiotics. The most important characteristic of the cell envelope of mycobacteria is its 
constitution (Figure 5B): a cell membrane followed by a cell wall kind skeleton. This 
“cell wall” is composed by mycolic acids in a unique arrangement of these long chain 
fatty acids (up to 90 carbons) covalently bound to the arabinogalactan, a single 
polymeric head group (49). This characteristic confers to the barrier much less 
permeability than the outer membrane of Gram-negative bacteria (38). For example, its 
lipid rich cell wall also makes it resistant to Gram staining used to identify Gram-
negative and Gram-positive strains. Acid-fast techniques are used instead. Ziehl-
Neelsen staining is the most common technique in which the mycobacteria stain a bright 
red, which stands out clearly against the background. 
 
2.2  Lipopolysaccharides composition 
 
Resistance to antibiotics can be achieved by changes in the permeability of the cell 
membrane of the bacteria. Acquired resistance to active antibiotics through a decrease 
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in the permeability of the cell membrane requires major changes in membrane 
organization (50). However, due to the composition of the cell barrier, there is a 
difference in the susceptibility to hydrophobic and hydrophilic compounds (51).  
Gram-negative bacteria have an extra “protection” given by the outer membrane. For 
this reason some antibiotics that are active against Gram-positives are not active against 
Gram-negatives. Its LPS composition increases the asymmetry in the membrane 
architecture and the cross binding between LPS and divalent cations decrease the 
permeability (23;50).  
An increase in the permeability can be achieved by disruption of the cross bindings by 
compounds that act as metal ion chelators such as EDTA, certain cationic antimicrobial 
peptides (AMP) and polyamines(50). LPS (Figure 6) is typically composed of lipid A, a 
short core oligosaccharide, and an O antigen that may be a long polysaccharide, and is a 
very effective barrier for spontaneous diffusion of lipophilic compounds through the 
outer membrane (23).  
 
 
Figure 6 - Lipopolysaccharide (LPS) composition 
A – The chemical structure of LPS; B – Molecular model of the membrane from Pseudomonas 
aeruginosa. Source: (42) 
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This effective barrier to hydrophilic compounds of the LPS leaflet is mainly due to 1) 
the low fluidity of the LPS hydrocarbon domain, 2) the strong lateral interactions 
between the LPS molecules, 3) conformation of the LPS in bilayers and 4) the 
conformation of LPS in a complex with the protein FhuA (23).   
Salmonella spp is an example of the LPS importance in virulence as well as intrinsic 
and acquired resistance to antibiotics (23;52). LPS modifications are the end result of 
activation of the two-step PmrA/B regulon. This activation involves the phosphorylation 
of plasma membrane embedded sensor PmrB, which in turn phosphorylates PmrA 
(Figure 7). The latter activates PmrD which de-represses an operon that consists of 9 
genes. Each gene codes for an enzyme in the lipid synthesis that is eventually 
introduced into the nascent LPS by the flipase MsbA protein. These modifications 
include both Ara4N and phosphoethanolamine additions to the lipid A and 
phosphoethanolamine addition to the LPS core. They mask the phosphate groups with 
positively charged moieties, affecting the electrostatic interaction of certain cationic 
antimicrobial peptides with the bacterial cell surface after its phagocytosis by the 
neutrophil (23;52). These mechanisms are part of two-component systems responsible 
for the response of the bacterial strains to their environment. Many of these systems 
activate virulence-factor expression. They are regulated by host-derived signals that 
control gene expression at the key time and place for optimal establishment and 
maintenance of infection. This two-component response of the bacterium strains allows 
them to survive within the neutrophil. The PmrA/B response activates virulence-factor 
expression. The PmrA/B response is regulated by host-derived signals that control gene 
expression at the key time and place for successful infection. (52).   
 
17 
Introduction 
 
 
Figure 7 - Model of the activation and interaction of the PhoP/Q and PmrA/B two-component 
system in Salmonella spp.  
PmrA/B can be activated in an indirect manner through PhoP/Q and PmrD or in a direct manner, 
involving activation and autophosphorylation of PmrB and subsequent phosphotransfer to PmrA, which 
enhances PmrA binding to regulated promoters. On sensing activating environmental signals, PhoP/Q 
enhances the transcription of several genes including pmrD (green arrow with ‘+’), whose product binds 
to and stabilizes PmrA in its phosphorylated state. This loop can be deactivated by the transcriptional 
repression of pmrD by PmrA. PmrB can sense environmental stimuli directly and can initiate a cascade to 
phosphorylate and activate PmrA. LPS modifications mediated by both systems aid in survival in host 
cells and in the environment. Source: (52) 
 
Three main proteins are involved in the PmrA/B complex: phosphoethanolamine 
phosphotransferase (PmrC), a response regulator (PmrA) and a sensor kinase (PmrB), 
which regulates the expression of other genes in bacteria such as the ones involved in 
the modification of the LPS (52). 
The PhoP/Q system is an example of another two-component system which affords 
either the indirect regulation of the PmrA/B or directly activates the operon that 
regulates Lipid A synthesis (Figure 7). Activation of PmrA/B in vitro takes place by 
acidic pH and certain antimicrobial peptides and is repressed by millimolar (mM) 
18 
Introduction  
concentrations of magnesium and calcium. This is an example of an indirect activation 
of the PmrA/B system (52;53). 
All of the regulatory systems that preserve the integrity of the cell envelope have 
physiological significance in pathology. The response of bacteria to cations may have 
significant importance in an environment such as the wild aqueous environment, or, 
when bacteria are internalized by phagosomes, where the divalent cations concentration 
can achieve 1mM (53). However, Murata and co-authors showed that in the presence of 
1mM of Mg2+ cells with a modified outer membrane were more resistant to the 
permeation of exogenous compounds than cells without modification. This can be an 
advantage to the bacterium because it slows the influx of antimicrobial compounds 
generated by the host cells, such as cationic, lipophilic antimicrobial peptides and nitric 
oxide (NO). The permeability properties of the bilayer are also indicators of the 
robustness of the membrane structure, because permeation of solutes involves local 
stretching and rearranging of the bilayer structure as solute molecules pass through it. In 
lipid A, the acidic phosphate and pyrophosphate residues of the neighbouring molecules 
are bound together by the bridging action of divalent cations. When some of these 
cations are removed, or their concentration is too low, or  competitively used by the host 
cell itself, the membrane structure becomes unstable - the survival of the bacterium is 
compromised (53). 
 
2.3  Other important functions of membranes 
 
Another function associated with membranes is the generation of energy by the electron 
transport chain (42). The protons generated are translocated to the surface of the 
bacterium via channels where they are attracted to proton loving components of the LPS 
creating an electrochemical gradient. This process creates a proton gradient with the 
higher concentration of protons on the surface and the lowest concentration in the 
medial side of the plasma membrane (54). The distribution of protons along the surface 
of the cell creates a pH of the medium immediately surrounding the cell that is at least 
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two to three units lower (55). The difference in proton concentration between the 
surface and medial side of the plasma membrane creates the proton motive force (PMF). 
Protons present in the periplasm of the Gram-negative are used by PMF dependent 
transport systems, and energise the transporter component (52). After this step, they are 
released to the cytoplasm of the cell. Used protons of the periplasm are replaced from 
surface bound protons. The protons released to the cytoplasm decrease the local pH 
thereby shifting the equilibrium of ATP synthase towards the synthesis of ATP. This 
ATP may be used by ABC transporters which bind and hydrolyse ATP to ADP and two 
protons. These protons serve as the energy source for the membrane bound ABC 
transporter (56).   
 
2.3.1 Plasma membrane bound enzymes. 
 
The synthesis of the cell wall of bacteria is performed by a collection of membrane 
bound enzymes. Their location on the membrane is highly specific.  Because these 
enzymes bind penicillin, they have been named “penicillin binding proteins” or PBPs. 
When penicillin or other β-lactam antibiotics bind to the PBPs the enzymatic activity of 
the enzymes is obviated, the cell wall cannot be made and the organism cannot 
replicate. Resistance to β-lactams may be the result of secretion of β-lactamases of 
which there are three groups - A, B and C. Inhibitors for A and B β-lactamases are 
available and used as adjunct to β-lactam therapy. There are at this time no inhibitors 
for Group C β-lactamases (57). 
The mode of action of the β-lactam family of antibiotics is a good example that shows 
how all of these factors are so important for the understanding of resistance 
mechanisms. β-Lactamases and penicillin-binding proteins (PBP) play a key role in the 
resistance to β-lactam antibiotics. These proteins take part in the cell wall synthesis and 
are located no randomly on the outer face of the cytoplasmic membrane. The DD-
transpeptidase is one of the activities under the responsibility of the PBPs (58).  
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Briefly, the compounds belonging to the family of β-lactams interfere with the 
biosynthesis of the peptidoglycan, the major component of the bacterial cell wall. The 
structural similarity of the β-lactam to the substrate of the DD-transpeptidase is the 
basis for the antibiotic being bound to the PBP. The inhibition of this enzymes leads to 
structural instability and death of bacteria. However before reaching the target, β-lactam 
antibiotics have to cross the outer membrane by interaction between the antibiotic and 
the lipid phase or through a specific channel protein (the porin) (59).   
Perhaps the most common example of PBP-mediated clinical resistance to β-lactams is 
methicillin resistance of Staphylococcus aureus (MRSA). MRSA is due to the 
acquisition of a DNA element from an unknown source and its introduction into the 
organism’s chromosome (58). Klitgaard and co-authors observed that the reversal of 
resistant to oxacillin in MRSA by thioridazine was due to a reduction in the 
transcription of the mecA and blaZ genes resulting in a reduced protein level of PBP2a 
(60) 
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3. Transport across the cell envelope (its outer and inner 
membranes)  
 
However, the transport of the majority of compounds across the membrane requires the 
intervenience of specialized structures – the transport systems. It can mainly be done 
through three basic types of transport (42). 
1) Simple diffusion: water, carbon dioxide and oxygen are among the few 
molecules that can cross the cell membrane by diffusion. The movement across 
the membrane is done in response to differences in concentration: lower to 
higher concentration of solute in water (osmosis) and higher to lower 
concentration in diffusion of the gas (CO2 and O2). 
2) Facilitated diffusion: this process is done via the binding of the molecule to a 
membrane protein and, by change of the conformation of the protein, the 
compound is moved across the membrane. An example is the transport of 
glucose into E. coli cell that, once inside the cell, is immediately 
phosphorylated; if not, it diffuses to the outside. 
3) Group translocation: It is a process similar to the facilitated diffusion but 
involves a specific biding of the molecule (ligand) to a membrane protein 
(receptor), followed by an energy dependent chemical modification of the 
ligand. Group translocation is unidirectional. 
4) Active transport: It is used to transport small molecules without any chemical 
alteration and it is an energy dependent process. The energy can be generated by 
ATP or ion gradients. An active transport protein can be highly specific for one 
molecule or recognise and transport chemically unrelated molecules. This type 
of transport will be discussed in detail in later sections of this thesis and is one 
of the important contributors to antibiotic resistance. 
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3.1  Outer membrane proteins and porins   
 
The regulation of membrane permeability of Gram-negative bacteria is a function of 
membrane proteins. Regulation involves the joint action of porins and efflux pumps.  
Porins are trimer of identical subunits, each consisting of an anti-parallel β-barrel 
containing a pore (61), found in Gram-negatives and mycobacteria (Figure 8) that form 
channels that traverse the outer membrane and end in the periplasm.  
 
 
Figure 8 – Structure of OmpF porin trimer.  
The looping strands of each porin protein bind with the adjacent loop of the next porin (Shown in the 
form of a triangle in the center of the three proteins). The constriction channels are the open spaces inside 
each porin. The internal loop can be seen as "wrapping around" this opening (61). Image produced by the 
Protein Data Bank.  
 
The tri-barrel structure consists of three identical outer membrane proteins (OMPs). The 
OMP for each porin is genetically controlled so that the type of OMP that makes up the 
porin bestows the specificity or non specificity of the porin. As an example, the main 
porin of E. coli is porin F and consists of three OmpF units (61).  
Not all OMPs contribute to porin structure. OmpA is an integral component of the cell 
envelope and provides structural integrity. Other OMPs make up many different porins 
which are highly specific for given compounds or nutrients that the cell requires for 
survival. Porins permit the entrance of small solutes, ions and water to the periplasm of 
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the Gram-negative bacterium. With respect to antibiotic effectiveness, porin F is the 
porin primarily used by antibiotics to penetrate the outer cell envelope of E. coli (62). 
OmpF, OmpC, PhoE, OmpD and Omp36 are representative examples of non-selective 
OMP / porins (63). OmpF and OmpC families show a slight preference for cations, 
whereas PhoE selects inorganic phosphate and anions (64). LamB or FhuA are selective 
membrane proteins responsible for the diffusion of sugars and metals. OmpA and TolC 
form channels to avoid the passage of a wide variety of molecules (63). 
Most porins that are involved in antibiotic transport belong to the classical OmpF or 
OmpC subfamilies. However, there are exceptions, such as OprD of Pseudomonas 
aeruginosa and porins from Acinetobacter baumannii and Neisseria spp (64). 
For example, the well studied OmpF from E. coli is considered the main entry for 
different classes of antibiotics such as β-lactams or fluoroquinolones as well as a large 
variety of small hydrophilic molecules to be translocated from the cytoplasm to the 
periplasm of the cell (34;38;59). Indeed, some β-lactam resistant strains of E. coli have 
shown a deficiency in OmpF expression or alterations in its loop structure, caused by 
mutations. This is very important because the interaction of the antibiotic with the 
surface of the channel determines its penetration inside the cell (59). In fact, clinical 
isolates with porin modification were already identified in many Gram-negative strains 
(64).  
The loss, downsizing or mutation of porins are mechanisms through which bacteria can 
decrease their permeability to antibiotics providing resistance (47). For example, porin-
deficient mutants are more resistant to quinolones, tetracyclines, chloramphenicol, 
nalidixic acid and trimethoprim (38). P. aeruginosa has innate low susceptibility to β-
lactams due to its low number of porins with distinct physico-chemical properties 
compared to other strains (64). 
It was shown that the expression of OmpC and OmpF, controlled by the concentration 
of some antibiotics in the environment, regulates the permeability of the outer 
membrane to glucose and nitrogen under nutrient deficient conditions (65). Most studies 
had been done in order to define which are the mechanisms involved in that regulation 
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(33;59;62;65). It was shown that some clinical isolates, from patients undergoing 
treatment, had changed their membrane permeability due a switch in expression from 
OmpF to OmpC, a porin whose pore size is smaller, suggesting that a modification in 
the porin balance had occurred during the treatment (64). OmpC-OmpF balance is 
strongly regulated by different genetic control systems, such as EnvZ-OmpR and RNA 
anti-sense regulators (MicF and MicC) (64;66). 
Some in vitro studies also showed that loss of OmpC is followed by the expression of 
another subfamily of porins. OmpN type of porin is structurally related to OmpC and 
OmpF. OmpN pore is a selective filter for charged molecules due to its structural 
organization. It allows the maintenance of bacterial fitness with the entrance of nutrients 
but not of the antibiotics. This increases the resistance to the β-lactams (64). OmpX is 
other important outer membrane protein. It is small and, together with OmpF, is 
involved in the response to external stress via different regulation cascades (33).  
 
3.2  Efflux pump mechanisms 
 
The cellular efflux systems (Figure 9) are responsible for the extrusion of both the 
endogenous and exogenous toxic compounds (17;67), playing an important role in the 
physiology and homeostasis of the cell (19). Some efflux pumps have also been shown 
to have a role in colonization and persistence of bacteria in the host, as well as in 
bacterial pathogenicity (68). Efflux pumps are also useful tools for the cell to remove 
antibiotics conferring resistance to a given drug or class of drugs (36). 
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Figure 9 – Schematic representation of the 5 families of membrane transporters in Gram-positive 
and Gram-negative bacteria.  
Source: (68) 
 
According to Marquez et al (19) and Bambeke et al (67), efflux pumps can be grouped 
into two major groups: 1) primary active transporters; and, 2) secondary active 
transporters (antiports, symports and uniports) (67).  
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3.2.1 Primary active transporters 
 
ATP-binding cassette (ABC) superfamily is the one responsible for the antibiotic 
efflux among the primary active transporters. It uses the hydrolysis of ATP for the 
source of protons that energise it. These transmembrane proteins are present in all 
membrane systems of the cell and play an important role in the transport of toxins, 
metabolites and drugs (67;69). 
ABC transporters are composed of six to, as many as, twelve transmembrane domains 
(TMDs). Among these domains are two nucleotide binding domains (NBDs) and two 
domains that recognise the agent to be transported. The remaining domains are 
integrally involved in membrane structure. NBDs are water soluble proteins associated 
with the TMDs on one side of the membrane. The TMDs form a transport channel. 
Their structure and number can vary in the ABC transporters, as well as the number of 
transmembrane helices (between 8 and 20) (70-72). In contrast, the NBDs are highly 
conserved with Walker A and B motifs which are characteristics of all the ATP-binding 
proteins. The signature motifs are specific sites of the ABC transporter where ATP is 
bound and hydrolysed. The protons released energise the pump for its transport function 
(70).  
The coupling mechanism between the two different domains of the transporter is still 
unknown. However, some crystallographic studies support the theory that when the 
ATP is bound and an NBD dimer is formed, TMDs change their conformation that 
results in their closing to the inside of the cell and opening to the periplasmic side. 
When the hydrolysis of ATP occurs, the structure returns to its initial state (70). 
These typical efflux pumps are usually involved in the resistance to only one drug 
(Single Drug Resistance – SDR transporters) (19). However ATP transport systems 
involved in multi-drug resistance have also been reported (67). ABC transporters are 
also frequent in antibiotic-producing prokaryotes, conferring to them self-resistance to 
the drug they produce. Streptomyces spp. is an example (19). These transporters when 
present, are also responsible for the resistance of Gram-positive bacteria to macrolides 
or bacitracin; examples: Staphylococci (69) and Enterococci (19). The DrrB pump of 
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Mycobacterium tuberculosis and the MacB pump of E. coli, which are responsible for 
the extrusion of macrolides (69) and the Sav1866 pump of S. aureus (70), also belong to 
this superfamily of ABC transporters.  
In mammals, the MDR1 and MRP1 pumps are two important groups of transporters 
(73) and exist in different kinds of cells of the human organism, including important 
cells of the immune system such as lymphocytes, monocytes and macrophages (74). 
The P-glycoprotein (P-gp) belongs to the family of the MDR1 transporters and it is 
responsible for the extrusion of physiological substrates such as phospholipids and 
cytokines. Moreover, they are also capable of extruding antibiotics such as 
fluoroquinolones, macrolides, β-lactams (lipophilic cephalosporins), tetracyclines and 
trimethoprim (74). When over-expressed in the cancer cell, P-gp confers resistance to 
cancer chemotherapy (41). The mechanisms responsible for the extrusion of 
fluoroquinolones, rifamycins and macrolides in cancer cells should also be mentioned 
as an example for the presence of MRP1 efflux pumps in eukaryotes (74). The special 
case of P-gp transporters in cancer and their inhibition by compounds isolated from 
Carpobrotus edulis is a subject that will be discussed in detail in the sections dealing 
with cancer. 
 
3.2.2 Secondary active transporters 
 
This group of multi-drug transporters utilizes the proton (or sodium) motive force – 
proton gradient across the membrane – as source of energy (67). They are present in 
bacterial cells and most of them confer intrinsic resistance to antibiotics and, when over-
expressed or acquired from external sources (plasmids), result in multi-drug resistance 
of the bacterium (67) (Figure 10). There are different concepts for their grouping 
(19;36;67), but it is consensual that these transporters have four main superfamilies (36) 
according to the followings:  
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• MFS (Major Facilitator Superfamily) transporters are the largest of the families 
and consist of over 1000 individual, genetically characterised transporters. MFS 
transporters are responsible for the transport (influx) of sugars, amino acids, and 
many other nutrients and extrusion (efflux) of intermediate metabolites, cellular 
toxins and drugs (19;67). The proteins from this superfamily efflux antibiotics 
such as, erythromycin, nalidixic acid, tetracycline, sulfamides, fluoroquinolones, 
rifampicin or chloramphenicol, and catalyse uniport, solute/cation (H+ or Na+) 
symport, solute/H+ antiport or solute/solute antiport (67). It is an ancient (highly 
conserved), large and diverse family and it is the most common family in the 
Gram-positive bacteria (72). These drug-efflux pumps can be grouped into 
smaller groups of which the Bmr of Bacillus subtilis, the QacA of S. aureus or 
the MefA of Streptococcus pyogenes are examples (72). The NorA pump of S. 
aureus, EmrB of E. coli, Tap of M. tuberculosis or LfrA of Mycobacterium 
smegmatis (67;69) are other well known members of this family. These proteins 
are situated in the inner membrane and contain 12- or 14- TMDs (72). These 
transporters function as single-component pumps (e.g. NorA); however, in some 
Gram-negative bacteria they function in conjunction with membrane fusion 
proteins (MFPs) and outer membrane components (e.g. EmrAB-TolC of E. coli). 
The tetracycline efflux pumps are some of the best characterized members of the 
MFS family. They are found in both Gram-negative and Gram-positive bacteria 
(72). Efflux of tetracycline by Gram-negative can be due to transposons that 
carry the efflux pump genes from unknown sources and which have been 
inserted into plasmids that infect the cell. Some authors suggest that there is an 
horizontal transfer of these plasmids among different genera of Gram-negative 
bacteria that share the same environment such as the colon of the tetracycline 
treated animal (75). 
 
• RND (Resistance Nodulation Division) family ensures the efflux of lipophilic 
and amphiphilic molecules and toxic divalent cations (19;67). These transporters 
are the main contributors for resistance in Gram-negative bacteria and consist of 
three different proteins: a transporter protein that is connected to a TolC protein 
(an outer membrane protein that provides the conduit of the agent from the 
transporter to the outside of the cell) and two fusion proteins that attach the 
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transporter firmly to the plasma membrane. The fusion proteins assist the 
extrusion of the agent from the transporter through the TolC by peristaltic action 
(19;72;76;77). The best studied RND efflux pump is AcrAB-TolC (78). The 
AcrAB-TolC is believed to function as follows: The agent present in the outer 
leaflet of the plasma membrane is recognised by AcrB transporter. The manner 
by which recognition takes place is currently unknown. Subsequent to 
recognition and binding of the agent to specific sites of AcrB, protons from the 
periplasm energise the transporter and the agent is extruded into the TolC 
conduit. The protons are released to the cytoplasm. The movement of agent 
through the TolC channel and its reaching the outside of the cell is assisted 
mechanically by the two fusion proteins. Recent evidence from Nikaido’s group 
indicated that ligands that bind to AcrB have dissociation constants (Kd) that are 
pH dependent. At low pH the Kd is high, thereby affording after recognition and 
binding of the agent, rapid dissociation and subsequent binding of a second 
agent. At high pH the Kd is very small. This is important for the creation of 
drugs that are to be recognised by the AcrB transporter as a “substrate” which, 
after binding, will not dissociate readily and hence, inhibiting further activity of 
the transporter. The complex AcrAB-TolC is the main efflux pump of E.coli and 
also of Salmonella spp. The homologous pump to AcrAB-TolC of  P. 
aeruginosa  is the MexAB-OprM (76). These pumps are responsible for the 
efflux of β-lactams, chloramphenicol, erythromycin, fusidic acid, nalidixic acid, 
rifampicin, tetracycline, aminoglycosides and fluoroquinolones (67) as well as 
heavy metals, dyes or detergents (72). All the known pumps belonging to the 
RND family efflux its substrates via a substrate/H+ antiport mechanisms. The 
transporter proteins have 12 TMDs with two large periplasmic loops and similar 
N- and C- terminals (72). 
 
• SMR (Small Multi-drug Resistance) family is responsible for the extrusion of 
lipophilic cationic compounds (19;67). For example the EmrE pump of E. coli 
(that extrudes erythromycin, sulfamides and tetracycline (67)), the Smr of S. 
aureus (72) and the Mmr pump of M. tuberculosis (that can remove 
erythromycin (67)) belong to this family. These proteins have approximately 
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110 amino acid residues with 4 TMDs and work as tetramers in the membrane. 
The extrusion of compounds is energized by the proton motive force (72).  
 
• MATE (Multi-Antimicrobial and Toxin Extrusion (69)) family members act as 
a Na+/drug antiport system (19), like for example the YdhE pump of E. coli 
which can extrude chloramphenicol, fluoroquinolones and trimethoprim (69). 
These proteins have approximately 450 amino acids and 12 TMD (72). 
 
 
 
Figure 10 - Schematic representation of each representative families belonging to the secondary 
membrane transporters.  
Adapted from: (79) 
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4. Mycobacterium tuberculosis – an emerging problem of 
resistance  
4.1  The bacillus of Tuberculosis 
 
The bacillus of M. tuberculosis was first identified by Robert Koch, in March 24, 1882. 
At that time the rate of death because of tuberculosis (TB) was 1 per 7 human beings. 
There are evidences that TB is a very ancient disease, as it was found in the skulls and 
spines of Egyptian mummies with more than 4000 years. (80).  
The identification of the TB bacillus was so important to the evolution of the treatment 
of the disease that, in 1905, Koch received the Nobel Prize in Medicine for his 
discovery. After this, lots of research has been done and three more scientists received 
the noble prize because of their discoveries and their contributions to TB treatment and 
related aspects of TB (80).  
? In 1908, Paul Ehrlich for his discovery of syphilis treatment. This was the start 
in the search for other chemical substances which could destroy disease-causing 
microorganisms;  
? In 1939, Gerhard Domagk for describing the use of "Prontosil," an organic 
compound containing sulfur (sulphanilamide), for treatment of bacterial 
infections;  
? In 1952, Selman Waksman for his discovery of streptomycin. 
M. tuberculosis is a relatively large non-motile rod-shaped bacterium, with 2 to 4 
micrometers in length and 0.2 to 0.5 in width. It is an obligate aerobe and that is the 
reason why its complexes are mainly found in well aerated upper lobes of the lungs. 
The mycobacterium is a facultative intracellular parasite, usually of macrophages, and 
has a slow generation time, 15 to 20h. Among other factors, discussed later, this 
physiologic characteristic may also contribute to its virulence. It is classified as an acid-
fast bacterium and not classified as either Gram-positive or Gram-negative, because it 
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does not have the chemical characteristics of either, although, as it was discussed in 
previous chapter, it does contain peptidoglycan in its cell wall. Once stained, this kind 
of bacteria will retain dyes when heated and treated with acidified organic compounds 
(e.g. Ziehl-Neelsen stain method). As it can be seen with the light microscope, M. 
tuberculosis often forms cords. It was also Robert Koch who made this observation for 
the first time. The formation of cords is due to the synthesis of cord factor which is, 
possibly, of significant importance to its virulence (81). 
 
4.2  The disease 
 
TB is an infectious bacterial disease which, most commonly, affects the lungs. It is 
transmitted from person to person via micro-droplets expelled when coughing, singing 
and shouting. Expulsion of M. tuberculosis indicates the infective phase of the disease, 
termed “Active Disease”.  
In healthy people, infection with M. tuberculosis is often asymptomatic since the 
immune system of the person acts to “wall off” the bacteria. The symptoms of active 
TB of the lung are coughing, chest pains, weakness, weight loss, fever and night sweats, 
and haemorrhage. Usually, the latter symptom is the cause for medical attention and 
subsequent diagnosis (82).  
A person gets infected with M. tuberculosis from the inhalation of bacilli which is then 
internalized by the alveolar macrophages (pneumocytes II). At this time the infection is 
in the lungs, and with severe cavitary disease the bacteria will, via lymphatic and 
capillaries, reach and infect other organs (disseminated TB). The sites of tissues 
indicative of disseminated TB reveal granuloma (collection of immune cells / lymphoid 
matter and epithelial components). Because many M. tuberculosis bacillus survive the 
immune functions that lead to a granuloma, the tissues, if not for the encasement of M. 
tuberculosis, would yield new sites for infection (horizontal tissue transfer) (83). 
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Infection with M. tuberculosis results in the development of active pulmonary TB in 
only 5 to 10 % of all infections. However, due to strife, poverty, famine and immune-
incompetence (HIV/AIDS; pregnancy; therapy for transplantation of tissues and organs) 
the frequency of active TB is considerably much greater (83). In the absence of the 
above active TB supporting causes, the 5 to 10 % of infections that progress to active 
disease status takes place after the 5th decade and is due to the decrease of T cell 
immune functions that are normally reduced with aging. Reactivation of the infection 
occurs and this is usually noted to take place in apical part of the right lobe of the lungs. 
Reactive TB can occur for various reasons such as HIV/AIDS, malnutrition, or a 
systemic infection that modifies the immune response (82). 
 
4.3  TB and antibiotic resistance 
 
Almost immediately after the start of the use of streptomycin in TB therapy, the TB 
bacillus acquired resistance to that antibiotic. 10 years later it was already used a 
combination therapy with streptomycin, isoniazid (INH) and para-aminosalicylic acid 
(PAS) (80). The addition of INH to rifampin (RIF) formed the most effective 
therapeutic combination providing that the M. tuberculosis was susceptible to these 
agents. When M. tuberculosis is resistant to both INH and RIF it is termed “MDR”. 
Therapy of MDRTB involves the addition of other first line of defence drugs, such as 
pyrazinamide (PZA), sulfonamide (SM), ethambutol (EMB) and thiacetazone, 
following the schedule proposed by the World Health Organization (WHO): Regardless 
of this therapy, mortality as high as 85% takes place within 12 months if the patient is 
co-infected with HIV, and as high as 70% within two years if infected only with MDR 
M. tuberculosis (84).  
Despite the therapies available, TB continues to be a global public health problem, and 
lots of informative and “fight TB” actions and guidelines have been provided by some 
organizations, especially the WHO (84).  
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According to the WHO, more than 400 000 cases of multi-drug resistant TB (MDRTB) 
emerge every year as a result of under investment to control TB, poor management of 
patient with anti-TB drugs and especially patient non-compliance (85). In Europe the 
rate of new MDRTB is 50 new cases and 7 deaths per hour with more than 70000 new 
cases of MDRTB per year.  
MDRTB has progressed to extensively drug resistant TB (XDRTB ) as reported for all 
regions of the world by 2006 WHO report on MDRTB (85). XDRTB is defined an M. 
tuberculosis that is resistant to multiple drugs (INH, RIF and other first line of defence 
drugs), streptomycin, plus resistant to any one of the fluoroquinolones and at least one 
of the three injectable second-line drugs (amikacin, capreomycin or kanamycin) (84). 
The extreme resistance of XDR M. tuberculosis is a serious emerging threat to global 
public health, especially in countries with a high prevalence of HIV (85). Figure 11 
shows the distribution of XDRTB up to the first half of 2008, with a huge number of 
countries with reported XDRTB. 
 
Figure 11 - Distribution of the confirmed cases of XDRTB all over the world, until June 2008.  
Source: The stop TB department of WHO (82;84;85). 
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Studies performed by Perdigão and co-authors revealed that the situation of MDR and 
XDRTB in Portugal had been underestimated. According to the authors MDRTB had a 
prevalence of 11% in the region of Lisbon against the 3% reported by the official 
authorities. Moreover, MDR M. tuberculosis strains were characterized as resistant to 
isoniazid, rifampin, streptomycin and pyrazinamide. From the cases studied in the cited 
work it was found that in 2003, 53% of the MDRTB detected were already XDRTB 
isolates, which is a prevalence much higher than others previously reported to other 
countries (86). 
The first MDR strains in Portugal were identified in the 1990s and the majority is 
genetically related. Its continuous disseminations in the community together with the 
high frequency of fluoroquinolones and third generation quinolones prescription to treat 
other respiratory tract infections had also contributed to the high prevalence of XDRTB 
in Portugal. The excessive use of quinolones is associated with the acquisition of 
resistance and may have contributed to the selection of resistant M. tuberculosis strains 
(86). 
 
4.4  Cell characteristics, infection and resistance 
 
The high lipid content of the mycobacterial cell wall confers to M. tuberculosis an 
intrinsic resistance, which is characterised by its low permeability to drugs. The most 
important lipid that is also the major component of the mycobacterial cell wall is 
mycolic acid, which is much bigger than the common fatty acids. It is covalently linked 
to arabinogalactan, which is, in turn, covalently linked to peptidoglycan. These 
characteristics are one of the main reasons for the general resistance of mycobacteria to 
the majority of the antibiotics (87;88). 
There were also identified different M. tuberculosis efflux pumps which confer 
resistance to different classes of compounds such as tetracycline (TetK-L (67), Tap 
(87)) or macrolides (Mmr or DrrB) (69), fluoroquinolones (Rv1634; Rv2686-2687c-
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2688c) (87), aminoglycosides (Tap) (87), rifampin and ofloxacin (Rv1258c) (87), and 
possibly isoniazid (mmpL7) (87) and ethambutol, erythromycin, streptomycin, 
chloramphenicol and anthracyclines (DrrAB) (87). The characterization of M. 
tuberculosis efflux pumps revealed that they belong to all the families described in 
chapter 3.2 (89).  
Although some studies have been carried out to identify the importance of over-
expression of efflux pumps in clinical isolates (90;91), the correlation between EP and 
antibiotic resistance is still unclear (92). However, it seems certain that, as described 
before, the drug concentration inside the cell is dependent on the equilibrium between 
its intake and efflux (87).  
It is known that the acidification of the phagosome is a major mechanism used by 
macrophages against bacteria, including M. tuberculosis. The clinical and cellular 
outcomes of M. tuberculosis and the role of the adaptive immune system are presented 
in Figure 12 (93).  
 
Figure 12 - Clinical and cellular outcomes of Mycobacterium tuberculosis and the role of the 
adaptive immune system. 
Source:(93). 
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An initial infection of the macrophage results in the production of pro-inflammatory 
cytokines such as interleukins (IL) IL-6, IL-1β, IL-12 and TNF-α (tumor necrosis 
factor-α). In latent infection, there is a balance between the mycobacterial proliferation 
and the capacity of the host defence. At this stage the mycobacterium is contained 
inside the macrophage with no presentation of clinical symptoms. Ten percent of those 
with latent M. tuberculosis infection will eventually develop clinically active disease 
that manifests as localized pulmonary infection, or disseminated disease, depending on 
the innate immune response of macrophages and/or dendritic cells. T-cell responses are 
shaped by interactions with dendritic cells, which depend on the innate immune 
response to M. tuberculosis. Th1 T cells produce interferon-γ (IFN-γ) and promote 
mycobacterial killing by infected macrophages. Th17 T cells secrete IL-17 and could be 
important for protective vaccine-induced responses. The role of Th2 T cells in host 
defence to M. tuberculosis infection is less clear. The combination of innate and 
adaptive responses influences the macrophage response to M. tuberculosis infection as 
well as the clinical outcome (93).  
Some authors have also studied the importance of the cell membrane, in particular some 
proteins, in the survival of the M. tuberculosis inside the phagosome and its virulence. 
M. tuberculosis survives within macrophages by preventing fusion of phagosomes with 
lysosomes, but it also persists within acidic phagolysosomes in activated macrophages 
(94).  
Mycobacteria block phagosome acidification, but interferon-γ (IFN-γ) restores 
acidification and confers antimycobacterial activity. In the studies performed by Vandal 
et al, in vitro, at pH 4.5, M. tuberculosis survived in a simple buffer maintaining the 
intra-bacterial pH and survived when phagocytosed by IFN-γ activated macrophages. 
Therefore, M. tuberculosis resists phagolysosomal concentrations of acid. The use of a 
strain disrupted in Rv3671c, a gene encoding a membrane-associated protein, was 
sensitive to acid and failed to maintain intra-bacterial pH in acidic in vitro conditions, as 
well as in activated macrophages. Growth of the mutant was also severely attenuated in 
mice. Thus, M. tuberculosis is able to resist acid, owing in large part to Rv3671c, and 
this resistance is essential for virulence (94).  
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The use of infected macrophage in the study of the action of new compounds that may 
be used in therapy is extremely important, mainly in M. tuberculosis infection. The 
demonstration that inhibitors of K+ and Ca2+ transport enhance the killing of 
intracellular MDRTB and XDRTB by the human macrophage suggests a totally 
different approach for the design of new antituberculosis agents. In addition to 
designing agents that have direct activity against these bacteria at intracellular sites, 
consideration may be given to designing agents that have activity against EPs that 
would normally transport K+ and Ca2+ into the human macrophage and which, due to 
the invagination of the plasma membrane during the phagocytosis of the bacterium, now 
transport these ions from the phagolysosome to the cytoplasm of the phagocytic cell 
(95).  
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5. Multi-drug resistance and cancer  
 
Neoplasma are divided in two categories: benign and malignant. The “benign” 
neoplasm is not benign inasmuch as, due to its rapid growth, it can affect the functions 
of tissues and organs in the immediate vicinity. The cells of a benign neoplasm do not 
migrate to distal sites. Malignancy is a neoplasm that due to the loss of inter-digitation 
between cells has been lost and the cell migrates (metastases) via the lymph or vascular 
channels to other sites where they may be trapped (lymphoid tissue) or settle and grow, 
eventually interfering with the functions of the issue or organ that they have colonised. 
Cancer is a generic term for a large group of diseases that can affect any part of the 
body. It can be defined as a malignant tumor of potentially unlimited growth that 
expands locally by invasion and systemically by metastasis (2). Concerning the 
biological characteristics of cancer cells, it should be emphasized the proliferation of 
abnormal cells and failure of programmed cell death (apoptosis) which promote cancer 
progression (82). 
According to data from the WHO, 7.9 million of people died from cancer in 2007. This 
is the second principal cause of mortality in the developed countries, after the 
cardiovascular diseases (82). However, the cancer rate is increasing also in the low and 
middle income countries (in particularly South America and Asia) that have already the 
majority of world deaths (>70%) (82).  
There are “external” factors, mainly due to tobacco, alcohol, diet, physical inactivity, 
pollution, radiation or some infections such as hepatitis B, human papilloma virus or by 
Helicobacter pylori which contribute to increase the number of cancer cases more than 
the natural ones. The frequency of cancer is also related to genetically determined 
factors. The increase of cancer however, is primarily due to significant increase of life 
expectancy (96). 40% of cancer can be prevented only by the changing of lifestyles 
(82). 
The organs/tissues more commonly affected by cancer are prostate, breast and colon, in 
developed countries, and liver, stomach and cervical, in the in developing countries. 
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However, with the exception of oat cell carcinoma of the lung, lung cancer and certain 
death are related primarily to smoking (82). There is a very strong relationship between 
the development of lung cancer and TB infections. However, as of today, the question 
of whether one precedes the other is still not known (97;98) 
The prevention and early diagnosis are very important in the control of the disease. 
Treatment of cancer includes different approaches such as surgery, radiation therapy, 
chemotherapy, or hormonal therapy (99). However, in the majority of the cases, cancer 
therapy does not result in a complete cure but may increase the life time (5 years or 
more in 75% of the cancer types) (99). However, the increase of life expectancy is more 
related to early intervention than to the intervention itself. New approaches for 
treatment of cancer are required. 
Studies of oncogenes and tumor suppressors, known to be involved in the development 
of human cancers, have improved the treatment of disseminated cancer. These new 
studies of cancer related genetic targets, has resulted in a molecular approach for 
therapy of cancer. These improve the response rate in cancer and reduce side effects of 
anticancer treatment. Therapies have progressed from the use of general cytotoxic 
agents, such as nitrogen mustard in the 1940s, to the development of natural-product 
anticancer drugs in the 1960s, such as Vinca alkaloids and anthracyclines, which are 
more cytotoxic to cancer cells than normal cells, and to the use of specific monoclonal 
antibodies and immunotoxins targeted to cell surface receptors and specific agents that 
inactivate kinases in growth-promoting pathways (12). 
The failure of therapy in cancer can be due to host factors or specific genetic or 
epigenetic alterations in the cancer cells. These failures include, for example: 
1. low serum levels of drugs because of poor absorption, rapid metabolism or 
excretion;  
2. poor tolerance to side effects of drugs, resulting in a need to reduce doses below 
optimal levels;  
3. inability to deliver drugs to the site of the tumor;  
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4. and, various alterations in the host-tumor environment that affect response of the 
tumor (local metabolism of drugs by healthy cells, unusual tumor blood supply 
that affects the drug deliver, etc) (12). 
As already discussed, eukaryotic cells develop resistance in a manner analogous to 
prokaryotic cells, and this is the major factor that promotes failure in cancer 
chemotherapy (100). It can affect a wide variety of cancer types and solid tumors, 
including breast, ovarian, lung, and lower gastrointestinal tract cancers (101).  
Every cancer expresses a different array of drug-resistance genes, and exhibits an 
enormous amount of heterogeneity with respect to drug resistance. In addition, even if 
tumors are not intrinsically resistant to a specific anticancer treatment, if they face the 
powerful selection imposed by potent anticancer drugs, and due to that heterogeneity, an 
overgrowth of drug-resistant variants can occur as well as rapid acquisition of drug 
resistance (12). 
As in bacteria, the phenomenon of resistance in cancer can be due to a variety of factors 
(100;102): 
• Adjustment of the cell to damage produced by drugs by mechanisms that 
increase repair of DNA systems. Alterations in the cell cycle through 
changes in the factors responsible for its control; blocking apoptosis or 
interrupting the signalling cascades;  
• Activation of detoxifying systems (usually involving glutathione (GSH) and 
GSH-S-transferase);  
• Reduction of intra-cellular concentration of drug by either increasing its 
efflux or decreasing its uptake. Drugs that affect membrane lipids such as 
ceramide can also reduce intracellular concentrations.  
• Inactivation of drugs;  
• Alteration of drug targets;  
• Expression of a major vault protein, termed lung resistance-related protein 
(LRP), which may regulate nuclear entry of drugs 
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Although all of these mechanisms are possible, resistance of cancer cells has been 
mainly described as the result of efflux of the drug used in the treatment (100). The 
efflux mechanisms of cancer cells will be presented in greater detail in the paragraphs 
that follow. 
The efflux can be the consequence of different mechanisms, also dependent on the 
cancer type, such as the up regulation of membrane proteins or by down-regulation of, 
for example, the caspase cascade (103).  
In humans, the three major types of multi-drug resistance proteins include members of 
the ABCB (ABCB1/MDR1/P-glycoprotein), the ABCC (ABCC1/MRP1, 
ABCC2/MRP2), and the ABCG (ABCG2/MXR/BCRP) subfamily (104) represented by 
Figure 13.  
 
 
Figure 13 – Membrane topology of the MDR-associated ABC transporters MDR1, MRP1. 
Source: (105) 
 
P-gp was purified for the first time in 1979 (106). The genes that code for this protein 
have a high sequence homology to the bacterial hemolysin transport protein and this 
relationship was the first step to understand the function of this protein (101).  
The P-gp can be expressed in cancers at different rates according to the cancer type. In 
renal carcinoma, adrenocorticoid, hepatocellular, pancreatic and colorectal carcinoma 
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the P-gp is usually highly expressed and these cancers are intrinsically resistant to 
chemotherapy. In other kinds of cancer, such as breast cancer or small-cell lung cancer, 
high level of this protein is expressed after chemotherapy suggesting an up-regulation of 
its expression or a selection of already resistant cells (102). 
P-gp is an ATP binding protein of the ABC super family of transporters and therefore 
uses ATP as the energy source. It was one of the first members of the ABC family to be 
described. It is the product of the mdr1 gene in the humans and two different related 
genes, mdr1a and mdr1b in the mouse (12;102;107). All the organisms have encoded 
within their genome pumps from the ABC family which are involved in the transport of 
nutrients and other biologically important molecules across plasma membranes and 
intracellular membranes in cells (12). 
P-gp is a 170,000 dalton phosphoglycoprotein consisting of two ATP binding cassettes 
and two transmembrane regions, each of which contains six transmembrane domains. P-
gp can detect and bind a large variety of hydrophobic natural product drugs as they 
enter the plasma membrane. These drugs include many of the commonly used natural 
product anticancer drugs such as doxorubicin and daunorubicin, vinblastine and 
vincristine, and taxol (12). When these drugs bind there is an activation of one of the 
ATP-binding domains and the hydrolysis of ATP causes a major change in the shape of 
P-gp, which results in the releasing of the drug into the extracellular space. Hydrolysis 
of a second molecule of ATP is needed to restore the transporter to its original state 
(12).  
Although the molecular mechanism of extrusion a wide range of structurally diverse 
drugs remains unclear (107), it is presumed that the ATP binding cassette acts as the 
engine for the transport of various of neutral and positively charged hydrophobic drugs 
within the plasma membrane (12). This extrusion can be blocked by many non-
cytotoxic drugs, including nifedipine, verapamil, quinine, chloroquine, progestogens, 
tamoxifen, cyclosporine A and its analogues, reserpine and tricyclic anti-depressants 
(108;109). Most of them cannot be used in therapy because they are toxic for the 
patients in the doses that are needed for successful combination chemotherapy. For 
example high doses of verapamil needed to reverse drug resistance produce congestive 
cardiac failure and heart block (110). Moreover, any drug that interacts with the 
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substrate-binding region of P-gp can be a competitive inhibitor of the binding of other 
drugs (12). 
MRP1 (multi-drug resistance associated protein 1) was the first member of the MRP 
family to be identified and confers resistance to a broad spectrum of anticancer drug like 
anthracyclines, alkaloids, epipodophyllotoxins and methotrexate, as the P-gp, but not to 
the taxanes (102). MRP1, unlike MDR1, transports negatively charged natural product 
drugs and drugs that have been modified, for example by glutathione, glycosylation or 
sulfation. MRP1 is also widely expressed in many human tissues and cancers (12). 
The BCRP (Breast cancer resistance protein) is another member of the ABC family and 
is responsible for the transport of mitoxantrone, topotecan, irinotecan and methotrexate. 
Unlike MDR1 and the MRP family members, it only has one region with six 
transmembrane domains and a single ATP-binding cassette but is presumed to function 
as a dimmer (12;102).  
The LRP, although it does not belong to the ABC transporters, it is also, highly 
expressed in drug resistant cell lines (102) 
All of these proteins are found in normal tissue with basal expression and are also 
involved in the normal physiology of the cell. However, in cancer cells their function 
increases as well as their importance in the resistance to the chemotherapy (102). 
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6. New therapy approaches   
 
Many approaches can be followed in order to look for efficient compounds against drug 
and multi-drug resistant strains. New classes of antibiotics with new targets are options 
that should be tested. However, much research has been performed to discover new 
adjuvants to be used with antimicrobial therapy. These compounds, together with the 
existing antibiotics, could increase the efficacy of the antibiotic against drug and multi-
drug resistant strains. 
A huge number of small molecules, many of natural origin, are able to reverse multi-
drug resistance by inhibiting the functions of EPs and their action has been considered a 
possible way to reverse MDR. However, while a few compounds have reached clinical 
trials, none of them has, so far, been cleared for therapeutic use (111). 
The adjuvants can act on many biochemical processes involved in influx of the 
antibiotic into the cell or its extrusion, the assembling of the cell membranes, the 
membrane potential, among others. 
 
6.1  Efflux modulators 
 
Various examples of efflux pump inhibitors (EPI’s) with a wide variety of structures 
and chemical properties, both synthetic and natural compounds, can be found in the 
literature (16-20;112-114). Among these are verapamil (74), quinidine (74), reserpine 
(74), compounds from terpenoids family (112;115;116), phenothiazines and their 
derivatives (117-119), and certain alkaloids (120).  
Some studies are presently in progress in order to recognize the similarities of 
antibiotic/cytostatic and EPI structures as well as their affinities to efflux pumps 
(121;122). This kind of work permits to find the occasional structural similarities 
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between the EPIs (123) and provides important information for the research of new 
active compounds. It can lead to the finding of 1) EPIs that are not substrate competitive 
and can directly inhibit efflux pump or 2) EPIs that are substrate competitors. To be a 
“substrate competitor” means that the EPI is recognized by the different pumps and 
competes for the active site of the transporter to which the antibiotic is bound. An EPI 
that competes for the binding site of two or more efflux pumps is a broad spectrum EPI 
(124).  
However, some precautions should be taken with the inhibition of efflux pumps. An 
effective EPI that inhibits the EPs of a bacterium should not be active in the eukaryotic 
cells. Because some efflux pumps of prokaryotic and eukaryotic cells are similar, given 
their genetically conserved regions, structure specificity of EPI compounds for bacterial 
EPs efflux pumps must therefore be determined. Moreover, the EPIs should not present 
toxicity to the infected host. Ex vivo, in vivo and toxicity assays are therefore very 
important. 
 
6.2  Other membrane interacting compounds 
 
In order to identify compounds that would destabilize the stability of the bacterial 
membrane and increase its permeability some authors have been following another 
approach for therapy (125;126). For example S. aureus dehydrosqualene synthase is the 
first enzyme involved in the synthesis of staphyloxanthin (127), the golden carotenoid 
pigment of that bacterium, which promotes resistance to reactive oxygen species and 
host neutrophil-based killing. Based on the similarity between this enzyme and the 
human squalene synthase involved in cholesterol biosynthesis, Liu et al. screened 
inhibitors of squalene synthase on the inhibition of dehydrosqualene synthase and found 
that the killing of bacteria by the immune system was increased. Furthermore, the 
virulence of the organism was decreased. This mechanism of inhibition does not affect 
the viability of host cells because the source of cholesterol provided by external sources, 
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such as food is sufficient to by-pass the effects of inhibition of human squalene synthase 
(125). 
Squalamine is another example of a compound that interacts mainly with membrane 
constituents of MDR strains such as LPS composition. Salmi and co-authors studied this 
compound against a wide variety of wild type and MDR Gram-negative and Gram-
positive bacteria. The study with wild type and clinical drug resistant isolates of Gram-
negatives showed that despite differences in membrane composition between strains, 
squalamine was effective against all strains tested and acted as a membranotropic 
compound (50). 
Antimicrobial peptides are constituents of the immune system and are being studied as 
models for new synthetic antibacterials (128) or membrane active compounds (129). 
Their role against bacterial and mycobacterial infections was also studied, and showed 
that: 1) in vitro, these compounds increase membrane permeability of mycobacteria, 2) 
in vivo, they can influence the immune response of the host; and 3) they are efficient 
bacteriostatic factors, once they bind and inactivate a crucial protein involved in the 
control of bacterial proliferation, the ftsZ (130;131). According to “the antimicrobial 
peptide database” (132;133), these little peptides are, also, being studied as 
antiviral/HIV, anticancer and antifungal compounds. Figure 14 shows the possible 
mechanisms of action of antimicrobial peptides.  
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Figure 14 – Proposed mechanism of action for antimicrobial peptides.  
In Gram-negative bacteria, it is hypothesized that cationic peptides interact with the highly negatively 
charged outer membrane. The peptides either bind tightly to the negatively charged membrane 
lipopolysaccharide (LPS) or neutralize the charge over an area of membrane subsequently distorting the 
membrane structure. Once this occurs the peptides can translocate across the outer membrane. The 
bacterial cytoplasmic membrane is also negatively charged. Cationic peptides can insert in a position 
parallel to the membrane lipids and fold into membrane-bound structures leading to cell lysis (although 
this is not very likely at physiological concentrations of cationic peptide), channel formation (the peptides 
reorient themselves in the cytoplasmic membrane in such a way that they form channels leading to a 
breakdown in membrane integrity), catastrophic breakdown of the membrane integrity or direct killing of 
the bacterial cell by peptides attacking internal targets after diffusing through both membranes. Source: 
(27). 
 
Plants are good sources of these kinds of compounds. In the next chapter some 
examples of the use of plants in therapy will be given. 
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7. Importance of plants in therapy 
 
Pharmacognosy is the science that studies the use of plants in pharmacy and describes 
the main characteristics of herbal medicines (phytomedicines) and their clinical use 
(phytotherapy). In general, pharmacognosy is the science of biogenic or nature-derived 
pharmaceuticals and poisons (134). Many plant derived pure compounds (natural 
products) are used in conventional medicine. Many compounds extracted from plants 
are commonly used. For example: 1) the analgesic morphine was first isolated from 
Papaver somniferum; 2) digoxin isolated from Digitalis spp. is used to treat heart 
failure; 3) taxol used in anticancer treatment, from Taxus brevifolia; 4) quinine used to 
treat malaria, from Cinchona spp.; 5) caffeine used as stimulant was isolated from 
Coffea arabica; 6) Salicin isolated from Salix spp. was the precursor for the 
acetylsalicylic acid or aspirin (134). Many other compounds used today in medicine are 
derived from plants and more of plant source will be discovered and effectively used. 
Herbal drugs derived from specific parts of plants such as leaves of Ginkgo biloba used 
in cognitive deficiencies, or the flower heads of chamomile (Chamomilla recutita) are 
referred to as phytomedicines and are used for mild gastrointestinal complaints and as 
an anti-inflammatory agent, respectively (134). Foods that are known to have beneficial 
effects on health such as garlic, ginger, anthocyanin, flavonoid containing plants or 
carotenoid containing plants such as tomatoes, carrots and many other vegetables are 
called nutraceuticals (134). 
Natural products and herbal drugs have been used for many centuries and their use 
recorded in archaeological documents. The traditional use of herbal drugs or natural 
products in some parts of the world is documented and it is known as traditional 
medicine. China (135;136), India (134), Japan (136) or some African regions are 
famous for their “traditional medicines” (137). A very important approach to improve 
therapy is to explore traditional use of plant material and search new active compounds 
in those plants.  
Another approach is to exploit the knowledge about the environment where the plant 
grows. As the soil is a media rich in bacteria, fungi and virus it is supposed that plants 
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produce their own antimicrobials, including antibacterial compounds to protect 
themselves against these microorganisms (16). Plants are known to produce an 
enormous variety of small molecule (MW <500 Da) antibiotics, generally classified as 
‘phytoalexins’. Their structure is diverse having characteristics of terpenoids, 
glycosteroids, flavonoids and polyphenols (138). 
Streptomyces spp is an example of soil bacteria that is taxonomically related to 
Mycobacterium species. Those plants that are resistant to Streptomyces spp should be 
studied for compounds that may have activity against Mycobaterium spp, hence, 
exploring taxonomic “closeness” and specificity is an important area for investigation 
(16). These relationships can also be useful for exploring chemical similarities between 
the natural compounds and their derivatives, in a quantitative structure/activity 
relationship (QSAR). For example 60% of the antimicrobials and anticancer drugs have 
their origin in natural products (16). 
Plants can be investigated for as sources of new antibiotics, new anticancer drugs or 
adjuvants for therapy. In these investigations attention must be paid to the properties of 
the plants and also to the characteristics of the bacteria or cancer type, as seen in the 
previous chapters.  
 
7.1  Plants as sources of chemotherapeutics and modulators of cell 
mechanisms 
 
Most of the antibiotic classes that are in use nowadays were derived from natural 
products (Table 1). This prevalence of natural derived compounds is in the main 
because plants produce biological active compounds needed for their own survival. It 
should be taken selective advantage from that fact. The potential use of natural products 
from plants for therapeutic purposes underlies the closely related physical and chemical 
properties of the substance to their effectiveness against fungi, viruses and bacteria all 
present in soil and atmosphere where the plant exists (10).  
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The isolation of compounds from plants has in recent years yield many different kinds 
of molecules with in vitro antibacterial activity against Gram-negative and Gram-
positive bacteria (139-143).  
 
Table 1 - Representative classes and examples of antibiotics derived from natural products and 
their site of action. 
Adapted from Butler et al (10) 
Antibiotic class Example Mode of action 
Cephalosporins Penicillin Bacterial cell wall 
Bacterial peptide Bacitracin Bacterial cell wall 
Aminoglycosides Streptomycin Protein Synthesis 
Cephalosporins Cephalosporin Bacterial cell wall 
Chloramphenicols Chloramphenicol Protein synthesis 
Tetracyclines Chlortetracycline Protein synthesis 
Macrolides Erythromycin Protein synthesis 
Antimycobacterials Cycloserine Bacterial cell wall 
Glycopeptides Vancomycin Bacterial cell wall 
Antimycobacterials Rifamycin RNA synthesis 
 
It is important to note that isoniazid is not a derived natural product and it is not 
included in the table. However, the structure of this very important antibiotic in TB 
therapy is based on that of nicotinamide, commonly known as vitamin B2 (10). 
Moreover, isoniazid is a pro-drug that is converted to its active form by the peroxidase 
system of the mycobacterium. 
Many reviews have been published in the last years about the use of plants or natural 
sources for new anti-mycobacterial agents (144-147). An important review is that from 
Coop and Pearce, describing a series of characterized natural compounds that inhibit the 
growth of mycobacteria, with special focus on the active ones against M. tuberculosis. 
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The isolation from different sources including terrestrial and marine plants, animals and 
microorganisms lead to the identification of more than 350 compounds distributed 
among different classes, such as: alkaloids, terpenes, phenolic compounds, steroids, 
quinones, simple aromatic compounds and peptides, among others (148). Examples of 
active compounds against mycobacteria are triterpenes such as ursolic or oleanolic acid 
and its derivatives with minimum inhibitory concentrations (MIC) between 28 and 50 
mg/L (148;149). 
Some of the active compounds were shown, for example, to inhibit the isocitrate lyase, 
an enzyme class required for fatty acid catabolism, virulence of M. tuberculosis, or the 
mycolic acid biosynthesis (148;150). Others were shown to inhibit bacterial protein 
synthesis by binding to the 23S rRNA of the 50S ribosomal unit or intercalating into 
DNA (148). 
However, it is interesting to note that most of the small molecules purified from plants 
have weaker antibiotic activity (sometimes several orders of magnitudes less) than that 
of common antibiotics produced by bacteria and fungi. Despite this fact, plants fight 
infections successfully. Apparently, plants adopt a different strategy – ‘‘synergy’’ – to 
combat infections. An example is the combined action of berberine and 50-
methoxyhydnocarpin, both of which are produced by berberry plants. Berberine, a 
hydrophobic alkaloid that intercalates into DNA, is ineffective as an antibacterial, 
because it can be pumped out easily by pumps that confer multi-drug resistance. Hence, 
the plant produces 50-methoxyhydnocarpin that blocks those pumps and this 
combination is a potent antibacterial agent (138).  
Recently, the search for new compounds from the class of the EPIs, that could improve 
the TB therapy, has also been described. For example, Lechner et al described the 
activity of an isoflavone, biochanin A (151), epicatechin, myrecitin, quercetin, rutin and 
other flavonoids (150;151) against mycobacteria efflux pumps (EP). These authors also 
suggest that, for example, the modulation of the INH activity by flavonoids is not only 
related with the inhibition of mycobacterial efflux pumps but also with their antioxidant 
capacity, which will scavenge the H2O2 available for the peroxidase KatG so that the 
INH can be more easily oxidized by that enzyme and be active inside the cell (150).  
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Thus, as it was presented in previous chapters of this introduction, EP are widespread in 
all types of cells from prokaryotes to eukaryotes. As TB infection involves these two 
kinds of cells (mycobacteria and host cell), it is important to keep in mind that adjuvant 
therapy should focus on a wide variety of different kinds of efflux pumps and be tested 
against its efficiency in vitro and ex vivo, before the in vivo use (152-155). Additionally, 
cancer adjuvant therapy should have particular attention to not interfere with the normal 
metabolism of the healthy cells of the organism. 
The plant kingdom has proved to be a valuable source of efflux modulators (16;112). 
Many natural compounds have been reported as “efflux pumps inhibitors”, decreasing 
the minimum inhibitory concentration (MIC) of antibiotics against bacteria such as S. 
aureus (156;157), Mycobacteria (150), or MDR cancer (114), among others. Reserpine, 
a natural compound which was isolated from Rauwilfia vomitoria in 1954 (120;158), or 
Toratol™, whose main source is the New Zealand Totara tree (159) are just two 
examples of numerous commercialized plant derived compounds which are described as 
EPIs. 
In relation to eukaryotic cells, P-gp, together with the MDR1, was shown to be one of 
the most important membrane proteins involved in cancer resistance to chemotherapy 
(160). Because of this reason, it has been a target of choice for the improvement of 
cancer chemotherapy. Nabekura et al, for example, studied, in vitro, inhibitors of these 
membrane proteins obtained from dietary phytochemicals that can also act as chemo-
sensitizing agents for the MDR and non MDR cancer. Among these compounds were 
sesamin (from sesame), matairesinol (from soybeans), glycyrrhetinic acid and glabridin 
(both from licorice) (161). 
The class of flavonoids has been described as an active class modulating and reducing 
the resistance of cancer cell to specific compounds, by inhibition of P-gp or through 
other mechanisms. However, opposite results were obtained with this class, and some 
flavonoids were shown to potentiate and increase that resistance. Some 
structure/activity relationship studies have been done in order to understand their 
mechanism of action (160). 
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The group of phenanthrenes have anticancer activity against different kinds of cancer. 
However, not all compounds of this family have similar activities and some of them 
were inactive, indicating, once again, that the relationship between the structure of the 
compound and the place and mechanism of action is an important step in the study of 
new chemotherapeutics (162). 
A large number of those plants, where these compounds were isolated from, has been 
used for a long time in the traditional medicine of many countries and their chemical 
and pharmaceutical studies showed the chemical basis of these applications (135-137). 
African and Chinese traditional medicines have been important sources of knowledge 
and many plants from these regions have been studied in order to identify their active 
constituents (163). 
The Carpobrotus edulis, topic of this thesis, is a particularly interesting example of this. 
According to literature data, this plant is used in South-African traditional medicine, 
some of which are of particular interest in the antibacterial research (see section 
bellow). One particular effect, relevant to this study, is the use against tuberculosis. As 
it is a very common plant (also in Portugal) and has a fast growth without any special 
requirements, this plant can be easily used as source of active compounds against 
infection and cancer. So that, it is interesting to complement the previous studies of this 
plant and characterize its constituents responsible for the observed activities. This was 
the essential motive of the choice of C. edulis as the subject of study in this thesis. 
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8. Carpobrotus edulis 
 
Few studies can be found in the literature about the genus Carpobrotus and for the 
species studied in this work. Plants from the genus Carpobrotus (Aizoaceae family) are 
well known in South Africa and their spread and use in traditional medicine, in that 
country, has been described by some authors (137;164-170).  
The genus Carpobrotus is one of the 143 genera of the Aizoaceae family, which 
contains about 2300 species (171). It is characterized by succulent leaves and fast 
growth through extensive areas, mainly sandy or dune soils along coastal areas (170). 
The most popular species of the genus Carpobrotus is C. edulis. Although C. edulis has 
been described mainly in the traditional medicine of South Africa (137;170), this 
species also occurs in coastal California (172) and in Europe (173). The first specimens 
of the plant were introduced in Europe between 1681 and 1690 and they are very well 
known along the Mediterranean coast (171). The Portuguese coast is rich in this plant 
(Figure 15) with flowers purple and yellow. 
 
 
Figure 15 - Carpobrotus edulis. 
Pictures taken in Cabo da Roca, Sintra, Portugal 
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8.1  Uses in traditional medicine 
 
As the different Carpobrotus species are very similar between each other, they have 
been used in an undefined manner by different communities (167). In the traditional 
medicine this species have been used to treat stomach ailments (169), mouth ulcers 
(166;167;169;170), throat infection (167;169;170), sinusitis (170), pains (169), oral and 
vaginal thrush (169), burns (166;169), tuberculosis (169;170), dysentery (169;170;174), 
or as a diuretic (169). 
 
8.2  Activity of Carpobrotus spp. 
 
Some species of Carpobrotus have already been studied by scientific methods to test 
those properties. Watt et al isolated five active compounds from C. edulis leaves with 
activity against Bacillus subtilis, S. epidermis, S. aureus, Streptococcus pneumonia, 
Moraxella cattharlis and Pseudomonas aeruginosa. The authors identified the 
compounds such as flavonoids rutin, ferrulic acid, hyperoside, cactichin and 
neohesperidin using standard colouring reagents and comparing UV-light spectra with 
those from known standard compounds (170). 
Ordway et al had previously demonstrated that C. edulis methanolic extract has 
immune-modulator activity and efflux pump inhibitor properties against MDR mouse 
lymphoma cell lines. In the same publication it was also demonstrated that the 
methanolic extract enhances the killing of phagocytosed S. aureus (175). Martins et al 
showed that the same extract inhibits the growth of phagocytosed multi-drug-resistant 
M. tuberculosis and methicillin-resistant S. aureus, but does not inhibit the growth of 
these bacteria in vitro (176). However, Springfield et al demonstrated that the ethyl 
acetate fraction of other three Carpobrotus species (C. muirii (167), C. quadrifidus (167) 
and C. mellei (168)) have antimicrobial activities against S. aureus and M. smegmatis in 
disc diffusion method, in direct bioassay in TLC plates and minimum inhibitory 
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concentration / minimum bactericidal concentration (MIC/MBC) determination. The 
extracts were not active against P. aeruginosa or C. albicans (167). 
From these previous studies, it has been shown that the genus Carpobrotus is reach in 
flavonoids (168;170), hydrolysable tannins, phytosterols and aromatic acids (168), and 
Springfield et al, as well as Watt et al, claim that the activity of the Carpobrotus species 
is mainly due to the presence of flavonoids (168;170). 
This Ph.D. research thesis proposes to isolate and identify components from the species 
C. edulis that are active against M. tuberculosis and MDR cancer cells. 
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Aims of the study  
The first part of the present work aims to contribute for a better understanding of the 
antibiotic resistance mechanisms of bacteria and the physiological processes that 
influence and modulate resistance to antibiotics and to other noxious agents in the 
environment. The main objectives of this work are: 
? To study the influence of the environment and growth conditions on the  
expression of outer membrane proteins of a bacterium; 
? To study the effect of different conditions of antibiotic pressure on the 
acquisition of resistance mechanisms, namely over-expression of efflux pumps; 
? To understand the role of efflux pump mediated resistance on the survival of the 
organism under extreme environmental conditions such as widely differing pH; 
? To study the physiological contribution of metabolic energy, protons / proton 
motive force on the regulation of efflux activity;  
? To study the role of ions such as calcium on the efflux pump mechanism of 
bacteria; 
? To study compounds which modulate efflux activity by interfering with key 
pathways of membrane stability and energy use.   
Because efflux is a key point for the efforts against multi-drug resistant infections, the 
second part of this thesis has for its main objective the search for new compounds that 
may modulate efflux mediated multi-drug resistance of bacteria and hence, if they are 
free of toxicity, can be used for therapy of infections caused by these bacteria.  
Plants are good sources of active (and most probably non-toxic) compounds against 
many diseases. Evidence of their use in traditional medicine must be present and the 
amount of plant material sufficiently must be large, so that complete investigation will 
yield enough quantities of compounds for evaluation, and that the growth of the plant 
during the year does not limit its access for investigation.   
61 
Aims of the study 
62 
The plant Carpobrotus edulis, chosen to this thesis, satisfies the aspects summarised 
above: 
? It is described in traditional medicine for use against several diseases. 
? Some extracts of this plant have been shown to have activity against bacteria, 
mycobacteria and cancer cell lines.  
? Its abundance in the Lisbon area is prominent and its growth is essentially 
continuous during the entire year. 
Therefore, for the second part of the thesis work, the main objectives were to isolate 
compounds from Carpobrotus edulis and evaluate them for activities relevant to their 
potential use for the therapy of multi-drug resistant bacterial infections and multi-drug 
resistant cancer. The following protocols were created for the above main aim and its 
objectives: 
1.  Extraction and isolation of active compounds of C. edulis following a bio-
guided purification protocol based upon some activities described in the 
literature for this species/genus; 
2. Characterise compounds isolated for molecular structure and identities. 
3. Test the pure compounds for their activity against Gram-negative and Gram-
positive bacteria. 
4. Test the isolated compounds for activity against mycobacteria.    
5. Test the isolated compounds for possible use as therapeutic adjuvants in 
particular for their activity as efflux modulators in bacteria; 
6. Test the activity of the compounds as enhancers of the killing activity of 
macrophages infected with bacteria; 
7. Test the pure compounds for: 
a. Antiproliferative activity against cancer cell lines and multi-drug 
resistance cell lines; 
b. Capacity to reduce or reverse multi-drug resistance of MDR cancer cell 
lines to anti-cancer compounds; 
c. Modulate the activity of an over-expressed transporter of MDR cancer 
cells.
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Materials and Methods  
In the following chapter the methods used during the work of characterization of efflux 
of E. coli under different conditions, as well as the isolation of C. edulis compounds and 
evaluation of the activity of the compounds in prokaryotic and eukaryotic cells are 
presented. The relevant information about the reagents and apparatus used during the 
experiments are given through the text. 
 
1. General bacteriology procedures 
 
1.1  Bacterial strains 
 
Antimicrobial activity was determined against representatives of Gram-positive, Gram-
negative bacteria and mycobacteria strains. The strains used were: 
• Staphylococcus aureus ATCC 25923 obtained from the American Type Culture 
Collection (ATCC)  ;  
• Clinical isolate methicillin resistant Staphylococcus aureus (MRSA) strain; 
• Staphylococcus aureus HPV 107 gently provided by Prof. Hermínia de 
Lencastre, Molecular Genetics Lab, Instituto de Tecnologia Química e Biológica 
da Universidade Nova de Lisboa (177-179); 
• MRSA COL gently provided by Prof. Hermínia de Lencastre, Molecular 
Genetics Lab, Instituto de Tecnologia Química e Biológica da Universidade 
Nova de Lisboa (178-180); 
• MRSA COL was adapted to 1600 mg/L of oxacillin, and named as MRSA 
COLOXA. Its characterization was published in (181); 
• Enterobacter aerogenes ATCC 13048 gently provided by Professor Jean-Marie 
Pagès, UMR-MD-1, IFR88, Facultés de Médecine et de Pharmacie, Université 
de la Méditerranée, Marseille, France. It exhibits an efflux pump that is involved 
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in macrolides and linezolid efflux and was previously described Chollet et al. 
(182); 
• Enterococcus faecalis ATCC 29212 obtained from the American Type Culture 
Collection (ATCC); 
• Escherichia coli K-12 AG100 strain (argE3 thi-1 rpsL xyl mtl delta (gal-uvrB) 
supE44) (183) was kindly offered by Hiroshi Nikaido, Department of Molecular 
and Cell Biology and Chemistry, University of California, Berkely, California, 
USA. 
• Escherichia coli AG100 strain was exposed to increasing concentrations of 
tetracycline (TET) (37) leading to an efflux pump over-expressed strain, 
Escherichia coli AG100TET8;  
• E. coli AG100TET8 strain was exposured to 10mg/L of tetracycline during a long 
period of time leading to the strain Escherichia coli AG100TET10; 
• Salmonella Enteritidis 104 and Salmonella Enteritidis 5408 were gently 
provided by Professor Seamus Fanning, Centre for Food Safety, School of 
Agriculture, Food Science and Veterinary Medicine, University College Dublin, 
Ireland; 
• Salmonella strains adapted to 4 e 16 mg/L of CIP respectively, Salmonella 
Enteritidis 104CIP and Salmonella Enteritidis 5408CIP were gently provided by 
Professor Seamus Fanning, Centre for Food Safety, School of Agriculture, Food 
Science and Veterinary Medicine, University College Dublin, Ireland; 
• Mycobacterium tuberculosis H37Rv (ATCC 27294) strain, which is susceptible 
to rifampicin, isoniazid, streptomycin and ethambutol. 
 
1.2 Cellular cultures  
 
With exception of any change specified during each specific protocol, E. coli strains 
were grown in Luria Bertani broth (LB) and Luria Bertani agar (LA) media 
(components for this media were purchased from: ppeptone and Yeast E from Merck, 
Germany and NaCl from Panreac, Spain); Salmonella, Enterobacter, Enterococcus and 
66 
Materials and Methods  
Staphylococci strains were grown in Tryptone Soya broth (TSB) and Tryptone Soya 
agar (TSA), both purchased from Oxoid, England) and Mycobacterium tuberculosis in 
Middlebrook 7H9 broth media and Middlebrook 7H11 solid media (purchased from 
Difco, USA). 
Stocks of each bacterial strain were maintained in 15% glycerol at -80ºC. 
 
1.3 Determination of Minimal Inhibitory Concentration (MIC) 
 
The MIC determination of the compounds used in the different assays was conducted by 
the broth micro dilution method in Muller-Hinton broth (MHB) (Oxoid, England), 
according to Clinical and Laboratory Standards Institute (CLSI) (184) 
recommendations. A stock solution of the compound to be tested was prepared and an 
aliquot added to MHB on the 96 well plate. Serial dilutions in the following wells were 
performed. Then, an over-night bacterial inoculum was diluted to McFarland 0.5 in 
MHB and added to wells. The MIC, defined as the lower concentration of compound at 
which the media does not present visible growth of the strain, was determined after 16h 
and 18h of incubation at 37ºC. This protocol was used to all the strains described above 
with exception to the M. tuberculosis H37Rv which protocol is described below. 
The susceptibility of M. tuberculosis H37Rv to the pure compounds was tested in the 
BACTEC 460 - TB system (Becton Dickinson Diagnostic Instrument Systems, Sparks, 
USA), which detects the production of 14CO2 from the 14C substrates of the medium, as 
a result of the metabolism of the mycobacteria. This detection is finally quantified as a 
growth index (GI) which varies from 1 to 999. The strain was grown in BACTEC 12B 
medium supplemented with 0.1 mL of PANTA (antibiotic supplement to avoid 
contamination by other microorganisms of fast growth) until it reached a maximum GI 
(GI=999). This inoculum was diluted ½ in phosphate buffer saline (PBS) (purchased 
from Sigma-Aldrich Química SA, Spain) and fresh 12B medium vials (Quilaban, 
Portugal), were inoculated with 0.1 mL of that dilution. One bottle was used as absolute 
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control and the others were inoculated with 0.1 mL of compound at different 
concentrations. A second control inoculated with 1/100 dilution of the original 
inoculum was also prepared, to work as a proportional control. The cultures were 
maintained at 37ºC until the control first reached the maximum GI and the second 
control reach GI=30 (185). An aliquot of each vial were after plated in 7H11 agar 
medium and incubated at 37ºC. The colony forming units (CFU) were counted after 3 
and 4 weeks of incubation (152;186). 
The rate of increase in the GI (ΔGI = GI of one day – GI of the previous day) were 
determined when the control rich GI=999 and the proportional e control a GI=30. If the 
ΔGI of the vial with the drug is lower than the one of the control the strain is susceptible 
to that compound. If it is higher, then the strain is resistant. 
For determination of antibacterial activity of a compound by Kirby-Bauer and E-test 
assays, a McFarland 0.5 inoculum of over-night cultures of the strains was prepared. 
The strain was, then, swabbed in MHA plates and the E-test or Kirby-Bauer discs 
applied on the plate. The halls of inhibition were measured after incubation of the plates 
at 37ºC during 16h and 18h. E-test® was purchased by AB BIODISK, Sweden and 
Kirby-Bauer discs from Oxoid, UK.  
 
1.4  Semi-automated EB method 
1.4.1 Accumulation Assay  
 
Assessment of putative efflux pump activity of E. coli AG100 and E. coli AG100 TET8 
strains conducted by the semi-automated ethidium bromide (EB) method was 
previously described (187). However, it was introduced a modification that affords the 
evaluation of efflux without the need to centrifuge for the removal of EB. This 
modification is described in the section that evaluates efflux of EB after addition of 
glucose or agent that is being evaluated for activity against efflux of EB. 
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For the assessment of accumulation of EB and conditions that affect it the following 
was performed. Briefly, strains were cultured in MHB medium until they reached an 
OD of 0.6 at 600 nm, centrifuged at 13,000 rpm for 3 minutes, the pellets re-suspended 
in saline, the OD adjusted to 0.6 and 1.0 ml aliquots transferred to micro tubes, the 
tubes centrifuged and the pellets re-suspended in saline of pH 5, 7 and 8. Aliquots of 
0.045 mL transferred to micro tubes of 0.1 mL and 0.045 mL of EB (Sigma-Aldrich 
Química SA, Spain) in glucose-free saline of pH 5, 7 and 8 added to the respective 
tubes of same pH. If metabolic energy is required for efflux of EB the absence of 
glucose assures sufficient accumulation of the agent. The final concentration of EB for 
all experiments was 1.0 mg/L. Concentrations of EB much greater than 1.0 mg/L 
exceed the ability of the cell to extrude the agent, the level of intracellular agent rapidly 
increases and results in its intercalation between the nucleic bases of DNA. EB when 
bound to DNA is no longer available for extrusion. The tubes were rapidly transferred 
to the Rotor-Gene 3000TM thermocycler with real-time analysis software (Corbett 
Research, Australia) programmed for number of 1 minute cycles at a constant 
temperature of 37ºC. The total average time from the addition of the EB-saline to as 
many as 12 individual tubes to the transfer of the tubes to the instrument and the 
instrument restarted did not exceed 60 seconds. Accumulation of EB of each tube was 
followed on a real-time basis by the assessment of fluorescence emitted. Excitation and 
emission wavelengths were 535 and 585 nm, respectively. Whereas the medium 
containing 1.0 mg/L of EB does not appreciably fluoresce, as the concentration of EB 
builds up in the periplasm of the Gram-negative bacterium, fluorescence is readily 
detected by the instrument (187). Accumulation of EB at the different pH was followed 
during a certain period of time. 
 
1.4.2 Efflux Assay  
 
Assessment of efflux of EB at pH 5, 7, and 8 was conducted as follows: accumulation 
of EB at pH 5, 7 and 8 as described above was first conducted for up to 25 minutes, 
after which time the instrument was stopped and 0.010 mL of saline at pH 5, 7 and 8 
lacking and containing glucose to yield a concentration of 0.4% was added to the 
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respective tubes. Similar solutions with the tested compound, in presence and absence 
of glucose were also added to the tubes at this time. The tubes were then transferred to 
the instrument and the instrument re-started. The total amount of time for this addition 
to the time the instrument was re-started did not exceed 2.5 minutes. Fluorescence was 
followed for a minimum period of 10 minutes.  
 
2. Evaluation of OMP from Salmonella 
2.1 Growth conditions 
 
Salmonella 104 and 5408 strains were grown over-night, in TSB and TSA. For the 
extraction, agar cultures were re-suspended in PBS and processed in the same way as 
broth cultures. 
 
2.2 Protocol of Extraction 
 
Extraction of OMP from Salmonella 104 and 5408 strains was conducted according to 
the previously published by Amaral et al (188). Briefly, cultures were centrifuged at 
3600 rpm for 20 min (Hettich Universal centrifuge, USA), and the pellets washed twice 
with 25 ml of 5 mM phosphate buffer (pH 7.5) containing 140 mM NaCl (Panreac, 
Spain) and 10 mM MgCl2 (Merck, Germany). The pellets were re-suspended in 10 ml of 
washing buffer and transferred to pre-weighed centrifuge tubes and centrifuged again. 
The supernatants were discarded, the tubes weighed and the pellets resuspended in 6 M 
urea containing 10 mM Tris hydrochloride (pH 7.5) (Sigma, USA) and 5 mM EDTA 
(Sigma, USA) at a weight:volume of 0.4 g to 1.0 ml of buffer. The tubes were stirred 
continuously for 1h at room temperature and then centrifuged at 3600 rpm and the 
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supernatant containing the extracted outer membrane proteins were evaluated for its 
content by SDS-acrylamide electrophoresis 8.5%. 
 
2.3 Role of antibiotic-promoted stress 
2.3.1 Step-wise increasing concentrations of antibiotic 
 
MRSA COL was initially grown in TSB until it reached its maximum optical density 
(OD) as determined spectrophotometrically at 600 nm. An aliquot of 10 μl was 
transferred to 10 mL tubes containing 50 mg/L of oxacillin (OXA) (Sigma, USA) in 10 
mL of TSB and the culture incubated until it reached full growth at 37ºC (culture 1). An 
aliquot of 10 μl was transferred from culture 1 to 10 mL TSB tubes containing 100 
mg/L of OXA and the culture (culture 2) incubated at 37ºC until it reached the 
maximum OD (ca. 16 hours). Employing this procedure, MRSA COL was serially 
grown in TSB containing as much as 3200 mg/L of OXA. 
MIC determination for OXA and erythromycin (ERY) were conducted at the beginning 
of the series and after each step-wise exposure to increasing concentrations of OXA.  
Susceptibility to kanamycin (KAN), ciprofloxacin (CIP) and amikacin (AMC) were 
conducted, as previously described. Kirby-Bauer susceptibility was similarly conducted 
and the zones of inhibition measured in millimetres (mm). The products of each OXA 
serial culture were sub-cultured in TSB broth containing 40 mg/L of reserpine (RES) 
and concentrations of ERY that ranged from 0.0 to that of the ERY MIC for each 
respective serial culture, in similar procedure as the one used for MIC determination, in 
order to determine if the acquired resistance could be reduced or reverse by the presence 
of the ERY, an EPI. ERY, KAN, AMC and RES were purchased from Sigma, USA and 
CIP from Fluka, Switzerland. 
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2.3.2 Serial passages in the same concentration of antibiotic 
 
E. coli AG100 TET8, when transferred to drug free medium or to medium containing the 
antibiotic and Phe-Arg-β-naphtylamide (PAβN), assumes tetracycline susceptibility of 
its parent (37;65). The E. coli AG100 TET8 strain was exposed to 10 mg/L of tetracycline 
for 60 serial passages in 500 ml of MHB: strain E. coli AG100 TET10.   
Minimum Inhibitory Concentrations (MIC) of antibiotics and PAβN against the strains 
employed in this study were conducted by the broth dilution method as per CLSI 
guidelines (184;189), described in the general procedures section. Antibiotic powders 
and PAβN were purchased from Sigma–Aldrich Química SA, Spain. 
Antibiotic susceptibility to tetracycline during exposure of E. coli to tetracycline was 
determined by broth microdilution and E-test® in accordance to manufacturer’s 
directions and CLSI guidelines (184;189). E-test® was purchased by AB BIODISK, 
Sweden. 
 
3. pH and energy roles on efflux by Gram - negatives 
 
E. coli AG100 strain, sensitive to tetracycline (MIC of 2 mg/L) was exposed to 
increasing concentrations of tetracycline. The resulting strain E. coli AG100 TET8 is 
resistant to 8 mg/L tetracycline and to other antibiotics of unrelated classes (37;65). 
This strain subsequently transferred to drug free medium or to medium containing 8 
mg/L tetracycline and PAβN assumes initial susceptibility to tetracycline of 2 mg/L 
(37;65). 
The effects of varying concentrations of carbonyl cyanide m-chlorophenylhydrazone 
(CCCP), verapamil (VER), chlorpromazine (CPZ), thioridazine (TZ) and PAβN at final 
concentrations of 5, 80, 15, 15 and 40 mg/L, respectively, on the efflux of EB were 
carried out as described in the general procedures section for the efflux assays. 
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Equimolar concentrations (5mM) of Calcium (Ca2+) (in the form of calcium chloride), 
ethylenediaminetetraacetic acid (EDTA) were also used. For some experiments, the 
additions at varying concentrations were in matched pH glucose-free medium. This 
component of the experiment afforded an additional control that would define any role 
of metabolic energy in conjunction with any effect produced by given concentrations of 
compound on efflux of EB and the modulation of efflux at a given pH. CCCP, VER, 
CPZ, TZ, PAβN, EDTA and CaCl2 were purchased from Sigma, USA 
 
4. Search for new active compounds against resistance 
4.1 Plant material 
 
Carpobrotus edulis (L.) N. E. Br. (Aizoaceae) leaves were collected at Guincho (Sintra, 
Portugal). The plant had been authenticated by Prof. António Viveiros (Professor 
Emeritus of Botany, Plant Biology Department, Sciences Faculty of the University of 
Lisbon) (176). 
 
4.2 General purification procedure  
 
For the purification vacuum-liquid chromatography in polyamide (ICN Biomedicals 
GmbH, EcoChrom, Germany) and in silica gel (Silica gel 60 G, 15 ím, Merck, 
Germany) were used. In each case, vacuum was achieved with a water vacuum pump. 
Gel chromatography was carried out on Sephadex LH20 (Pharmacia Fine Chemicals 
AB, Sweden) using MeOH as eluent; rotation planar chromatography in silica gel (silica 
gel 60 GF254, Merck, Germany). 
Preparative NP-TLC was performed on Si gel plates (Merck 5715, Merck, Germany) 
and preparative RP-TLC in RP-18F254S plates (Merck, Germany). 
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High performance liquid chromatography (HPLC) was carried out on a Waters 
Millipore instrument on a LiChrospher® 100 RP-18 (10µm) column with MeOH-H2O 
(3:7) as mobile phase and detection at 220 nm and 254 nm.  
Chromatographic fractions were monitored by normal phase-TLC (NP-TLC) on silica 
gel plates (60F254 plates, Merck, Germany) and reverse phase – TLC (RP-TLC) (RP-
18F254S plates, Merck, Germany) and visualized by spraying with concentrated H2SO4, 
followed by heating. 
Structure elucidation was carried out by extensive spectroscopic analysis, including 1D 
and 2D nuclear magnetic resonance (NMR) (1H-1H COSY, HSQC and HMBC) on a 
Bruker Avance DRX 500 spectrometer at 500 MHz (1H) and 125 MHz (13C). The 
stereochemistry of the compounds was studied by NOESY measurements. 1D NMR 
spectra were recorded. Two dimensional experiments were performed using the 
standard Bruker software. The signals of the deuterated solvents were taken as 
reference.  
Electronspray-Impact Mass Spectrometry (ESI-MS) was recorded on a Finnigan MAT 
95SQ hybrid tandem mass spectrometer. 
The following solvents were used during the purification procedure: methanol, 
cyclohexane, n-hexane, acetone and acetic acid (Molar, chemicals KFT, Hungary); 
dichloromethane (Fluka, Germany); formic acid (Riedle-de Haën, Germany); iso-
propanol (Reanal, Hungary); ethyl acetate and chlorophorm (Merck, Germany) and 
acetonitrile (Sigma, Germany). 
 
4.3 Extraction and isolation 
 
The fresh plant material of C. edulis (5 kg) was homogenized and percolated with 
MeOH (13 L) at room temperature (aprox. 25ºC). The crude extract was concentrated 
under vacuum (Rotavapor-RE, Büchi) at 40ºC to 0.5 L and extracted with n-hexane four 
times (0.4 L each). After evaporation fraction (A) had a dry residue of 4.5 g. The 
aqueous methanol phase was extracted with chloroform (5 x 0.5 L) and evaporated to 
dryness under vacuum yielding a residue of 4.3 g for this fraction (B). The methanol 
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water phase was also extracted three times with ethyl acetate (3 x 0.4 L). After 
evaporation, the ethyl acetate fraction (C) had a dry residue of 4.4 g. All the fractions 
were re-dissolved in methanol (Figure 16).  
Fraction A and B (Figure 16 - A) were joined and adsorbed to 17.6 g of polyamide and 
chromatographed on a polyamide column (44g) – column 1. A stepwise gradient elution 
was performed from 20 to 80 % of aqueous methanol by increasing methanol by 10 % 
in each step (10 fractions of 5 mL each).  
The fractions obtained with 60, 70 and 80% of MeOH elutions (D) were combined, 
adsorbed onto 2 g of silica gel and chromatographed on silica gel (60 g) – column 2 
using a gradient system of 0.1 L of n-hexane:CHCl3:MeOH (70:30:0, 60:40:0, 50:50:0, 
and 50:50:1), and CHCl3:MeOH:H2O (95:5:0, 90:10:0, 80:20:0 and 70:26:4). 10 mL 
fractions were collected. 
The fractions obtained with n-hexane:CHCl3:MeOH (50:50:1, v/v/v) and CHCl3:MeOH 
(19:1, v/v) – (E) were further purified on Sephadex LH 20 (50 g) – column 3, using 
MeOH as elution solvent. Fractions of 2 mL were collected. Aliquots 15 to 23 (F) were 
combined and then fractionated by using a rotation planar chromatography (RPC) on 
silica gel eluted with n-hexane:dichloromethane (50:50, v/v) and increasing 
concentrations of methanol (¼, ½, 1, 2, 3, 5, 10 and 50). It was used 0.1 L of each 
solvent and collected 5 mL of each fraction. Fractions 6 to 13 eluted with n-
hexane:CH2Cl2:MeOH (50:50:¼, v/v/v) (13.1 mg) – (G) and fractions 57 to 80  n-
hexane:CH2Cl2:MeOH (50:50:5, 50:50:10 and 50:50:50, (v/v/v)) (14.3 mg) – (H) yield 
compounds 1 (13.1 mg) and 2 (14.3 mg), respectively. Fraction 46 to 53 eluted with n-
hexane:CH2Cl2:MeOH (50:50:3, v/v/v) (22.3 mg) – (I) was purified by preparative TLC 
with a solvent system of n-hexane:CH2Cl2:MeOH (40:60:2, v/v/v) to obtain 3 (12.4 
mg).  
From column 1 the fractions obtained with 50% MeOH (J) were chromatographed on a 
silica column (30 g – column 4) by using dry-loading technique (0.8 g of silica for 
adsorption) and the same gradient system as that of column 2. The fraction obtained 
with CHCl3:MeOH (95:5, v/v) (18.8 mg) – (L), was further purified by preparative TLC 
with a mobile phase of c-hexane:EtOAc:EtOH (60:40:4,v/v/v) to obtain compound 4 
(10.6 mg). The elution with n-hexane:CHCl3 (1:1, v/v) originated a fraction (M) (19.4 
mg), that yield compound 3 (15,8 mg) by crystallization, in MeOH. Also from column 
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4, the fractions eluted with n-hexane:CHCl3:MeOH(1:1:1, v/v/v) (3.5 mg) – (N) was 
submitted to a preparative TLC with the solvent system n-hexane:CHCl3:MeOH 
(50:50:3, v/v/v) and yielded compound 3 (2.9 mg). 
Fraction C (Figure 16 - B) was adsorbed onto 8.6 g of silica gel and chromatographed in 
a silica gel (40 g) column – column 5 with a gradient system of CH2Cl2:MeOH (95:5, 
9:1, 85:15, 8:2, 7:3, v/v), CH2Cl2:MeOH:H2O (70:30:1, v/v/v) and MeOH:H2O (8:2). 50 
mL of each solvent were used and from each it was collected 10 fractions of 5 mL. The 
fraction eluted with CH2Cl2:MeOH (85:5 and 8:2, v/v) (133 mg)  - (O) was fractionated 
in a silica gel (40 g) column – column 6 with a gradient of CHCl3:MeOH (95:5 to 7:3, 
v/v) and from this, the one eluted with CHCl3:MeOH (8:2, v/v) – (P) was purified by 
RP-HPLC with MeOH-H2O (3:7) as solvent system and compounds 5 (7,7 mg) and 6 
(5,6 mg) were obtained.  
From column 5, the fraction eluted with CH2Cl2:MeOH:H2O (70:30:1, v/v/v) – (Q) was 
chromatographed in a Sephadex LH20 - column 7, and 5 mL aliquots were collected. It 
was collected aliquots of 5mL each. Aliquots 12 and 13 were combined (R) and 
subjected to preparative TLC in EtOAc: HCOOH:H2O (95:10:5, v/v/v). The most polar 
fraction (S) was again separated by preparative RP-TLC in MeOH:H2O (1:1, v/v) and 
afforded compounds 5 (6.3 mg) and 6 (3.2 mg). 
Aliquot 21, from column 7 (U) was separated by preparative RP-TLC eluted with 
ACN:H2O: CH3COOH (30:70:0.5, v/v/v ) yielded also compound 7 (3.6 mg).   
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Figure 16 –Protocol of purification of the compounds from the plant C. edulis. 
Purification of the (A) hexane and (B) ethyl acetate fractions of the methanolic extraction. 
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4.4  Activity measurements against bacteria  
4.4.1 Minimum Inhibitory Concentration of C. edulis compounds 
 
MIC determination was performed as previously described in this thesis. Each C. edulis 
compound was tested to a maximum concentration of 200 mg/L. MIC of C. edulis 
compounds were tested against all the strains mentioned at the beginning of the 
Materials and Methods section of this thesis, as presented by Table 12 of the Results 
section. 
 
4.4.2 Modulation of resistance 
A) Synergistic effect on the MIC 
Effect of the C. edulis compounds on the reduction of the MIC of a given antibiotic to 
which the strain was made resistant. The assay was performed as per an antibiotic MIC 
determination in the presence and absence of each C. edulis compound at final 
concentrations of ½ and ¼ of its MIC.  
 
B) Semi-automated EB method 
The accumulation and efflux modulation activity of each compound was assessed by the 
semi-automated EB method using the Rotor-Gene 3000TM thermocycler with real-time 
analysis software (Corbett Research, Australia) (187), as described in the general 
procedures section.  
Briefly, E. coli AG100, E. coli AG100 TET8, S. enteritidis 5408CIP and S. aureus COL 
were tested for the activity of the compounds for modulation of EB accumulation by 
these strains. Each compound was tested at 50 mg/L in presence and absence of glucose 
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and at pH 7. C. edulis compounds were also tested for their influence of efflux of EB by 
both E. coli strains. 
 
4.4.3 Toxicity assays 
 
Pure compounds were also evaluated for toxicity using the Trypan Blue exclusion 
method. The compounds that cause less than 10% of the lymphocyte population to stain 
blue after 3 days of culture were considered non-toxic (190). Lymphocytes were 
obtained from human whole blood from healthy donors by ficoll-saline gradient 
centrifugation at 1400 rpm during 20min (Rotanta 46R Hettich Zentrifuge, Germany) in 
histopaque 1077-1. The monocytes were separated, washed three times with Hank’s 
Balanced Salts solution (HBSS) and count for the number of viable cells by the trypan 
blue method in a burker chamber, on the microscope. The concentration of cells were 
adjusted to 1x107 cells/mL in Roswell Park Memorial Institute medium (RPMI) – 1640 
supplemented with plasma from the same donor obtained in the centrifugation and 0.09 
mL were added to each well of a 96 wells plate. 0.01 mL of the pure compounds at final 
concentration of 1, 0.1 and 0.01 were added to each well. Dimethyl sulfoxide (DMSO) 
was used to the dilution of the compounds and was presented in the assay at a maximum 
concentration of 10%. The concentrations of 10, 1 and 0.1% of DMSO were tested. The 
cells were maintained at 37ºC, under 5% CO2 (Heraeus instruments incubator, USA) 
and its number was counted in the following 3 days, as described above. Histopaque, 
HBSS, RPMI and DMSO were purchased from Sigma-Aldrich, USA. 
 
4.4.4 Ex-vivo assays 
 
The ex vivo activity of the compounds will be assessed by the method previously 
published (152;176). Briefly, human macrophages were derived from monocytes of 
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human whole blood that were obtained, as described for the toxicity assay, from human 
whole blood from healthy donors by ficoll-saline gradient centrifugation at 1400 rpm 
during 20 min in histopaque 1077-1. The monocytes were separated, washed three times 
with Hank’s Balanced Salts solution (HBSS) and count for the number of viable cells 
by the trypan blue method. After counting, the number of cells was adjusted to 1x106 
cells/mL in supplemented RPMI. 1 mL of the cellular suspension was distributed in 
each well of a 24 well microplate (Sarstedt, Germany). After incubation for 3 days at 
37ºC, under 5% CO2 (Heraeus instruments incubator, USA), the macrophage cells had 
adhered to the bottom of the wells. The media with the non-adherent cells, as the 
lymphocytes, was removed and the macrophages washed 3 times with RPMI. The cells 
were maintained under 5% CO2 at 37ºC during 3 more days. The wash step was 
repeated and followed by the addition of S. aureus ATCC, MRSA or M. tuberculosis 
H37Rv cells at 1x107cell/mL. The plates were then incubated for 30 min and cells were 
washed, as before, to avoid the presence of any unphagocytosed bacteria. Fresh 
supplemented RPMI medium, containing varying concentrations from 0.0 and 1 mg/L 
of each compound, was added. One set of triplicate wells will receive sodium dodecyl 
sulfate (SDS) (Sigma-Aldrich, USA) to lyse the macrophages and release the bacteria. 
The contents were subjected to colony forming units (CFU) to determine the number of 
bacterial cells at zero time. The plates were returned to the incubator. For the S. aureus 
strains the replicate wells were treated with SDS, and the contents of the wells 
processed for CFU, after 3 and 6h. For M. tuberculosis H37Rv assays this procedure 
was done after 24, 48 and 72h (1, 2 and 3 days). 
The content of the wells for M. tuberculosis assay were also used to inoculate a 
BACTECTM 960 tube (BD BBLTM MGITTM Mycobacteria Growth Indicator tubes, 
Becton Dickinson and Company, USA) and its growth was monitorized by the 
MGIT960TB system with the Epicenter V5.53A software equipped with TB eXIST 
(eXtended Individual Susceptibility Testing) (Becton Dickinson, USA). This system 
allows the real time monitoring of growth and the time for detection of a positive 
culture is directly proportional to the amount of cells in the inoculum. Faster growth 
detection more cells in the inoculum. It provides a qualitative and comparative measure 
of the amount of mycobacterial cells present in the inoculum. BACTEC 960 MIGIT 
tubes were inoculated with 0.8 mL of supplement (BACTECTM MGITTM 960 SIRE 
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supplement, Becton Dickinson and Company, USA) and 0.5 mL of the well suspended 
content of each well, and the growth of the strain in each tube followed along the time.  
 
4.5  Activity measurements on eukaryotic cell lines 
4.5.1 Cell lines 
 
Parental (PAR) and multi-drug resistant (MDR) cell lines used in the biological assays 
were the L5178 mouse T-cell lymphoma cells and the L5178 mouse T-cell lymphoma 
cells transfected with pHa MDR1/A retrovirus, as previously described (191). MDR cell 
lines were selected by culturing the infected cells with 60 µg/L of colchicine which 
maintain the expression of the MDR phenotype (192). Both cell lines were cultured in 
McCoy’s 5A medium supplemented with 10% heat inactivated horse serum, L-
glutamine and antibiotics (penicillin and streptomycin), at 37ºC and 5% CO2 
atmosphere. Colchicine, L-glutamine, penicillin and streptomycin were purchased from 
Difco, USA. 
 
4.5.2 Antiproliferative assay 
 
The antiproliferative activity of the compounds was tested in triplicate by the MTT 
assay (193). The MTT assay is a colorimetric assay that can be used to determine 
cytotoxicity of potential medicinal agents and other toxic materials, since those agents 
would result in cell toxicity and therefore metabolic dysfunction. Yellow MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole) is reduced to 
purple formazan in living cells. A solubilisation solution (sodium dodecyl sulphate in 
diluted hydrochloric acid) is added to dissolve the insoluble purple formazan product 
into a coloured solution. The absorbance of this coloured solution can be quantified by 
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measuring at a certain wavelength. This reduction takes place only when reductase 
enzymes are active, which is taken as an indicator of the number of viable cells with 
metabolic activity.  
The assay was performed in 96-well plates in serum free McCoy’s 5A medium. The 
compounds were added to the wells of the third column of the plate and serial diluted in 
the following wells. Then it was added the MDR1 cells or the PAR cells to a final 
concentration of 6000 cells per well. After 72h of incubation under CO2 and at 37ºC 
(Heraeus instruments incubator), it was added the MTT (Sigma, USA) to a final 
concentration of 10% per well, and after 4h of incubation, in the same conditions, it was 
added SDS 10% to a final concentration of 5% in the well. The optical density at 540 
nm and 630 nm was read, after 24h hours of incubation in the same conditions, using a 
Dynatec MRX vertical beam ELISA reader (Dynatec, USA). 
 
4.5.3 Inhibition of P-gp on mdr1 gene transfected mouse lymphoma cells  
 
The activity of the fractions was evaluated by following the accumulation of rhodamine 
123 on mdr1 gene transfected mouse lymphoma cells (103). L5178 MDR cell line and 
L5178 Y parental cell line were cultured in McCoy’s 5A medium (Sigma, USA) with 
and without colchicine, respectively. Briefly, the cells were re-suspended to a final 
concentration of 1 million cells in 0.5 mL of serum free McCoy’s 5A medium. Each 
sample was treated with the purified fractions and incubated for 10 min. Rhodamine 123 
(Sigma, USA) was added to each tube, at a final concentration of 5.2 µM. The samples 
were incubated for 20 min at 37ºC in water bath, centrifuged at 2000 rpm for 2 min and 
the pellet re-suspended in 0.5 mL of PBS. The PBS washing procedure was repeated 
twice. The fluorescence of the samples was measured by flow cytometry (Becton 
Dickinson FACScan). Verapamil (EGIS, Hungarian Pharmaceutical Company, 
Hungary) at 10 mg/L was used as the positive control of activity. Each compound was 
previously solved in DMSO and the activity of the solvent was measured as reference. 
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4.5.4 Checkerboard assay for interaction of compounds with anti-cancer 
agents.  
 
The most active compound isolated from C. edulis for modulation of P-gp was 
determined for its synergistic effect on the activity of an anti-cancer agent against an 
MDR cell line. The assay was performed by the checkerboard microplate method for the 
study of drug interaction between the pure compound and doxorubicin on MDR cancer 
cells. This method is similar to the antiproliferative assay but doxorubicin is serially 
diluted in the wells as previously described (horizontal direction) and the compound 
diluted in the vertical direction. Cell suspension was added to each well to a final 
concentration of 5 x 104 cells per well. Plates were incubated for 72 h at 37°C under 
CO2 and cell growth rate determined through MTT staining as previously described in 
this section. 
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Results 
The results obtained will be presented in this section. The first part of the Results 
section focuses on the influence of the growth conditions on the characteristics of the 
cell envelope. Next section focuses on: influence of the growth media conditions (agar 
versus broth); resistance profile of E. coli under specific conditions of pH, temperature, 
calcium availability; the relationship between efflux pumps and outer membrane 
proteins in the resistance to antibiotics; the relationship between the efflux pumps that 
are over-expressed and the challenge of MDR bacteria to the same concentration of 
antibiotic for prolonged periods of time. From these results important information was 
collected to guide the following experiments in search of new compounds that may 
modulate efflux mediated multi-drug resistance of bacteria and cancer cells 
In the second section of Results, the main subject of this dissertation, it will be 
presented the purification and the identification of the compounds isolated from 
Carpobrotus edulis. The purification procedure was done at the Pharmacognosy 
Institute of the Faculty of Pharmacy of the University of Szeged under supervision of 
Professor Judit Hohmann.  
The third section of Results presents studies of the antibacterial activity of the 
previously isolated compounds on bacteria and the synergism between the pure 
compounds and anti-bacterials against prokaryotes. The evaluation of the compounds as 
modulators of the efflux activity of the bacterial cells will be presented.  
Because TB is an intracellular infection (194), and previous studies showed that the 
methanol extract of C. edulis enhanced the killing activity of macrophages infected with 
M. tuberculosis or S. aureus strains (175;176), the compounds were tested for their 
capacity to enhance the killing of intracellular bacteria by non-killing macrophages. S. 
aureus ATCC and MRSA were used as a model because our previous studies 
demonstrated that the effects of compounds on intracellular S. aureus predicted the 
effect of the compounds on a M. tuberculosis infection of the macrophages. These 
assays were done at the Institute of Medical Microbiology of University of Szeged. 
Similar assays with M. tuberculosis H37Rv are still in progress at the moment of the 
writing of this dissertation. 
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Finally, and because it was already described by other authors that there are similarities 
between some prokaryotic efflux pumps and the eukaryotic efflux pump P-pg (195), the 
compounds were also tested for their inhibitory activity against the human P-gp that was 
coded by the human gene mdr1 subsequent to the transfection of mouse lymphoma cells 
with this gene. These assays were done at the Institute of Medical Microbiology of 
University of Szeged under supervision of Professor Jozseph Molnár.  
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1. Growth conditions and the bacterial cell envelope 
1.1 Growth environment and OMP expression  
 
The investigation of the activity of any compound on a cell or organism, including 
bacterial cell, should take into account the behaviour and characteristics of that cell as 
well as the environment in which the cell exists.  
The cell envelope plays a crucial role in this aspect: lipid content, its porins and efflux 
systems are the major components of the cell envelope and these are known to be 
modified under different environmental conditions (19;23;24;33;34). The first two limit 
the entrance of substances into the cell. Decrease in the availability of nutrients 
increases the number of porins and the expression of the OMPs that are assembled into 
these units (23;196). Moreover, the activation and modulation of OMP genes by 
nutritional conditions result in an increase of large pore porins which favour the 
penetration of a larger gamut of nutrients (23;196). Exposure of the bacterium to toxins, 
antibiotics or other noxious agents results in the down-regulation of porins (62;197) 
either by reduced expression (48;198;199) or increased proteases that degrade the 
OMPs prior to their being assembled into the porin unit (200).  
Exposure of Salmonella strains to CPZ, a resistance modulator that has been studied in 
this thesis, has been shown to alter the composition of the outer cell membrane (188). 
Other studies have shown that media of high hydrostatic pressure affect the composition 
of the cell envelope (201). Extractions of outer membrane proteins from the cell 
envelopes of S. enteritidis that were cultured in solid and liquid media of the same type 
were conducted and the distribution of the extracted outer membrane proteins 
compared.  
The outer membrane proteins were extracted (page 70 of the Material and Methods 
chapter) from two strains cultured in TSB and TSA and the extracted proteins subjected 
to 8.5% SDS-polyacrylamide gel electrophoresis (PAGE). The distribution of the 
extracted proteins from the two Salmonella enteritidis strains 104 and 5408 is presented 
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by Figure 17. From Figure 17, it may be noted that for both strains when grown in broth 
the major proteins specie is a 56 kDa that is almost absent when these strains are grown 
in agar. However, the strains do differ with respect to the amount of this protein: the S. 
enteritidis 104 strain clearly contains a greater amount. These extractions and 
subsequent electrophoretic analyses were repeated three times. As will be seen later, the 
S. enteritidis 5408 strain has reduced permeability to antibiotics and other noxious 
agents due to its high lipopolysaccharide content of the outer cell membrane (202;203). 
The extracts were studied by Prof Dr Jean-Marie Pages of UMR-MD1, Transporteurs 
Membranaires, Chimiorésistance et Drug-Design Facultés de Médecine et de 
Pharmacie, France, for the determination of whether they contained components of the 
main efflux pump of Salmonella AcrAB and the main porins of this organism. The 
extracts did not contain AcrA, AcrB, and TolC and the porin content was similar 
regardless of the type of culture conditions employed (203). However, the identity of 
the main 56 kDa protein has been made by Foulaki (204) and will be discussed later.  
 
Figure 17 - Gel SDS-PAGE 8,5% of S. enteritidis 104 and S. enteritidis 5048. 
1. S. enteritidis 104 – growth in agar; 2. S. enteritidis 104 – growth in broth; 3. Marker – Pre-stained 
SDS-PAGE standards Broad Range (kDa), Bio-Rad; 4. S. enteritidis 5048 – growth in agar; 5. S. 
enteritidis 5048 – growth in broth. 
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1.2 Role of antibiotic-promoted stress 
1.2.1  Step-wise increasing concentrations of antibiotic 
 
It was previously shown that exposure of E. coli to stepwise increases in tetracycline 
concentrations induces resistance from 2.0 mg/L to 12 mg/L of TET (37). 
Accompanying this induced resistance are significant increases in resistance to many 
other antibiotics and non-antibiotic agents. Similarly exposure of M. tuberculosis 
sensitive to isoniazid (INH) to increasing concentrations of this antibiotic increases the 
MIC from 0.2 mg/L to more than 40 mg/L (205). However, increased resistance to INH 
was not accompanied by resistance to any other drug employed for the therapy of 
pulmonary tuberculosis.  
If it is assumed that events at the level of the bacterial cell envelope that result in 
increased efflux pump activity are independent of a chromosomal mutation that confers 
high-level resistance of the bacterium to a given antibiotic, then prolonged exposure of 
that bacterium to increasing concentrations of the antibiotic to which it is resistant may 
induce the appearance of an MDR type efflux pump. Similar experiments were done 
with a Methicillin-resistant Staphylococcus aureus (MRSA).  
MRSA COL strain whose resistance to 400 mg/L oxacillin (OXA) is due to the acquired 
mecA element (60) was exposed to stepwise increasing concentrations of OXA ranging 
from 50 mg/L to 3200 mg/L and at each level of increased resistance to OXA, a parallel 
increase of resistance to ERY was evident as demonstrated by Table 2. The increased 
resistance to ERY could be completely eliminated by the addition of 40 mg/L of RES to 
the culture (Table 2).  
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Table 2 - Minimum Inhibitory concentration of erythromycin for MRSA COL strain during the 
adaptation passages in increasing concentrations of oxacillin. 
Inducing resistance of methicillin-resistant Staphylococcus aureus COL strain to erythromycin (ERY) by 
prolonged exposure to increasing concentrations of oxacillin (OXA), and reversal of ERY resistance by 
the efflux pump inhibitor reserpine (RES) 
OXA (mg/L) 
MIC (mg/L) 
ERY ERY + 40 mg/L RES 
0 <0.4 <0.4 
50 <0.4 <0.4 
100 <0.4 <0.4 
200 1.0 <0.4 
400 1.0 <0.4 
800 4.0 <0.4 
1600 >16.0 <0.4 
3200 30 <0.4 
 
Kirby–Bauer susceptibility assays showed that the strain that had been adapted to 1600 
mg/L OXA produced resistance to KAN, AMC, ofloxacin (OFX), norfloxacin (NOR) 
and RIF (Table 3).  
Table 3 - Changes in sensitivity to other antibiotics as determined by the Kirby–Bauer 
susceptibility assay after adapting Staphylococcus aureus COL strain to 1600 mg/L oxacillin 
 
Zone of inhibition (mm) 
KAN 
(30µg) 
AMC 
(30µg) 
OFX 
(5µg) 
NOR 
(10µg) 
RIF 
(5µg) 
ERY 
(15µg) 
Before exposure to OXA 27 13 29 28 36 32 
After exposure to OXA 0 0 0 0 29 0 
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1.2.2  Serial passages in the same concentration of antibiotic 
 
In the previous experiment it was seen that a strain initially resistant to an antibiotic 
when exposed to increasing concentrations of that antibiotic promotes the acquisition of 
resistance to other antibiotics. The next question asked was “What happens in terms of 
resistance profile if a strain was maintained at the same concentration of antibiotic to 
which it was adapted?” The chosen strain for the answering of this question was the E. 
coli AG100TET8. This strain presents an MDR phenotype after the adaptation procedure 
that was mediated by the over-expression of the AcrAB efflux system as well as by an 
increase in the expression of genes that code for AcrB, AcrF and other transporters as 
well as regulators soxS, rob, marA, marB and ompX (65). This strain was chosen 
because initially it was not resistant to the antibiotic, which is not the case of the MRSA 
COL which due to the acquisition of the mecA element has extremely high resistance to 
a beta-lactam (60). With respect to the E. coli AG100TET8 strain, adaptation to 
tetracycline was solely due to over-expression of genes that control the permeability of 
the organism to noxious agents and not due to any mutation (65). Resistance of this 
strain to tetracycline as well as to the antibiotics that contributed to its MDR phenotype 
could be reversed by transfer to drug free medium or by the addition of an agent that 
competes with an AcrAB substrate such as PAβN (37;206) or an inhibitor of an efflux 
pump such as thioridazine or chlorpromazine (37). Serial passage of the E. coli 
AG100TET8 in medium containing the same concentration of antibiotic, 10 mg/L of 
tetracycline, resulted in increase of the MIC of tetracycline from 10 to over 200 mg/L 
(181). This strain now named E. coli AG100TET10 was evaluated for its response to 
PAβN and noted that after the 10th serial passage in medium containing 10 mg/L of 
tetracycline, the resistance to tetracycline could not be altered.  
Table 4 - The effect of serial exposure of the E. coli AG100TET8 strain to 10 mg/L of tetracycline on 
the MIC of this antibiotic. 
 AG100TET8 AG100TET10 
Passage number 1 10 20 30 40 50 60 
E-Test MIC 10 64 64/96 96 96/128 128 256 
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The activity of the global regulator genes and genes that code for the transporters of 
eight efflux pumps of the E. coli AG100TET8 and E. coli AG100TET10 relative to those of 
the E. coli AG100 un-exposed to tetracycline was accessed by real time Reverse 
Transcription polymerase chain reaction (rtRT-PCR) (37;65). The results showed that, 
whereas the activity of the regulators marA and ompX, stress genes rob and soxS and the 
transporter genes acrB and acrF of the E. coli AG100TET8 strain were significantly 
elevated, those of the E. coli AG100TET10 were practically identical to the ones of the 
wild type E. coli AG100 strain suggesting that the resistance of the E. coli AG100TET10 
strain was not mediated by the efflux pumps of that strain.  
Evaluation of the E. coli AG100TET8 and E. coli AG100TET10 strains for resistance to 
other antibiotics (ex. ampicillin, ciprofloxacin, norfloxacin, nalidixic acid, streptomycin, 
etc.) demonstrated that both strains were resistant to these antibiotics and therefore 
maintained a MDR phenotype. These results were confirmed by evaluation of 
phenotypic resistance of the E. coli AG100TET8 and E. coli AG100TET10 strains by 
micro-array relative to that of the wild-type E. coli AG100 (gently performed by 
Fanning and co-workers, Ireland). Briefly, increased resistance to antibiotics that target 
the cell envelope, gyrase and the ribosome is shown for the E. coli AG100TET8 strain; 
resistance to these antibiotics is even greater for the E. coli AG100TET10 strain (Table 5).  
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Table 5 - Phenotypic Array evaluation of E. coli AG100TET8 and E. coli AG100TET10 strains. 
 
Test Increase in TDRU*1 Class of antibiotic and target 
 TET8 TET10  
Lomefloxacin 
Enoxacin 
Ofloxacin 
Norfloxacin 
Ciprofloxacin 
 
19450 
40488 
18895 
20519 
21984 
 
41154 
44797 
21316 
21240 
21352 
 
fluoroquinolone, DNA unwinding  
(gyrase and topoisomerase) 
 
Nalidixic acid 
Oxolinic acid 
Cinoxacin 
Pipemidic Acid 
 
36125 
19749 
38867 
19522 
 
41336 
21048 
40375 
21029 
 
quinolone, DNA unwinding  
(gyrase and topoisomerase) 
 
Kanamycin 
Sisomicin 
Tobramycin 
 
18700 
19532 
21158 
 
20991 
21523 
22107 
 
aminoglycoside, protein synthesis  
(30S ribosomal subunit) 
 
Chlortetracycline 
Demeclocyline 
Penimepicycline 
Rolitetracycline 
Oxytetracycline 
 
18629 
41074 
18013 
38366 
20910 
 
21997 
45607 
20270 
40913 
20558 
 
tetracycline, protein synthesis  
(30S ribosomal subunit) 
 
Geneticin (G418) 
 
20325 
 
21749 
 
aminoglycoside, protein synthesis 
 
Doxycycline 
 
19558 
 
20840 
 
tetracycline, protein synthesis 
 
Cefazolin 
Cephalothin 
 
19308 
19623 
 
22623 
23278 
 
1st generation cephalosporin, cell wall  
 
Cefuroxime 
 
20110 
 
22397 
 
2nd generation cephalosporin, cell wall 
 
Cefotaxime  
Cefoperazone 
 
58973 
60936 
 
61403 
60582 
 
3rd generation cephalosporin, cell wall  
 
Amoxicillin 
Cloxacillin  
Nafcillin  
Oxacillin  
Carbenicillin  
Aztreonam  
Phenethicillin 
19914 
40098 
19322 
37677 
41948 
20157 
40768 
23548 
44947 
21372 
41972 
45618 
20760 
40166 
β-lactam, cell wall  
 
  
                                                 
1 TDRU, tetrazolium dye reduction units, the increase in the area under the kinetic plot in comparison to 
the wild-type parent strain AG100 is given; an increase of ≥20,000 TDRU is considered significant. The 
highlighted TDRUs are highly significant and suggest high resistance to the corresponding agents. 
Results 
2. pH and energy roles on efflux by Gram-negatives 
 
E. coli AG100 and its progeny E. coli AG100TET8 were previously characterized for 
alteration in the expression of regulator and transporter coding genes during the 
adaptation process. These genes collectively control the permeability of the organism to 
noxious agents such as antibiotics, biocides and detergents (65). In addition, although 
genes that code for porins remain at the level of the unexposed control, the amount of 
porins retrieved from cells during the adaptation process decreased (37;65). The 
decrease was hypothesised to be due to the increase of proteases that degraded the 
OMPs prior to their assembling into the porin unit (37;65). Based upon the previous 
findings and relating the membrane alterations when a bacterium is exposed to a 
noxious agent and the genetic response towards this exposure, attention was now 
focused on the role of pH and energy in these responses, using a real-time assay to 
quantify and compare the efflux activity in the adapted and parental strains. 
The evaluation of influx and efflux of an AcrAB efflux pump substrate such as ethidium 
bromide (EB) was conducted by the method described by Viveiros et al. (187). EB is a 
common substrate of efflux pumps  (207-209) and does not affect the cell viability or 
cellular function at the concentrations used in the assay. The signal of the EB inside the 
cell can be detected by real time fluorescence spectroscopy. It allows the assessment of 
the transport of the EB molecule across the cell membrane which results in fluorescence 
as a consequence of its increased concentration in the periplasm of the cell (187) 
(accumulation assays). The method also affords the evaluation of EB extrusion (efflux 
assays). It must be noted that the concentration of EB employed in this method does not 
produce fluorescence by its presence in the medium. 
The method provides assessment of influx and efflux on a real-time basis. Moreover, it 
can be readily used for the simulation of physiological conditions that are known to 
affect permeability, accumulation and efflux. The application of the EB method to 
Gram-negative strains that differed with respect to the degree of efflux pump expressed 
afforded the characterization of these strains at the level of their capacity to extrude the 
fluorochrome substrate EB.  
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The conventional assay employed by others involves the fluorometric analyses of EB 
retained at pH 7, at room temperature and buffer without an energy source (210). This 
method does not approach physiological conditions that are known to affect the efflux 
apparatus of a Gram-negative bacterium. To correlate in vivo responses to antibiotic that 
involve extrusion the assay should be conducted at 37ºC, with metabolic energy and an 
ionic strength of the medium that corresponds to that of the medium in which the 
organism is cultured. In the work to be described, the accumulation and efflux assays 
were first conducted at 37ºC, pH 7.4 in the presence and absence of metabolic energy.  
 
2.1 Role of glucose  
 
Glucose was used in the assays as an energy source (Figure 18). Because the importance 
of metabolic energy has not been explored by the use of the conventional EB assays, its 
role will be focused on the Discussion Section. Nevertheless, because the cells will face 
starving conditions in an EB type of assay will also place the organism under stress, the 
presence of glucose will restore the osmotic conditions and provide the cell a carbon 
(energy) source needed for the maintenance of a proton motive force (PMF) energy 
source of protons that drive the RND efflux pump of the Gram-negative bacterium 
(211;212). The PMF, proton gradient and concentration of protons on the surface of the 
cell and in the periplasm will be subjects discussed in the Discussion Section. 
The influence of glucose on the accumulation of EB by E. coli AG100 and the adapted 
to tetracycline strain E. coli AG100TET8 at pH 7 can be seen by Figure 18. The strains 
were incubated in the presence of EB, with and without glucose, during 30 min and the 
fluorescence was recorded during that period. In the presence of glucose both strains 
present less fluorescence. However, the curves have similar behaviour in both 
conditions. The accumulation of EB by the parental strain E. coli AG100 is 
comparatively higher and constant than for the adapted strain, E. coli AG100TET8, whose 
efflux systems are over-expressed.  
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Figure 18 - The effect of glucose on the accumulation of EB by E. coli AG100 (A) and E. coli 
AG100TET8 (B). 
 
A variation of the experiment of Figure 18 was done to evaluate the influence of 
glucose on the efflux of EB as shown by Figure 19. Firstly, accumulation of EB was 
permitted in the absence of glucose. Secondly, the instrument is paused and additions of 
glucose-free saline and glucose containing saline were made, and the instrument re-
started. Whereas the addition of glucose-free saline blank does not affect the rate of 
increased fluorescence, the addition of glucose containing saline immediately reduces 
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fluorescence to a basal level. This reduction of fluorescence is due to the presentation of 
metabolic energy needed by the efflux pump system of the cell, without which efflux of 
EB cannot take place. A description of this efflux assay may be found at Section 1.4.2 
of Materials and Methods.  
 
0
5
10
15
20
25
30
0 5 10 15 20 25 30 35 40
Fl
uo
re
sc
en
ce
 (
ar
bi
tra
ry
 u
ni
ts
)
Time (min)
without glucose with glucose
0
5
10
15
20
25
30
0 5 10 15 20 25 30 35 40
Fl
uo
re
sc
en
ce
 (
ar
bi
tr
ar
y 
un
its
)
Time (min)
without glucose with glucose
A. E. coli AG100
B. E. coli AG100TET8
Additions
Additions
 
Figure 19 - The effect of glucose on the efflux of EB by E. coli AG100 (A) and E. coli AG100TET8 (B). 
Accumulation of EB in glucose-free saline for 25 minutes. Instrument is stopped and glucose-free and 
glucose-saline is added and the instrument restarted. 
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Because glucose is vital for the function of the efflux pump system of E. coli, all of the 
EB assays to be described were done in the presence and absence of glucose. 
 
2.2 Role of pH 
 
Efflux of antibiotics by bacteria is performed by a variety of transporters that use 
different energy sources to pump the noxious compounds out of the cell. This variety of 
efflux pumps ensures the survival of the bacterium in widely diverse media. For 
example bacteria that colonize the human digestive tract need to survive the exposure to 
noxious agents such as toxic bile salts (ex: duodenum and colon) (213).  
The ingestion of food containing a Gram-negative or positive bacterium that 
subsequently results in the colonisation of the colon means that the bacterium needs to 
successfully pass portions of the gastro-intestinal tract that present noxious agents in a 
milieu that differs widely in pH. Obviously, because the organism does colonise the 
colon, passage through the gastro-intestinal tract does not pose a problem. Moreover, it 
is known that wide ranges of pH do not alter the PMF of bacteria (54). Thereby 
assuming that efflux dependent upon the PMF will not be affected by pH, the question 
of whether pH modifies the efflux pump activity when the organism is under stress 
imposed by a noxious agent has not been asked before. This question has been 
investigated and answered in this thesis. The modulation of accumulation and efflux of 
EB by E. coli AG100 and E. coli AG100TET8 by pH and glucose is described below.  
Firstly, as evident by Figure 20, whereas no significant accumulation of EB during the 
first 25 minutes takes place in absence of glucose, at pH 8 the degree of accumulation is 
inversely dependent upon metabolic energy. At pH 5 the addition of glucose or its 
absence does not affect efflux. 
Efflux of EB at pH 8 needs metabolic energy as it is illustrated with the addition of 
glucose to the cells after 25 minutes of accumulation of EB in glucose free-saline and 
pH 8. The addition of glucose-saline pH 8 causes fluorescence to drop to that initially 
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present during the accumulation period of the assay. The addition of glucose-free saline 
at pH 8 does not produce a drop of fluorescence and the rate of EB accumulation noted 
in the absence of glucose during the accumulation phase is maintained. Because of the 
dependence on metabolic energy for extrusion of EB, these results suggest that the 
intrinsic efflux pump system of the E. coli AG100 strain that is operating at pH 8 is one 
of an ABC superfamily type (214). At pH 5, the glucose does not have effect on the 
efflux suggesting that at this pH of 5 the PMF is the driving force for efflux. 
Similar results were obtained with the E. coli AG100TET8 strain that over-expresses the 
AcrAB efflux pump as compared to its parent E. coli AG100 (37;65). As evident by 
Figure 20B, glucose is needed for efflux of EB at pH 8 but plays no role at pH 5. 
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Figure 20 - The effect of pH and the need for metabolic energy for efflux of EB by E. coli AG100 
(A) and E. coli AG100TET8 (B). 
Accumulation of EB in glucose-free saline at pH 5 and 8 for 25 minutes. Instrument is stopped and 
glucose-free and glucose-saline pH 5 and 8, respectively, is added and the instrument restarted.  
 
The accumulation of EB by cells grown in MHB of pH 5, 7 and 8 was conducted in 
order to determine if growth conditions would affect the accumulation and efflux of EB 
at varying pH of the assay. As evident by the example presented by Figure 21, cells 
grown in MHB of pH 8 when assayed for accumulation at pH 5, 7 and 8 in presence and 
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absence of glucose yielded the same data as if the cells had been grown at pH 5 or 7. 
These results were similarly obtained with cells grown at pH 5 or 7 and evaluated for 
accumulation at pH 5, 7 and 8 (data not shown). It can be conclude from these 
experiments that the accumulation and efflux of EB is primarily regulated by the pH of 
the assay and the presence/absence of glucose and not by the pH of the medium in 
which they had been cultured. 
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Figure 21 – Accumulation of EB in glucose and glucose free media pH 5, 7 and 8 by E. coli AG100.  
E. coli AG100 cells were grown at pH 8 and, then, submitted to different pH during the assay. 
 
2.3 Role of efflux modulators 
 
Some efflux modulators, commonly called EPIs (efflux pump inhibitors), were also 
tested in order to evaluate the efflux of EB by the parental and their MDR progeny. The 
modulators used were the proton un-coupler carbonyl cyanide m-
chlorophenylhydrazone (CCCP), Phe-Arg-beta-naphtylamide (PAβN), verapamil 
(VER) and phenothiazines (thioridazine (TZ) and chlorpromazine (CPZ)). 
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2.3.1 CCCP 
 
The demonstration of an RND type efflux pump of a Gram-negative is usually 
conducted with the un-coupler of the proton motive force CCCP at pH 7 and in the 
absence of metabolic energy. Given the demonstration that at pH 8 metabolic energy 
optimizes efflux, the activity of varying concentrations of CCCP at pH 5 and 8 on the 
efflux of EB after the fluorochrome has accumulated in the absence of glucose has been 
studied and the results obtained described by Figure 22 for the E. coli AG100 and E. 
coli AG100TET8 that over-expresses its AcrAB efflux pump (37;65).  
At pH 5 and 8 the addition of CCCP prevents efflux and increases the rate and extent of 
accumulation of EB by E. coli AG100 and E. coli AG100TET8 in a concentration 
dependent manner. However, whereas at pH 8 a very low concentration of CCCP 
produces a very steep increase of EB retained (efflux is inhibited) at pH 5 a far greater 
concentration of this agent is needed for a similar retention of EB (Figure 22A and 
Figure 22B).  
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Figure 22 – Effect of CCCP concentrations on efflux of EB by E. coli AG100 (A) and E. coli 
AG100TET8 (B) at pH 5 and 8.  
The same protocol of accumulation was followed as for Figure 20. After 25 minutes, saline with glucose 
and CCCP was added to the tubes. The control without CCCP and without glucose is also presented. 
 
Slopes of EB accumulation in the first 25 minutes are presented in Table 6 and  Table 7 
presents the slopes of increased accumulation (amount of increased fluorescence per 10 
minutes after the addition of varying concentrations of CCCP) for both parental and its 
MDR progeny. Comparing the difference in slopes between the period of accumulation 
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and the period after additions, it is observed that, at pH 5 and for both strains, they are 
maintained with no considerable difference (as observed also in the graph of Figure 22) 
when in absence of CCCP and without glucose. The same occurred when glucose is 
added to E. coli AG100. However for E. coli AG100TET8 the addition of glucose 
promotes efflux at both pH. At pH 8 this is also observed for the E. coli AG100.  
When CCCP is added, even in presence of glucose, the slopes increase for both strains 
at both pH 5 and 8 providing evidence of increased accumulation due to reduction of 
efflux activity. However this increase is greater at pH 8 than at pH 5. At pH 5 the effect 
of CCCP is similar for the E. coli AG100 and E. coli AG100TET8. At pH 8 the MDR 
strain is more affected by the addition of CCCP than the E. coli AG100 strain as evident 
by the difference in the slope of accumulation. 
Table 6 – The slopes (rates) of EB accumulation by E. coli AG100 and E. coli AG100TET8. 
Conditions of accumulation Slope (fluorescence/min) 
pH glucose CCCP (mg/L) E. coli AG100 E. coli AG100TET8 
5 without 0 0.09 0.21 
8 without 0 0.46 0.31 
 
Table 7 – Slopes of EB accumulation / Efflux after the addition of CCCP (Figure 22). 
Conditions of efflux Slope (fluorescence/min) 
pH glucose CCCP (mg/L) E. coli AG100 E. coli AG100TET8 
5 
without 0 0.02 0.34 
with 0 0.02 -0.09 
with 2.5 0.67 0.48 
with 5 1.18 1.41 
8 
without 0 0.23 0.53 
with 0 0.23 -0.06 
with 2.5 2.18 3.83 
with 5 2.52 4.13 
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2.3.2  PAβN 
 
PAβN has been used to reveal the presence of efflux pump activity in Gram-negative 
bacteria. In this case PAβN is considered as an inhibitor of RND type of efflux pumps. 
Considering the previous results that the efflux of EB at pH 5 is independent of 
metabolic energy and dependent upon the PMF, this compound should, then, inhibit the 
efflux of EB at pH 5. However, previous studies suggested that PAβN is not an inhibitor 
of an efflux pump but rather a competitor of other efflux pump substrates for extrusion 
(65;215). Preferential extrusion of PAβN would result in an increasing of concentration 
of the antibiotic which eventually reaches an active concentration against the organism.  
Previous studies showed that PAβN affects the accumulation of EB in a concentration 
dependent manner at pH 7 but do not have an effect in the efflux of EB by the strain E. 
coli AG100 (187). 
In this study was observed the effect of PAβN in the accumulation of EB by the parental 
and MDR E. coli strains at pH 5 and pH 8. Addition of PAβN has no effect on the 
efflux of EB neither at pH 5 nor at pH 8, as presents on Figure 23 for E. coli AG100. It 
is visible that the efflux is only affected by the presence of glucose. 
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Figure 23 - Effects of PAβN on efflux of EB by E. coli AG100 at pH 5 and 8. 
The same protocol of accumulation was followed as for Figure 20. After 25 minutes media with glucose 
and PAβN was added to the tubes.  
 
Based on the accumulation results and because PAβN has no effect on efflux of EB, it 
was considered the hypotheses of competition between PAβN and EB. If PAβN 
competes with EB, as the concentration of PAβN is increased more EB would be 
expected to accumulate, as it was observed. In that situation a derivation of a Km for 
PAβN relative to EB at pH 5 should be possible. pH 5 was chosen because at this pH 
metabolic energy is not needed. Moreover, the dissociation constant of EB from the 
AcrB transporter is lowest at pH 5 (216), a condition that is necessary for continuous 
efflux of EB.  
As described by the Figure 24, as the concentration of PAβN is increased from 1 to 40 
mg/L, the amount of EB accumulation by E. coli AG100TET8 is proportionately 
increased.  
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Figure 24 - Effects of different concentration of PAβN on efflux of EB by E. coli AG100TET8 at pH 5 
and 8. 
 
Employing Michaelis-Menten formulae, the Km for PAβN representing competition 
between PAβN and EB was calculated and obtained the value of 4.21 mg/L (Figure 25). 
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Figure 25 - Competition between EB and PAβN: calculation of Km for PAβN relative to EB. 
Increasing concentrations of PAβN from 1 to 40 mg/L caused increase of fluorescence (A). This data was 
then used for the derivation of the PAβN Km initially plotted by (B) and data employed in the 
Lineweaver-Burk plot (C). 
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2.3.3  Verapamil 
 
Verapamil inhibits ABC transporters of S. aureus (217) and mycobacteria (218). 
However, there is little information regarding the effects of verapamil on efflux activity 
of a Gram-negative such as E. coli. Considering the possibility that the study of agents 
for inhibitory activity against efflux pumps is always conducted at neutral or near 
neutral pH, and because at pH 8 efflux of EB by E. coli is dependent upon metabolic 
energy, suggesting the involvement of an ABC type transporter, the effects of 
concentrations of verapamil on efflux of EB were evaluated. 
As evident from Figure 26, and consistent with previously presented data, at pH 8 efflux 
of EB is dependent upon the presence of metabolic energy. The addition of verapamil in 
the absence of glucose, promotes a concentration dependent inhibition of efflux which 
causes proportional increases in the accumulation of EB. The inhibitory effect on efflux 
by verapamil is significantly decreased when metabolic energy is present. 
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Figure 26 - The effects of concentrations of verapamil on the efflux of EB by E. coli AG100 at pH 8. 
 
110 
Results 
2.3.4 Phenothiazines 
 
Phenothiazines are calcium channels inhibitors and have been evaluated for EPI activity 
by other authors (20;152;154). Because calcium plays a crucial role in cell signalling 
and transport activity of the cell, the phenothiazines thioridazine and chlorpromazine 
were used in this study to observe their effect on accumulation and efflux of EB. As 
evident from Figure 27 and Figure 28, TZ and CPZ increase the accumulation of EB in 
a concentration dependent manner; CPZ promotes a much greater effect than TZ on the 
accumulation of EB. The accumulation of EB by E. coli AG100 is more influenced by 
the presence of these phenothiazines than the adapted strain. However, because higher 
concentrations of CPZ are needed to increase EB accumulation by the E. coli 
AG100TET8 strain, one may conclude that this result is due to the over-expressed AcrAB 
transporter of this MDR strain. Similar results were obtained with the addition of CPZ 
and TZ in the presence and absence of glucose (Figure 29 and Figure 30). 
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Figure 27 - Accumulation of EB by E. coli AG100 (A) and E. coli AG100TET8 (B) at pH 7 and in the 
presence and absence of glucose and different concentrations of CPZ.  
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Figure 28 - Accumulation of EB by E. coli AG100 (A) and E. coli AG100TET8 (B) at pH 7 and in the 
presence and absence of glucose and different concentrations of TZ. 
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Figure 29 - Efflux of EB by E. coli AG100 (A) and E. coli AG100TET8 (B) at pH 7 and in the presence 
and absence of glucose and different concentrations of CPZ. 
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Figure 30 - Efflux of EB by E. coli AG100 (A) and E. coli AG100TET8 (B) at pH 7 and in the presence 
and absence of glucose and different concentrations of TZ. 
  
Because it was already observed that pH plays an important role in the efflux 
characteristics of these strains, the effects of TZ on efflux was also studied at pH 5 and 
pH 8 (Figure 31 and Table 8). As shown by this figure 15 mg/L of TZ influences the 
efflux of EB at both pH. However, this effect is significantly greater with E. coli AG100 
than that with E. coli AG100TET8 (Table 8). The effect of TZ on the efflux is also 
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dependent on the presence of glucose as was observed with the accumulation assays. 
Similar results were obtained with CPZ.  
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Figure 31 - Efflux of EB by E. coli AG100 at pH 5 and 8, in the presence and absence of glucose and 
different concentrations of TZ. 
 
Table 8 - Slopes of EB accumulation / Efflux after the addition of TZ by E. coli AG100 (Figure 31) 
and E. coli AG100TET8. 
Conditions of efflux Slope (fluorescence/min) 
pH glucose TZ 
(mg/L) 
E. coli AG100 E. coli AG100TET8 
5 
without 0 0.118 0.144 
with 0 0.026 0.192 
without 15 0.057 0.209 
with 15 0.212 0.259 
8 
without 0 0.264 0.342 
with 0 0.258 0.162 
without 15 0.426 0.956 
with 15 1.927 0.352 
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2.4  Role of Calcium 
 
Phenothiazines such as CPZ and TZ inhibit the binding of Ca2+ to enzymes involved in 
furnishing energy from the hydrolysis of ATP (154). Ca2+ plays a crucial role in the 
biochemical pathways of the cell and is of extreme importance for cell signalling, for 
the membrane transport channels and for activity of some type of ATPases, as well 
(219;220). Because, as shown by the previous section, the phenothiazines CPZ and TZ 
have major effects on the accumulation and efflux of EB, and these effects are modified 
by metabolic energy, the role of Ca2+ in the modulation of EB accumulation and efflux 
was evaluated. Because CPZ has a greater effect on accumulation of EB by the E. coli 
AG100 strain, CPZ will be used in the study of the role of Ca2+ on the efflux of EB by 
this strain. Moreover, because EDTA is a chelating agent and has the ability to 
"sequester" metal ions such as Ca2+ and Fe3+, this agent was also used in the 
experiments described below to study the role of Ca2+.  
The results obtained are presented by Figure 32 and Figure 33. At pH 8 the amount of 
EB accumulated inside the cell is glucose dependent (metabolic energy) and greater 
than at pH 5. At pH 8, CPZ enhances the retention of EB, especially with the omission 
of glucose. The CPZ promoted retention of EB at pH 8 can be nullified by the addition 
of calcium to the medium. The role of calcium in the accumulation and efflux of EB is 
further illustrated with the addition of EDTA, which by binding the calcium that is 
present, promotes the increase of EB retained. The addition of calcium to an EDTA 
containing medium nullifies the accumulation of EB promoted by EDTA. The 
simultaneous presence of CPZ and EDTA synergistically increases accumulation of EB. 
At pH 5 the effects of CPZ, EDTA and calcium are minimal on the accumulation and 
efflux of EB.  
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Figure 32 – Calcium role on the efflux of EB by E. coli AG100 at pH 5.  
Accumulation was done in saline pH 5 (■), saline pH 5 with 5mM EDTA (▲), saline pH 5 with 5mM 
CaCl2 (♦) and (A) without 25 mg/L CPZ and without glucose, (B) without 25 mg/L CPZ and with 0.4% 
glucose, (C) with 25 mg/L CPZ and without glucose, (D) with 25 mg/L CPZ and with 0.4%glucose. 
Addition of saline free pH 5, saline pH 5 with 5mM CaCl2 and saline pH 5 with 5mM EDTA were made 
after 10 minutes of accumulation of EB, in medium as defined above, and identified by the legend of the 
graphs A, B, C and D. 
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Figure 33 – Calcium role on the efflux of EB by E. coli AG100 at pH 8.  
Accumulation was done in saline pH 8 (■), saline pH 8 with 5mM EDTA (▲), saline pH 8 with 5mM 
CaCl2 (♦) and (A) without 25 mg/L CPZ and without glucose, (B) without 25 mg/L CPZ and with 0.4% 
glucose, (C) with 25 mg/L CPZ and without glucose, (D) with 25 mg/L CPZ and with 0.4%glucose. 
Addition of saline free pH 8, saline pH 8 with 5mM CaCl2 and saline pH 8 with 5mM EDTA were made 
after 10 minutes of accumulation of EB, in medium as defined above, and identified by the legend of the 
graphs A, B, C and D. 
 
The slopes corresponding to Figure 32 and Figure 33 are presented by Table 9 and 
Table 10, respectively, in order to provide a more easily observed comparison between 
the effects resulting from conditions in the medium and additions made. 
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Table 9 - Slopes of EB accumulation / efflux corresponding to the different conditions and influence 
of CPZ, Calcium and EDTA at pH 5. 
Conditions of accumulation 
Slope 
(fluorescence/min) 
Conditions of 
efflux Slope 
(fluorescence/min) 
pH glucose 
CPZ 
(mg/L) 
EDTA 
(mM) 
CaCl2 
(mM) 
EDTA 
(mM) 
CaCl2 
(mM) 
5 
without 0 0 0 0.012 
0 0 -0.004 
0 5 -0.032 
5 0 0.235 
5 5 -0.018 
without 0 5 0 0.381 
0 0 0.087 
0 5 -0.073 
without 0 0 5 0.029 
0 0 -0.012 
5 0 0.166 
without 25 0 0 0.134 
0 0 0.094 
0 5 -0.111 
5 0 1.468 
5 5 -0.118 
without 25 5 0 0.791 
0 0 0.622 
0 5 0.472 
without 25 0 5 0.033 
0 0 0.001 
5 0 0.693 
with 0 0 0 0.002 
0 0 0.024 
0 5 -0.026 
5 0 0.070 
5 5 0.057 
with 0 5 0 0.242 
0 0 0.051 
0 5 0.036 
with 0 0 5 0.036 
0 0 -0.004 
5 0 0.166 
with 25 0 0 0.108 
0 0 -0.001 
0 5 -0.059 
5 0 0.675 
5 5 0.232 
with 25 5 0 0.792 
0 0 0.717 
0 5 0.187 
with 25 0 5 0.033 
0 0 -0.004 
5 0 0.418 
 
NOTE.   Highlight in blue identifies significant effect produced on accumulation. 
 Highlight in red identifies compound that significantly reversed the inhibitory effect 
 produced on accumulation by an agent in the medium. 
 Highlight in green identifies compound that significantly enhanced the inhibitory effect 
 produced on accumulation by an agent in the medium.  
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Table 10 - Slopes of EB accumulation / efflux corresponding to the different conditions and 
influence of CPZ, Calcium and EDTA at pH 8. 
Conditions of accumulation 
Slope 
(fluorescence/min) 
Conditions of 
efflux Slope 
(fluorescence/min) 
pH glucose 
CPZ 
(mg/L) 
EDTA 
(mM) 
CaCl2 
(mM) 
EDTA 
(mM) 
CaCl2 
(mM) 
8 
without 0 0 0 0.155 
0 0 0.119 
0 5 0.107 
5 0 1.290 
5 5 0.120 
without 0 5 0 1.172 
0 0 0.892 
0 5 0.542 
without 0 0 5 0.058 
0 0 0.088 
5 0 0.424 
without 25 0 0 3.149 
0 0 3.158 
0 5 2.980 
5 0 4.121 
5 5 2.183 
without 25 5 0 6.608 
0 0 4.639 
0 5 3.382 
without 25 0 5 0.608 
0 0 1.906 
5 0 4.403 
with 0 0 0 0.021 
0 0 0.037 
0 5 0.076 
5 0 0.241 
5 5 0.080 
with 0 5 0 0.674 
0 0 0.615 
0 5 -0.027 
with 0 0 5 0.077 
0 0 0.448 
5 0 0.233 
with 25 0 0 2.181 
0 0 0.756 
0 5 -0.248 
5 0 4.039 
5 5 2.085 
with 25 5 0 8.012 
0 0 2.708 
0 5 1.764 
with 25 0 5 0.223 
0 0 1.587 
5 0 2.956 
NOTE.   Highlight in blue identifies significant effect produced on accumulation. 
 Highlight in red identifies compound that significantly reversed the inhibitory effect 
 produced on accumulation by an agent in the medium. 
 Highlight in green identifies compound that significantly enhanced the inhibitory effect 
 produced on accumulation by an agent in the medium.  
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In the first part of this thesis it was gathered information about the antibiotic resistance 
mechanisms of bacteria and the physiological processes that influence and modulate 
resistance to antibiotics and to other noxious agents, namely it was studied the influence 
of the environment and growth conditions on the expression of outer membrane proteins 
of a bacterium, the effect of different conditions of antibiotic pressure on the over-
expression of efflux pumps, the role of efflux pump mediated resistance at different pH, 
the physiological contribution of metabolic energy, protons / proton motive force and 
ions such as calcium on the regulation of efflux activity and the activity of compounds 
which modulate efflux by interfering with key pathways of membrane stability and 
energy use. With this information and experimental procedures it was possible to design 
an effective strategy to search and detect new compounds isolated from plants that may 
modulate efflux mediated multi-drug resistance of bacteria. The focus of attention will 
be the plant Carpobrotus edulis. 
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3. Search for new active compounds against resistance 
3.1  Purification and identification of the compounds 
 
The different techniques used for the isolation of compounds from C. edulis are   
described in the Methods section. From that schematic procedure seven compounds 
were purified. 
After purification, the structures of compounds were determined by NMR spectroscopy. 
Their identification was done on the basis of one- and two-dimensional NMR studies, 
including 1H-NMR, JMOD, NOESY, HSQC and HMBC characterisation and the data 
obtained compared with that present in the literature for the same compounds (221-
229). 
Table 11 summarises the structure of the compounds, their common and International 
Union of Pure and Applied Chemistry (IUPAC) recommended names and also their 
molecular weight and chemical formula. The compounds purified, already described in 
the literature, have been isolated from other plants. However, this is the first time that 
they have been isolated and described from Aizoaceae family. Table 11 provides the 
references for the previous characterization and identification of these compounds. 
From the hexane/acetone fractions of the methanolic extraction four compounds were 
purified and characterised: β-amyrin (1), oleanolic acid (2), Uvaol (3) and 
Monogalactosyldiacylglycerol (acyls = linolenoyl group) (4). From the ethyl acetate 
fraction of the same extract three flavonoids were similarly isolated and characterised: 
catechin (5), epicatechin (6), and procyanidin B5 (7). 
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Table 11 - Structures of the isolated compounds from the methanolic extract of C. edulis. 
 Structure Characteristics Ref. 
1 
OH
 
IUPAC name 
(3S,6aR,6bS,8aS,11R,12aS,14aR,1
4bR)-11-(hydroxymethyl)-
4,4,6a,6b,8a,11,14b-heptamethyl-
1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-
tetradecahydropicen-3-ol 
(226) 
Common name β-amyrin 
Chemical formula C30H50O 
MW (g/mol) 426.72 
2 
OH
CO2H
 
IUPAC name 
(4aS,6aR,6aS,6bR,8aR,10S,12aR,1
4bS)-10-hydroxy-2,2,6a,6b,9,9,12a-
heptamethyl-
1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-
tetradecahydropicene-4a-carboxylic 
acid (223) 
Common name Oleanolic acid 
Chemical formula C30H48O3 
MW (g/mol) 456.70 
3 CH2OH
OH
 
IUPAC name 
(3S,4aR,6aR,6bS,8aS,11R,12S,12a
S,14aR,14bR)-8a-(hydroxymethyl)-
4,4,6a,6b,11,12,14b-heptamethyl-
2,3,4a,5,6,7,8,9,10,11,12,12a,14,14
a-tetradecahydro-1H-picen-3-ol (227;
229) Common name Uvaol 
Chemical formula C30H50O2 
MW (g/mol) 442.73 
4 
O
OHOH
OH
O
OH
O
O
O
O
 
IUPAC name 
[2-[(Z)-hexadec-7-enoyl]oxy-3-
[3,4,5-trihydroxy-6-
(hydroxymethyl)oxan-2-
yl]oxypropyl](9Z,12Z)-octadeca-
9,12-dienoate 
(228) 
Common name 
MGDG 
(Monogalactosyldiacylglycerol) 
(acyls = linolenoyl group) 
Chemical formula C45H74O10 
MW (g/mol) 774.53 
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 Structure Characteristics Ref. 
5 
O
OH
OH
OH
OH
OH
 
IUPAC name 
(2S,3R)-2-(3,4-dihydroxyphenyl)-
3,4-dihydro-2H-chromene-3,5,7-
triol 
(222;
224) 
Common name Catechin 
Chemical formula C15H14O6 
MW (g/mol) 290.27 
6 
O
OH
OH
OH
OH
OH
 
IUPAC name 
(2R,3R)-2-(3,4-dihydroxyphenyl)-
3,4-dihydro-2H-chromene-3,5,7-
triol 
(222;
224) 
Common name Epicatechin 
Chemical formula C15H14O6 
MW (g/mol) 290.27 
7 
O
OH
HO
OH
OH
OH
O
HO
OHHO
OH
OH
 
IUPAC name 
(2R,3R,4S)-2-(3,4-
dihydroxyphenyl)-4-[(2R,3R)-2-
(3,4-dihydroxyphenyl)-3,5,7-
trihydroxy-3,4-dihydro-2H-
chromen-6-yl]-3,4-dihydro-2H-
chromene-3,5,7-triol (225) 
Common name Procyanidin B5 
Chemical formula C30H26O12 
MW (g/mol) 578.52 
 
3.2  In vitro activity of the isolated compounds on bacteria 
 
The minimum inhibitory concentration (MIC) of each compound against pathogenic 
bacteria was determined in order to define the antibacterial activity of the isolated 
compounds2. A maximum concentration of compound of 200 mg/L was used. As shown 
by Table 12, the majority of the bacteria tested were resistant to more than 200 mg/L of 
each compound. Greater concentrations of the compounds were not tested because 
                                                 
2 Compound 7 (procianidin B5) was not included in the study due to timing reasons of its identification 
because of which it was not possible to test the compound before the end of this thesis. 
Results 
higher concentrations of these compounds would not be expected to have clinical 
significance as shown by other studies (16). 
The compound oleanolic acid was very active against E. faecalis with an MIC of 6.25. 
The same compound showed also moderate activity against the S. aureus strains that 
differed with respect to their antibiotic susceptibility pattern: MRSA COL, MRSA 
COLoxa and HPV 107. The latter two strains were also the most sensitive strains to all 
the compounds tested. Moreover, comparison of all the compounds tested, oleanolic 
acid had the greatest activity against the reference M. tuberculosis H37Rv strain.  
Because the methanolic extract of Carpobrotus edulis was previously shown not to have 
in vitro antibacterial activity against S. aureus nor M. tuberculosis strains but enhanced 
the killing of these bacteria post-phagocytosis (175;176), regardless of the presence or 
absence of in vitro activity, all the compounds were evaluated for ability to reduce or 
reverse resistance of pathogenic bacteria to antibiotics to which they were resistant as 
well as evaluated for activity on the efflux pump system of these bacteria by the semi-
automated EB method. These results will be described in the next section.  
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Table 12 – Minimum inhibitory concentration of C. edulis purified compounds on Gram-negative, 
Gram-positive and mycobacteria strains. 
Strain  β-amyrin Oleanolic acid Uvaol MGDG Catechin Epicatechin
E. coli AG100  >200 >200 >200 >200 >200 >200 
E. coli AG100TET8  >200 >200 >200 >200 >200 >200 
S. enteritidis 104  >200 >200 >200 >200 >200 >200 
S. enteritidis 104CIP  >200 >200 >200 >200 >200 >200 
S. enteritidis 5408  >200 >200 >200 >200 >200 >200 
S. enteritidis 5408CIP >200 >200 >200 >200 >200 >200 
E. faecalis ATCC 29212 >200 6.25 200 >200 >200 >200 
S. aureus ATCC 25923  >200 >200 >200 >200 >200 >200 
MRSA clinical strain  >200 >200 >200 >200 >200 >200 
MRSA COL  >200 50 200 200 >200 200 
MRSA COLoxa  200 25 100 50 100 100 
S. aureus HPV >200 25 200 50 >200 100 
M. tuberculosis H37Rv  >200 100 >200 >200 200 >200 
NOTE: significant MIC values are highlighted (bold) 
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3.3  Modulation of resistance in bacteria 
 
One of the approaches to find new therapies against multi-drug resistance is to search 
for compounds that increase the susceptibility of the organism to the antibiotics to 
which it is resistant. The use of such compounds as adjuvants results in a form of 
synergism which renders the inactive antibiotic active (138).  
The assays that evaluate the modulation of antibiotic resistance by a non-antibiotic are 
performed as follows: firstly, the MIC of each antibiotic to which the bacterium is 
resistant and the compound that is to be assayed for modulation of resistance is 
determined; secondly, the assay is repeated for each antibiotic at concentrations from its 
MIC to one that is deemed as “clinical susceptibility” in the absence and presence of a 
concentration of the non-antibiotic that has no effect on the growth of the bacterium. 
The concentrations chosen for each compound were equal to or less than one halve of 
their MIC. The results of this modulation assay are presented by Table 13 to Table 17. 
A minimum fourfold reduction of the MIC of an antibiotic by a given compound was 
considered significant and that value is highlighted in the tables.  
 
3.3.1 The modulation of antibiotic resistance of Gram-negative strains  
 
The ability of oleanolic acid, uvaol, and epicatechin to decrease resistance of E. coli 
AG100TET8 strain to tetracycline is described by Table 13. These compounds decreased 
the MIC of tetracycline from 25 to 6.25 mg/L. However, their activities were not equal 
inasmuch as the reduction of the MIC by some of these compounds required higher 
concentrations (example: the effective concentration of epicatechin was 100 mg/L as 
opposed to that of oleanolic acid which was 50 mg/L). With respect to oleanolic acid, 
the concentration of 50 mg/L apparently had reached a saturation of the target (efflux 
pump) such that higher concentrations of this compound would not increase its 
effectiveness.  
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Table 13 – Effect of compounds isolated from C. edulis on the MIC of tetracycline on E. coli 
AG100TET8. 
MIC (mg/L)   
Strain TET 
TET + Compound (mg/L) 
β-amyrin  Oleanolic acid Uvaol  MGDG Catechin Epicatechin 
50 100 50 100 50 100 50 100 50 100 50 100 
E. coli 
AG100TET8 
25  12.5 25 6.25 6.25 12.5 6.25 12.5 12.5 25 6.25 12.5 6.25 
 
Evaluation of the isolated compounds for reduction of the MIC of CIP against 
Salmonella strains resistant to ciprofloxacin demonstrated that significant reductions 
could be achieved only by uvaol, MGDG and epicatechin and only for the strain S. 
enteritidis 5408CIP (Table 14 and Table 15). It is important to note that S. enteritidis 
104CIP strain that has been induced to high level resistance to CIP is not affected by any 
of the compounds. Because resistance to CIP of this strain is the result of increased 
AcrB transporter, mutations in gyrase 1A and two-mutations in the stress gene soxS 
(202), the inability of the compounds to reduce resistance of the S. enteritidis 104CIP to 
CIP suggests that the mutated targets beyond the efflux pump itself, such as gyrase, are 
not sensitive to the isolated compounds.  
 
Table 14 – Effect of compounds isolated from C. edulis on the MIC of ciprofloxacin on S. enteritidis 
5408CIP. 
MIC (mg/L)   
Strain CIP 
CIP + Compound (mg/L) 
β-amyrin  Oleanolic acid Uvaol  MGDG Catechin Epicatechin 
50 100 50 100 50 100 50 100 50 100 50 100 
S. enteritidis 
5408CIP 
>50  25 50 25 25 6.25 6.25 6.25 12.5 25 25 12.5 12.5 
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Table 15 – Effect of compounds isolated from C. edulis on the MIC of ciprofloxacin on S. enteritidis 
104CIP. 
MIC (mg/L)   
Strain CIP 
CIP + Compound (mg/L) 
β-amyrin  Oleanolic acid Uvaol  MGDG Catechin Epicatechin 
50 100 50 100 50 100 50 100 50 100 50 100 
S. enteritidis 
104CIP 
>50  >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 
 
3.3.2 The modulation of antibiotic resistance of Gram-positive strains 
 
A methicillin resistant Staphylococcus aureus (MRSA) clinical strain was used to test 
the capacity of the C. edulis compounds to reduce the MIC of oxacillin, an antibiotic to 
which that strain is resistant. Resistance of MRSA to β-lactams is due to the acquisition 
of mecA, a genetic element that carries the resistant gene to this class of antibiotics 
(60;230;231). The origin of this genetic element remains unknown. Because the mecA 
element is known to be lost during the process of exposure to an antibiotic of a different 
class (232), the response of an MRSA strain such as the MRSA COL strain that is 
already resistant to 400 mg/L of oxacillin to increasing concentrations of a beta-lactam 
was studied in section 1.2.1 of the Results. In the present section, MRSA COL strain 
that had been induced to high level resistance to oxacillin (MIC > 1600 mg/L) was 
challenged with each of the compounds for the purpose of determining whether one or 
more compounds were able to reduce resistance of this strain to oxacillin. The results 
are presented in Table 16 and demonstrate that uvaol reduces the MIC of oxacillin. The 
ability of these compounds to have a similar effect on an MRSA clinical strain was 
studied and as noted by Table 17, none of the compounds reduce the MIC of oxacillin. 
These experiments show that the ability of any of the compounds isolated from 
Carpobrotus edulis to reduce the resistance of an MRSA strain to a given antibiotic 
depends upon the presence of an over-expressed efflux pump system, a system that has 
been induced in the MRSA COL when the organism was exposed to increasing 
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concentrations of a β-lactam (181) and is not over-expressed in the clinical MRSA 
strain studied.  
 
 Table 16 – Effect of compounds isolated from C. edulis on the MIC of oxacillin on MRSA COLOXA. 
 
 
Table 17 – Effect of compounds isolated from C. edulis on the MIC of oxacillin on MRSA clinical 
strain. 
MIC (mg/L)   
Strain OXA 
OXA + Compound (mg/L) 
β-amyrin  Oleanolic acid Uvaol  MGDG Catechin Epicatechin 
50 100 50 100 50 100 50 100 50 100 50 100 
MRSA  >500  >500 >500 >500 >500 >500 >500 >500 >500 >500 >500 >500 >500 
 
3.4 Activity on the accumulation of EB 
3.4.1 Gram-negative bacteria 
 
The semi-automated EB method affords the real time detection of the EB accumulation 
inside the cell by following the evolution of fluorescence of EB during a period of time. 
It can be used to evaluate a compound for the modulation of accumulation / efflux of 
                                                 
3 Minimum concentration of OXA used was 100 mg/L and no growth was observed for uvaol.  The 
results of the assay were read after 48h when the strain control also grow.  
MIC (mg/L) 
Strain OXA 
OXA + Compound (mg/L)3 
β-amyrin  Oleanolic acid Uvaol  MGDG Catechin Epicatechin 
50 100 10 25 50 12.5 25 25 50 25 50 
MRSA 
COLoxa 
1600 1600 1600 1600 <100 <100 1600 1600 1600 1600 1600 1600 
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EB. For this phase of the method, the modulating activity of the compound increases 
accumulation and decreases efflux of EB, presumably by having an effect, direct on the 
EP or otherwise on the activity of an efflux pumps system. Because of the multiplicity 
of efflux pumps in Gram-negative bacteria, one cannot at this time specify any given 
efflux pump as being the one that is affected. However, because the main efflux pump 
of Gram-negative bacteria such as E. coli and Salmonella is the AcrAB pump, and 
because for these bacteria representatives that have an over-expressed AcrAB pump are 
available at the laboratory, the results described may reflect the activity of any 
compound studied to primarily be one that affects the main efflux pump AcrAB (37;65). 
Employing this rationale, the semi-automated EB method has been used to screen for 
the activity of the purified compounds against the presumptive AcrAB efflux pump of 
E. coli strains that have been genetically characterised for the degree of expression of 
genes that regulate and code for the AcrB transporter (37;65;187). 
The strains used in this assay were the E. coli AG100 and the E. coli AG100TET8 as the 
main strains characterized in the first part of this dissertation, and are examples of 
susceptible and MDR Gram-negative strains, respectively. 
The effect of each compound on the accumulation and efflux of EB by E. coli strains 
was restricted to medium of pH 7.4. This pH was selected inasmuch as if the 
compounds are to serve an eventual clinical role for activity against E. coli that has 
colonised the colon, the pH under which they are to have activity in a physiological 
system is essentially one that is close to neutrality. 
The compounds catechin and epicatechin were the most effective compounds for 
increasing the accumulation of EB on the strain E. coli AG100 (Figure 34 and Figure 
35), and hence, assumed to inhibit the intrinsic efflux pump system of E. coli AG100. 
However, the effects of epicatechin and catechin on the accumulation of EB are 
inhibited by the presence of glucose. These two compounds do not affect the 
accumulation of EB by the MDR E. coli AG100TET8 strain at the concentrations used. 
The compound oleanolic acid had a modest effect on the accumulation of EB (Figure 
36) and this effect was also inhibited by glucose.  
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Figure 34 – Effect of catechin on the accumulation of EB by E. coli AG100 in presence and absence 
of glucose. 
 
 
Figure 35 – Effect of epicatechin on the accumulation of EB by E. coli AG100 in presence and 
absence of glucose. 
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Figure 36 – Effect of oleanolic acid on the accumulation of EB by E. coli AG100TET8 in presence and 
absence of glucose. 
 
In the efflux assay conducted at pH 7, the addiction of oleanolic acid or epicatechin 
promotes the accumulation of EB by inhibiting its efflux (Figure 37 and Figure 38). 
These compounds and catechin produced similar effects against the adapted strain E. 
coli AG100TET8 (Figure 39, Figure 40 and Figure 41). 
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Figure 37 - Effect of oleanolic acid on the efflux of EB by E. coli AG100 in presence and absence of 
glucose. 
 
 
Figure 38 - Effect of epicatechin on the efflux of EB by E. coli AG100 in presence and absence of 
glucose. 
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Figure 39 - Effect of oleanolic acid on the efflux of EB by E. coli AG100TET8 in presence and 
absence of glucose. 
 
 
Figure 40 - Effect of epicatechin on the efflux of EB by E. coli AG100TET8 in presence and absence 
of glucose. 
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Figure 41 - Effect of catechin on the efflux of EB by E. coli AG100TET8 in presence and absence of 
glucose. 
 
Similar assays were done with S. enteritidis 5408CIP strain but increase in the 
accumulation of EB by the strain in the presence of any of the compounds was not 
observed.  
 
3.4.2 Gram-positive bacteria 
 
Because it was observed that some of the compounds reduced the MIC of OXA against 
MRSA COL strain (see Section 1.2.1 of the Results), the EB accumulation assay was 
employed to see if these compounds could affect accumulation/efflux of EB by that 
strain. The MRSA strain used was the MRSA COL adapted to 1600 mg/L of oxacillin 
since it was this strain for which the MIC of OXA was reduced by some of the isolated 
compounds. Furthermore, the use of the EB assay would also provide an understanding 
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of the physiological conditions that could modulate any noted effect by the compounds 
on accumulation/efflux of EB.  
The compounds uvaol and MGDG increased accumulation of EB by the MRSA 
COLOXA in a glucose dependent manner. However, the glucose effect is opposite for the 
two compounds. Whereas in the presence of MGDG the strain MRSA COLOXA 
accumulates more EB in absence of glucose, in presence of uvaol accumulation takes 
place in the presence of glucose. The increase of EB accumulated by that strain is 
promoted by uvaol and is dependent upon metabolic energy. This is unusual and 
interesting because it suggests that, in order for uvaol to inhibit efflux, the penetration 
of this agent to the site of the efflux pump affected is regulated by an ATP type activity. 
This observation and its preliminary assumption are supported by a very recent report 
that shows that some agents that have activity against ATPases in turn reduce the 
energy needed for efflux (206). Access of uvaol to the plasma membrane sites where the 
efflux pump is situated is probably regulated by a putative ABC type influx transporter 
which is activated by the generation of ATP, a process primarily resulting from ATP 
synthase at a pH below 7 (206). Consequently, before uvaol has an opportunity to 
inhibit the efflux pump, it must first penetrate the cell envelope, and reach the plasma 
membrane situated efflux pump. This latter penetration is therefore postulated to be 
dependent upon metabolic energy. Further discussion on this new observation may be 
found in the Discussion section. 
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Figure 42 - Effect of uvaol on the accumulation of EB by MRSA COLOXA in presence and absence 
of glucose. 
 
 
Figure 43 - Effect of MGDG on the accumulation of EB by MRSA COLOXA in presence and 
absence of glucose. 
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3.5  Activity ex-vivo against S. aureus strains 
 
The methanolic extract of C. edulis was previously described as containing active 
compounds that increased the killing activity of macrophages infected with M. 
tuberculosis and S. aureus strains (175;176). As was the case for those previous studies 
(175;176), it was used the S. aureus strain model for the evaluation of the isolated 
compounds on the killing of these bacteria subsequent to their phagocytosed by non-
killing human macrophages.  
The results of this ex vivo assay, described in Section 4.4.4 of Materials and Methods, 
are presented as the percentage of CFUs retrieved from the cultures after 3 and 6 h of 
incubation in the presence and absence of the compounds. Results for S. aureus ATCC 
strain and MRSA are presented by Figure 44 and Table 18 and are the average of three 
independent experiments. 
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Figure 44 - Effect of the purified compounds from C. edulis on the increasing of the killing activity 
of macrophages infected with S. aureus strains. 
A. S. aureus ATCC; B. MRSA. The values correspondent to the data showed in the graphs are presented 
by Table 18. 
 
By the results presented it is shown that after three hours of the incubation of the 
macrophages infected with S. aureus ATCC strain did not increase its killing activity. 
However, the majority of the compounds enhanced the killing activity of the 
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macrophages after 6h. The compound catechin followed by oleanolic acid were the 
most active compounds against S. aureus ATCC strain, while uvaol and epicatechin 
were as active as the positive control thioridazine.  
When the macrophages were infected with the MRSA clinical strain the compounds 
catechin, epicatechin, and MGDG increased the killing activity of the macrophages as 
evident from a decrease in CFUs. However, after 6h, the most active compounds were 
uvaol, catechin, oleanolic acid and MGDG whose activity is compared to the TZ that 
serves as a positive control.  
 
Table 18 – Effect of the purified compounds from C. edulis on the increasing of the killing activity 
of macrophages infected with S. aureus strains. 
Macrophages infected with S. aureus ATCC and MRSA were treated with 1 mg/L of compound and 
disrupted after 3 and 6 hours. The bacterial cells where plated and the CFU counted after 24h of 
incubation. Relative percentages of CFU (CFUcompound / CFUcontrol x 100) are presented in this table. 
Relative percentage of CFU (%) 
Compound S. aureus ATCC MRSA 
3h 6h 3h 6h 
control 100 100 100 100 
TZ 119 85 232 57 
Oleanolic acid 136 55 85 80 
β-amyrin 226 95 242 64 
Catechin 145 35 24 77 
Epicatechin 135 86 45 78 
MGDG 1mg/L 201 119 39 41 
Uvaol 1mg/L 272 83 145 40 
 
Similar assays with M. tuberculosis H37Rv are still in progress and the results are not 
presented on this dissertation. 
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3.6  Activity on Eukaryotic cell lines 
 
Our previous studies, as well as those of others, have shown that some inhibitors of 
bacterial efflux pumps also inhibit the product of the mdr1 gene, the P-gp (195;233). 
Moreover it was previously observed that the methanol extract of C. edulis that 
enhanced the killing activity of infected macrophages was also able to reduce the P-gp 
activity and increase the amount of rhodamine 123 that was accumulated by the cancer 
cells that over-express that protein (176). Because some of the purified compounds from 
C. edulis have been shown in this thesis to inhibit the efflux system of pathogenic 
bacteria, these latter studies were extended to examine the capability of the purified 
compounds for inhibition of the P-gp transporter that is responsible for the resistance of 
the mouse lymphoma cell transfected with the human mdr1 gene. 
 
3.6.1  Anti-proliferative assays 
 
The anti-proliferative activity of the purified compounds on mouse lymphoma parental 
cells and human mdr1 transfected mouse lymphoma cells is summarised in Table 19. 
The data presented identifies the concentration of the compound that produces a fifty 
percent reduction of the replication of the respective parental and mdr1 transfected cells. 
Although all of the compounds reduced the proliferation of both parental and mdr1 
transfected cells, some compounds were more effective against the parental cells 
(oleanolic acid and uvaol) and others more effective against the mdr1 transfected cells 
(MGDG and epicatechin). It should be noted that in this study the parental cells are 
cancer cells and therefore, compounds that reduce the replication of these cells also 
merit attention. 
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Table 19 - Antiproliferative activity (IC50) of the compounds isolated from C. edulis 
Compound IC50 (mg/L) 
PAR MDR 
β-amyrin 11 10 
Oleanolic acid 10 21 
Uvaol 7 13 
MGDG 9 5 
Catechin 10 12 
Epicatechin 8 6 
Procyanidin B5 nd 13 
 nd – not determined 
 
3.6.2  Reversal of resistance in eukaryotic cells 
 
Often, compounds that modulate resistance to antibiotics in bacterial cell are also shown 
to modulate resistance of MDR cancer cells to cytotoxic agents, and vice versa. For that 
reason the compounds isolated from the plant C. edulis were tested for their capacity to 
reverse or reduce the resistance of the human mdr1 transfected mouse lymphoma cell 
line to agents to which it is resistant. Two techniques were used for this propose: the 
first one is based upon flow cytometry that measures the effects of an inhibitor of the 
transporter such as verapamil on the accumulation of rhodamine 123 (when the 
transporter is inhibited more rhodamine 123 is accumulated) and; the second technique 
is an adaptation of the semi-automated EB method, described in the previous sections 
for bacteria, that follows the increase in the accumulation of EB by the cells in the 
presence of the compound as compared to its unexposed control (234). 
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A) Flow cytometry assay 
 
The effect of the isolated compounds on the inhibition of P-gp and consequent 
accumulation of rhodamine 123 inside the cells was measured in terms of fluorescence 
(Fl), by flow cytometry in presence and absence of the compounds. The activity is 
presented as a fluorescence activity ratio (FAR), which is equal to:  
FAR = (FlMDR treated – FlMDR control)/ (FlPAR treated – FlPAR control).  
FAR values are summarized in Table 20. The antiproliferative assay indicates that IC50 
(concentration of compound that inhibits cell proliferation in 50%) values smaller than 
40 mg/L when the assay is conducted with the mouse lymphoma mdr1 transfected, do 
not affect the viability of the cell. Therefore, concentrations of the compounds isolated 
from C. edulis that were equal and below this value were used for the evaluation of the 
compounds abilities to inhibit the P-gp transporter. Nevertheless, to insure that the 
concentrations employed were below that which affects cell viability, integrity of the 
cells were checked by comparing the values obtained with the flow cytometry assay and 
cells in the presence and absence of the agent. Under these conditions, the agents did 
not produce toxicity effects during the period the assays were conducted.  
Base on the FAR values, the compound uvaol has high inhibitory activity against P-gp 
as shown by Figure 45.  
 
MDR PAR
4ug/mL
40ug/mL
Figure 45 - Histogram of amount of rhodamine accumulated in the MDR cell line and parental cell 
line (red) and in the MDR cell line treated with 4 mg/mL and 40 mg/L of uvaol (green). 
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Oleanolic acid has a lower activity and only slightly increases the retention of 
rhodamine123. Whereas active inhibitory compounds showed a concentration 
dependent activity, β-amyrin, MGDG, catechin, epicatechin and procyanidin B5 were 
devoid of any inhibitory activity. These results are summarized by Table 20. 
 
Table 20 - Fluorescence activity ratio (FAR) values for the isolated compounds at the two 
concentrations tested as well as the DMSO control. 
Compound Concentration 
(mg/L) 
FAR 
Verapamil 10 6.97 
β-amyrin 4 n.d. 40 1.26 
Oleanolic acid 
4 1.26 
40 5.29 
Uvaol 
4 40.93 
40 76.07 
MGDG 
4 1.16 
40 2.05 
Catechin 
4 2.50 
40 2.93 
Epicatechin 
4 1.16 
40 0.97 
Procyanidin B5 
4 0.89 
40 0.58 
DMSO 4% 0.69 
 
B) Semi-automated EB method 
 
The activity of the compounds isolated from C edulis was also evaluated with the aid of 
the semi-automated EB method. As previously explained, a compound that inhibits an 
efflux system that extrudes the fluorescent substrate EB produces an increase of 
fluorescence as a consequence of the build up of EB concentrations within the cell. The 
use of two distinct methods that evaluate efflux reinforces the significance of inhibitory 
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activity noted for a given compound. Therefore, the flow cytometry evaluation of the 
isolated compounds was followed by the use of the semi-automated EB method, 
previously described for bacteria and now extended to the evaluation of agents that 
inhibit the P-gp transporter.  
The results obtained from the use of the EB method are presented by Figure 46, Figure 
47 and Figure 48.  
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Figure 46 - Accumulation of EB in MDR mouse lymphoma cells in the presence of uvaol. 
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Figure 47 - Accumulation of EB in MDR mouse lymphoma cells in the presence of oleanolic acid. 
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Figure 48 - Accumulation of EB in MDR mouse lymphoma cells in the presence of MGDG. 
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Once again uvaol was the most active inhibitor of P-gp followed by the oleanolic acid 
and MGDG. From the real-time data the relative final fluorescence (RFF) of the last 
time point (minute 90) of the assay was calculated (Table 21). 
 
Table 21 - Relative fluorescence factor (RFF) values for the isolated compounds at the two 
concentrations tested. 
Compound 
Concentration 
(mg/L) RFF 
Verapamil 10 100 
β-amyrin 4 4.9 40 8.9 
Oleanolic acid 
4 15.8 
40 8.8 
Uvaol 
4 11.1 
40 18.4 
MGDG 
4 12.4 
40 6.9 
Catechin 
4 4.9 
40 4.6 
Epicatechin 
4 8.6 
40 9.9 
Procyanidin B5 
4 nd 
40 nd 
DMSO 4% <1 
 
3.6.3  Checkerboard assay 
 
Uvaol, the most effective compound that reversed resistance of the mdr1 transfected 
mouse lymphoma cell to cytotoxic compound producing the greatest degree of 
inhibition of P-pg, was evaluated by an antiproliferative assay for synergistic properties 
when combined with chemotherapeutic doxorubicin. The proliferative assay employed 
was described earlier in Section 4.5.4 of Materials and Methods.  
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The interaction of any compound with the chemotherapeutic agent is evaluated based on 
the fractional inhibitory concentration index (FIX). The FIX value is obtained as the 
sum of the FIX values for each compound separately (29): FIX = FIXuvaol + 
FIXdoxorubicin. The FIX value of each compound is the fractional IC50 of the combined 
drugs divided by their individual IC50 as follow:  
FIX(uvaol) = IC50(uvaol+doxorubicin) / IC50(uvaol) and; 
FIX(doxorubicin) = IC50 (uvaol+doxorubicin) / IC50doxorubicin.  
If the FIX value is equal to 1 it represents an additive effect of the two drugs that is 
equal to the sum of the individual results for each of the drugs when used separately. If 
the FIX value is equal to any of the individual values it means that the result with the 
two drugs does not significantly differ from the result with the most effective drug 
alone. FIX values larger than 1 represent antagonism and mean that the result of the two 
drugs is significantly less than the additive response. Synergism corresponds to FIX 
values equal to or less than 0.5 (29).  
The combination of uvaol and doxorubicin produced a FIX value of 0.49 and therefore 
we may conclude that the two compounds act synergistically. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
V. DISCUSSION  
 
 
   
 
Discussion 
1. Role of the environment in the membrane of Gram–negative 
bacteria 
 
Therapy of the majority of bacterial infections may focus on different approaches 
dependent on the causative pathogen and site of infection. Successful infection is 
dependent upon the pathogen and the immune system of the host. Therapeutic failure 
due either to antibiotic resistance of the organism or to ineffective therapeutic modality 
(ex. dose, patient non-compliance) contributes to the continuation of infection. The 
severity of infection is dependent upon the virulence of the organism and the degree of 
immune function. Therefore, this thesis focused on one of the above aspects that 
contribute to the infective process, namely, antibiotic resistance and its modulation. It 
was studied the physiologic mechanisms that contribute to antibiotic resistance, the 
behaviour of bacteria under constant antibiotic stress and ensuing MDR resistance, the 
mechanisms by which MDR develops, and the role of distinct transient mechanisms that 
are invoked when the organism is under stress and when that stress is obviated. Lastly, 
because much is now known about the environmental conditions that affect the response 
of bacteria to stress, the thesis also included biochemical parameters that elicit 
responses of the organism as well as affect the degree of resistance to given antibiotics. 
 
1.1 Growth, environment and OMP expression  
 
The first part of Results section revealed important information relevant to the infection 
process and the role of the environment. If bacteria are to survive in an altered 
environment, they must adapt to the new conditions. Because the outer membrane is the 
organelle that is in contact with the environment, it is reasonable to suspect that it is this 
organelle which may first respond to altered environmental conditions that are noxious 
to the organism (19;23;24;33;34). Among the alterations of the outer membrane of 
adapting bacteria are reduction of the number of porins (196), over-expression of efflux 
pumps (19), changes in the lipid constitution of the membrane (23), among others. For 
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example, with respect to salmonella, its survival within the neutrophil post-phagocytosis 
is totally dependent upon changes of outer membrane structure (52). Because these 
changes are the result of differential gene expression such as the two step PmrA/B 
regulon, the organism escapes the deleterious effects of the neutrophil’s lysosomal 
enzymes (52). Alterations of outer membrane composition such as down-regulation of 
OMPs that go into porin assembly, increased amount of LPS that render the organism 
impermeable (etc), are examples. Moreover, in vitro exposure to antibiotics such as 
polymyxin B and chlorpromazine alter the structure and protein composition of outer 
membrane of Gram-negative bacteria (235;236).   
The first set of results described in this thesis involved the study of OMPs and 
conditions under which the organism is culture. When Gram-negative bacteria are 
grown in liquid media (TSB), the major protein that is differentially extracted from the 
outer membrane is a 55 kDa protein. When this same organism is grown in the agar 
(TSA), this 55 kDa protein is barely evident in the extract (Figure 17). This variation of 
expression of a major OMP may be a response to the hydrostatic pressure exerted by a 
liquid medium as opposed to the lesser pressure exerted by a solid medium. Previous 
work from Foulaki showed a similar 55 kDa protein which was the major protein 
extracted from the outer membrane of Salmonella (204). Immunization of rabbits with 
this protein led to afforded significant protection against experimental infection with 
Salmonella (204).   
Salmonella are the major cause of food-borne infections (237). Acquisition of a 
salmonella infection takes place via two main sources: infection due to salmonella 
introduced by handlers of food such as salads, or from canned products that were 
contaminated with the organism during processing of the canned food (238). Conditions 
present in canned food that are designed to inhibit bacterial growth (239) include 
hydrostatic pressure (201) and low pH (240). Because the environment of canned food, 
with respect to hydrostatic pressure is similar to broth, and Salmonella that have 
contaminated the food during processing would be expected to express the 55 kDa 
protein that enhances the virulence of the organism. However, as of this writing nothing 
has been published that relates the virulence of a salmonella infection acquired from 
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canned foods or from contaminated water versus that acquired from contaminated salad 
due to the handling of the salad ingredients by a carrier. 
Because salmonella grown in broth containing chlorpromazine do not express the 55 
kDa protein (235), and because recent studies have shown that derivatives of this 
phenothiazine has antimicrobial activity in vivo against salmonella whereas in vitro the 
organism is very resistant (241;242), the ability of thioridazine to prevent a highly 
virulent salmonella infection can be due to the inhibition of expression of the virulent 
factor 55 kDa protein. This assumption may be highly relevant for the use of 
phenothiazines such as thioridazine for the therapy of MDR Gram-negative infections. 
The mechanisms by which phenothiazines produce their in vitro and in vivo effects 
relevant to susceptibility of Gram-negatives to antibiotics will be discussed in Section 
2.3.4 of Discussion.   
 
1.2 Role of antibiotic-promoted stress 
 
As shown in the previous sections, environmental conditions that bacteria face are of 
extreme importance to its survival and when in an intracellular environment (as for 
intracellular infections), if it is to survive, bacterium must initiate a response that 
protects it from intracellular mediated damages. Because macrophages that 
phagocytosed bacteria tend to concentrate antibiotics (194) to which the organism is 
susceptible while infecting the host, the organism may respond by expressing a number 
of outer membrane alterations that reduce its permeability to antibiotics. This decrease 
in permeability affords the organism time to accumulate mutations which render it even 
more resistant. With respect to intracellular infections by M. tuberculosis, isolation of 
the organism has shown that it presents a series of cell envelop changes that together 
render the organism more resistant to the antibiotic that had accumulated in situ. Among 
these alterations are decreased porin expression (243) and increased efflux pump 
expression (244).  
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With respect to salmonella, another example, immediately after its phagocytosis by the 
neutrophil, the two step PmrA/B regulon is activated and a cascade of as many as nine 
genes are activated, resulting in the synthesis of LPS (52). An increase of LPS decreases 
permeability of the organism to antibiotics (202), to biocides (52) and to antimicrobial 
peptides (52;245).  
These situations are expected to occur during the infectious process, as well as during 
therapy. If therapy is to be successful, it is important to know exactly the resistance 
profile of the infectious agent. In vitro studies conducted in this dissertation aimed at 
developing an understanding of what happens in vivo when the infected patient is 
treated for a prolonged period of time with one concentration of antibiotic and the 
organism develops resistance to much higher concentrations of that antibiotic as well as 
to other antibiotic classes that have not been used in the therapy of the given infection. 
Antibiotic therapy commonly results in the appearance of resistance of the infecting 
bacterium to the agent (246). Although a variety of mechanisms account for distinct 
forms of resistance (247), the mechanism now recognized as playing a major role in the 
resistance of clinical isolates is the over-expression of efflux pumps which extrude the 
antibiotic before it reaches its target (248). Because the tri-partite efflux pumps of 
Gram-negative bacteria, for reasons yet to be understood, have the capacity to recognize 
and extrude a wide variety of unrelated compounds such as antibiotics from different 
classes, biocides and other noxious agents like bile salts (35), their over-expression 
results in a multi-drug resistant phenotype which presents difficulties for the therapy of 
the MDR bacterial infection (249).  
The mechanism by which these MDR efflux pumps are over-expressed has been studied 
in the laboratory; gradual and prolonged exposure of the bacteria to increasing antibiotic 
concentrations of the antibiotic that are just below its MIC promote the over-expression 
of individual efflux pumps that is accompanied with increasing resistance to the 
antibiotic as well as to other non-related antibiotics (37;65;202). Transfer of the now 
MDR phenotypic bacterium to drug free medium restores over time, initial 
susceptibility to the inducing antibiotic, as well as eliminates its MDR phenotypic status 
(37;65). Nevertheless, these studies do not entirely explain how MDR phenotypes 
develop in a clinical setting, since therapy does not involve progressive increases of 
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dose levels. Furthermore, because the level of resistance of the MDR clinical isolate, to 
a given antibiotic, may be hundreds of times greater than that of its wild-type reference 
strain, it is difficult to reconcile laboratory studies that induce high level resistance with 
continuous exposure to increasing concentrations of an antibiotic, to that high level 
present in MDR clinical isolates that have never been exposed beyond a level of drug 
compatible with therapeutic dosage. There must be more to the process by which MDR 
develops in a clinical setting and therefore, the studies to be described attempt to 
simulate the relationship between exposure of a given bacterium to an antibiotic under 
conditions expected to exist when a patient that is infected with this organism, is treated 
for a prolonged period of time with a constant dose of the antibiotic. 
It has previously been shown that exposure of E. coli to stepwise increases in 
tetracycline concentrations increases resistance to TET (37) that is accompanied by 
increases in resistance to many other antibiotics and non-antibiotic agents, producing an 
MDR phenotype. This MDR phenotype is accompanied by significant increased activity 
of genes that code for transporter proteins (37). Similarly, exposure of isoniazid - 
sensitive M. tuberculosis to increasing concentrations of INH also increased the 
resistance of the organism to this antibiotic (205) but resistance to INH was not 
accompanied by resistance to any other drug employed for the therapy of pulmonary 
tuberculosis.  
If it is assumed that events at the level of the bacterial cell envelope that result in 
increased efflux pump activity are independent of a chromosomal mutation that bestows 
high-level resistance of the bacterium to a given antibiotic, then prolonged exposure of 
that bacterium to increasing concentrations of the antibiotic to which it is resistant may 
induce the appearance of a MDR type efflux pump. In order to study the possibility that 
continuous exposure to an antibiotic results in the development of further increase of 
resistance to the given antibiotic as well as produce an MDR phenotype, methicillin-
resistant Staphylococcus aureus (MRSA) COL strain whose resistance to 400 mg/L of 
OXA is due to the acquired mecA element (250) was exposed to stepwise increases of 
OXA and at each level of increased resistance the organism was examined for any 
changes in its susceptibility to other antibiotics and for evidence of efflux activity.  
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The results obtained in this study and described in Section 1.2.1 of Results demonstrate 
that when MRSA COL is placed under increasing antibiotic stress, regardless of the fact 
that it contains the mecA element and is highly resistant to OXA, as it adapts to 
increasing levels of OXA parallel increases of resistance to ERY take place. Because 
RES can eliminate the increased resistance to ERY, the MDR phenotype induced by 
increasing concentrations of OXA is, probably, due to an efflux pump. Accompanying 
the increased resistance to ERY were significant increases in resistance to other 
antibiotics, thus indicating the acquisition of an efflux pump-mediated MDR phenotype. 
To our knowledge, this was the first demonstration of how a MDR type efflux pump 
can develop due to continuous exposure to increasing concentrations of an antibiotic to 
which the organism is chromosomally highly resistant. 
The second approach (section 1.2.2 of Results) was to maintain an already MDR strain 
under the same antibiotic concentration for prolonged periods of time, and simulate the 
situation when a patient infected with an MDR strain is maintained under the same 
antibiotic pressure during a long period of time. For this study, as described by Section 
2.3.2 of Materials and Methods, a serial culture of an E. coli strain whose efflux pump 
had been over-expressed, in medium containing a constant amount of the antibiotic to 
which the strain had been induced to high level resistance, results in the restoration of 
the activity of genes that regulate and code for the efflux pump transporters, relative to 
those of the antibiotic susceptible E. coli AG100. Accompanying this restoration is the 
continued increase of resistance to the antibiotic even though the bacterium had not 
been exposed to higher concentrations of the antibiotic to which it had been made 
resistant. This strain also displayed progressively increased resistance to compounds 
that target cell envelope constituents, gyrase and ribosomes, supporting the assumption 
that a large number of mutated targets resulted from continuous sub-culture in medium 
containing a constant concentration of an antibiotic. The inability of the E. coli 
AG100TET10 strain to revert in drug-free medium to the initial susceptibility to 
tetracycline or to the antibiotics that contributed to its MDR status, as did its E. coli 
AG100TET8 parent (65), supports the contention derived from phenotypic array studies 
that indeed mutations had taken place.  
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Bacteria obey the second law of thermodynamics - conservation of energy. The 
maintenance of an over-expressed efflux pump system must consume a large, yet 
undefined, amount of energy given the dependence on metabolic energy as the main 
source of protons contributing to the proton motive force (54). To the bacterium, one 
may suppose that after exposure to an environment that remains noxiously constant, the 
genetic system of the organism responds by activation of a mutator system (251) that 
results in the accumulation of mutations that render the organism multi-drug resistant. 
Although as long as the organism remains in that environment its survival is assured, if 
the environment returns to that initially present, the organism cannot compete with its 
counterpart which has its relevant targets fully functional.  
The study therefore demonstrates “evolution of a bacterial strain” within a laboratory 
environment, and, may parallel what takes place within a patient who is infected with a 
bacterium and is treated for a prolonged period of time with a constant dose of a given 
antibiotic, ultimately resulting in the increased resistance of the bacterium to that given 
antibiotic as well as to other non-related antibiotics. Lastly, this study demonstrates, for 
the first time, that an over-expressed efflux pump provides the opportunity by which 
other mechanisms of resistance may ensue. 
 
1.2.1 Correlation between the two studies 
 
Both of the studies described above showed that exposure of a bacterium to increasing 
concentrations of antibiotic invokes a phenotypic adaptation that not only increases the 
resistance of the bacterium to the antibiotic to which it is exposed, but also results in an 
MDR phenotype. Serial exposure of a strain that is already resistant to the given 
antibiotic also results in further increases of resistance when the strain is exposed to 
further increases of antibiotic. Therefore, generalisations may be made between the two 
sets of studies: 1) Continued exposure of an already resistant strain to the same 
antibiotic whose concentration remains constant, yields ever increasing resistance (the 
AG100TET8 example). 2) Continued exposure of an already resistant strain to a given 
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antibiotic whose concentration is continuously increased yields further increases of 
resistance to the antibiotic (the MRSA example). 3) Both examples yield MDR 
phenotypes that are mediated by an increased expression of the main efflux pump of the 
bacterium. 4) When the medium remains constantly noxious, the organism receives 
protection by the development of mutations. The latter renders the bacterium less fit if 
co-cultured in drug-free medium with its wild-type counterpart. Interestingly, a recent 
study demonstrated the presence of mutations which did not affect the fitness of the 
organism but which insured its survival if the medium were to contain fluoroquinolones 
(252). This is an example of pre-adaptation which may be an explanation for the some 
of the observations made in this thesis.   
The response of an already resistant bacterial strain to further increases of concentration 
of the same antibiotic is highly relevant to the clinical observation that prolonged 
therapy of the patient with the same dose of antibiotic also yields further increased 
resistance to the agent.  
The above studies show that at first, the induced MDR phenotype is subject to reversal 
by common inhibitors of efflux pumps. However, after further serial passages in high 
concentrations of the antibiotic, the strain remains resistant and cannot revert to wild 
type phenotype. These observations are related to those that demonstrate that whereas 
some MDR clinical isolates may yield a reduced resistance to a given antibiotic when 
an EPI is added to the medium other strains are not affected by the EPI. It can be 
assumed that the former case represents the early response to prolonged therapy with 
the same antibiotic either at the same or greater dose levels whereas the latter represents 
a much later adaptive response. 
During long term therapy such as that used for pulmonary infections produced by M. 
tuberculosis, the prolonged and sustained pressure of high concentrations of antibiotic 
actually contributes to the selection of spontaneous mutants. This reality was 
reproduced in the laboratory (253) as well as in the studies described in this Section. 
Adaptation of bacteria develops via a series of mechanisms each one of which, at the 
time of exposure, when invoked, assists the bacterium to survive. The studies described 
in this section, coupled to others (254;255) also suggests a controlled series of adaptive 
responses each one of which minimizes the amount of energy consumed. Among the 
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earliest responses is that of over-expression of an efflux pump system. The maintenance 
of this system is energy dependent and therefore, energy that would otherwise go for 
physiological processes such as replication, are channelled for the maintenance of 
efflux. That this hypothesis is correct is supported by the observation that whenever 
efflux pumps are over-expressed the organism replicates more slowly (205;206). When 
the noxious environment remains “eternal”, the organism invokes a “mutator” system 
that produces mutations of key targets normally and more readily reached by noxious 
agents-namely those of the cell envelope. Hence, as expected by this “mutator” 
hypothesis (251), prolonged exposure to the same concentration of an antibiotic 
(“eternal noxious environment”), results in mutations of β-lactam targets as shown in 
this thesis. However, there is the possibility that mutations of genes such as those that 
code for penicillin binding proteins or gyrase need not take place if the sole mutation is 
restricted to a site of the 16S ribosome unit involved translation. Such a mutation may 
cause a shift in the reading of the mRNA as is the case for streptomycin dependency 
(256) and yield altered targets. Nevertheless, it remains for future studies, the 
elucidation of “a mutator gene” system that is activated when the organism faces an 
“eternally noxious environment”. 
The concepts that result from the studies described above involve conservation of 
energy. Because efflux pump systems of Gram-negative bacteria are dependent upon 
protons generated by metabolism, and metabolism that yields energy is regulated by 
enzymes with distinct optimal pH, the next section of this Discussion interprets the 
results obtained from experiments where the efflux pumps of bacteria are modulated by 
metabolic energy and pH. 
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2. Energy and pH roles on efflux by Gram - negatives 
 
The cell membrane is the most dynamic structure of the cell. Its main function is to act 
as a permeability barrier that regulates the passage of substances into and out of the cell. 
Group translocation system, more commonly known as the phosphotransferase system 
(PTS), in E. coli, is primarily used for the transport of sugars. Like binding protein-
dependent transport systems, they are composed of several distinct components. 
However, group translocation systems specific for one sugar may share some of their 
components with other group transport systems. In E. coli, glucose may be transported 
by a group translocation process that involves the phosphotransferase system. The 
actual carrier in the membrane is a protein channel fairly specific for glucose. Glucose 
specifically enters the channel from the outside, but in order to exit into the cytoplasm, 
it must first be phosphorylated by the PTS. The PTS derives energy from the metabolic 
intermediate phosphoenol pyruvate (PEP). PEP is hydrolyzed to pyruvate and glucose is 
phosphorylated to form glucose-phosphate during the process. Thus, by the expenditure 
of a single molecule of high energy phosphate, glucose is transported and changed to 
glucose-phosphate (81;257). 
Bacteria do not have intracellular organelles for energy producing processes such as 
respiration or photosynthesis as do eukaryotes. Instead, the plasma membrane of the cell 
envelope carries out these functions. The cytoplasmic side of the plasma membrane is 
the site of electron transport systems (ETS) used to produce energy (ATP) and it is the 
location of the ATP synthase. The equilibrium for the synthesis or hydrolysis of ATP is 
pH dependent: at pH below 7 the reaction favours the synthesis of ATP; at pH above 7 
it favours the hydrolysis of ATP (258). 
The electron transport system establishes a pH gradient across of the membrane as a 
consequence of protons (H+) that are generated and not used for the formation of H20. 
The protons accumulate on the surface of the cell and are distributed unevenly-with 
higher concentrations in the pits present on the outer cell surface such as those that exist 
in salmonella (54). The concentration of protons on the surface is affected by the pH of 
the medium such that at low pH their dissociation into the bulk medium is extremely 
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low whereas at pH above 7, the dissociation into the bulk medium is increased 
accordingly (54). Therefore, the proton gradient that is formed from the energy 
producing metabolic activities of the cell creates the proton motive force (PMF) and it is 
this PMF which is responsible for the transfer of protons to the periplasmic space of 
Gram-negative bacteria that are then used for the activation of PMF dependent transport 
processes such as those involved in the extrusion of noxious agents such as antibiotics, 
biocides and toxins. Under normal circumstances, severe alteration of the pH of the 
medium (environment) does not alter the PMF of bacteria (259;260). However, the 
situation involving alteration of pH and presentation of a noxious agent is different due 
to the energy requirements of the transporter. Consequently, when the PMF force is 
under duress due to high pH, the protons available to the periplasm of the Gram-
negative bacterium are limited inasmuch as when the proton binds to the transporter and 
activates it, it is translocated to the cytoplasmic side of the plasma membrane. This 
translocation decreases the pH of the cytoplasm medial to the plasma membrane and 
therefore the synthesis of ATP is assured. This newly synthesised ATP is now available 
for ATP binding transporters that can now assist in the extrusion of the noxious agent 
from the periplasm of the cell (206).  
A familiar example of energy-producing and energy-consuming functions of the 
bacterial membrane, related to the establishment and use of PMF and the production of 
ATP, is described for the plasma membrane of E. coli by Figure 49. 
cytoplasm
environment
 
Figure 49 - The plasma membrane of Escherichia coli. 
The membrane in cross-section reveals various transport systems, the respiratory electron transport 
system, and the membrane-bound ATPase enzyme. At certain points in the electron transport process, the 
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electrons pass "coupling sites" and this results in the translocation of protons from the inside to the 
outside of the membrane, thus establishing the PMF on the membrane. The PMF is used to do work or 
conserve energy: active transport (e.g. lactose symport; calcium and sodium antiport) and ATP synthesis 
Adapted from (81)  
Production of ATP can also occur at a substrate level phosphorylation in which ATP is 
made during the conversion of an organic molecule from one form to another. Energy 
released during the conversion is partially conserved during the synthesis of the high 
energy bond of ATP. It occurs during glycolysis, intermediary metabolism, 
fermentations and respiration (the TCA (tricarboxylic acid) cycle) processes. 
As an example, the net equation for producing ATP after glycolysis and the TCA cycle 
in E. coli is as follows:  
Glucose + 6 O2 → 6 CO2 + 10 NADH2 + 2 FADH2 + 4 ATP 
Two NADH2 and 2 ATP are formed during glycolysis, while 8 NADH2, 2 FADH2 and 2 
ATP are formed during the TCA cycle. In E. coli, 2 ATP are produced for each pair of 
electrons that are introduced into the ETS by NADH2. One ATP is produced from a pair 
of electrons introduced by FADH2 (a prosthetic group). Hence, the total equation can be 
rewritten: 
Glucose + 6 O2 → 6 CO2 + 6 H2O + 26 ATP (81) 
The penetration of hydrophilic compounds through the cell envelope takes place via 
porins ultimately reaching the periplasm of the Gram-negative bacterium. As noted 
before, the plasma membrane is an important organelle and contains proteins that are 
involved in the resistance of cells to noxious agents. Its lipid composition forms a 
barrier to hydrophilic molecules which, when noxious to the cell and its concentration 
builds up in the periplasm, are recognised by efflux pumps and extruded to the surface 
of the cell (environment).  
For the study of efflux pump activity, the semi-automated EB method was used as 
described in the Method Section of this thesis. The method relies on the absence of 
detected fluorescence by the fluorochrome EB in the medium and the detection of 
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fluorescence when the fluorochrome is accumulated in the periplasm of the cell. 
Accumulation of EB is due to the periplasmic concentration of EB that exceeds the 
capacity of the efflux pump to extrude the agent (187). Accumulation of EB is also 
accented by the presence of efflux pump inhibitors (187), modulation by pH (206), 
agents that interfere with accessibility to protons (e.g. CCCP) (187), or by compounds 
that successfully compete with EB for extrusion by the efflux pump system (206).  
Therefore, the study that involves different conditions that influence the response of the 
cell to given noxious agents provides an understanding of the mechanisms involved in 
the adaptive response to a given noxious agent resulting in increased resistance to that 
agent. 
Bacteria contain multiple efflux pumps that are involved in the extrusion of a noxious 
agent. This multiplicity provides pre-adaptation to the presence of a large gamut of 
agents that are normally not present in the habitat of the organism (206). As of this 
writing, only one study has shown that, in the absence of a given efflux pump of a 
Gram-negative bacterium, the organism can over-express one or more other efflux 
pumps when challenged with a noxious agent such as tetracycline (64). However, as 
shown by the studies of Viveiros et al, the over-expressed efflux pump is not nearly as 
efficient as the main efflux pump that has been deleted, and it is more susceptible to the 
majority of the antibiotics tested (37). The involvement of efflux pumps that 
complement the main efflux pump of E. coli has been demonstrated by others (261).  
During the infectious process, bacteria have to survive in different environments of the 
host that are toxic to the organism (262;263). As an example food-borne bacteria 
traverse the digestive tract that differs widely with respect to pH. During this passage, 
the organism is threatened by toxic bile salts in the duodenum where the pH is acidic 
and by the same bile salts in the colon where the pH is near neutral. An aspect of the 
thesis studied the effects of pH on the efflux system of Gram-negative bacteria. 
Moreover, the role of metabolic energy in the extrusion of a noxious agent at different 
pH was studied and this afforded the understanding of conditions that regulate the 
preferential activity of the different kinds of efflux system of bacteria.  
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2.1 Role of glucose  
 
The first assays performed for the assessment of the accumulation and efflux of EB by 
E. coli AG100 and E. coli AG100TET8 were in the presence and absence of glucose, as 
previously described (187). Glucose plays an important role in the efflux mechanism as 
noted previously (187) but this work was conducted at pH 7. The question of efflux at 
varying pH with and without metabolic energy and the results obtained from this study 
are presented in Section 2.4 of Results. Glucose, as an energy source will be used 
preferentially for ATP synthesis via glycolysis and tricarboxylic acid (TCA) cycle, as 
described earlier in this Discussion Section. This ATP will be used preferentially by 
transporters from the ABC superfamily. Similar glucose-activation of H+-ATPase was 
previously shown by Pereira and co-authors in Saccharomyces cerevisiae (258). In this 
study, one specific phospholipase and one specific kinase of yeast are involved in the 
glucose-activation of ATPase. However, the role of these enzymes in the glucose 
activated-ATPase of bacteria is still not defined. 
In the study of the role of efflux modulators or modifiers, or compounds that interfere 
with the integrity and stability of the plasma membrane, glucose is important because it 
helps to clarify the action of the compound. Because the study showed that the effects 
of glucose on accumulation and efflux of EB were pH modulated, the role of glucose 
will be discussed in more detailed in the following section that deals with varying pH 
and agents that modify or modulate accumulation and efflux of EB. 
 
2.2  Modulation of accumulation and efflux of EB by pH.  
 
Environmental conditions play major roles in the physiology of the cell envelope as 
note in the section dealing with protons and the PMF. As noted earlier, bacteria face 
widely different environments with respect to pH and presence of noxious agents. 
Because EB is a noxious agent and is recognized and extruded by efflux pump systems 
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of bacteria (187;234;264;265), the use of EB provides a general understanding of how a 
given bacterium deals with noxious agents in its habitat or environment.  
Previously, it was shown that exposure of Salmonella to mild pH activates the PmrA/B 
two component regulatory system which not only allows the organism to survive the 
low pH of the phagolysosome but also increases its resistance to antibiotics (266). The 
activation of the PmrA/B system is not solely by low pH since its activation has now 
been shown to take place at pH 8 (267). Other authors also observed that exposure of E. 
coli to low pH activates a wide spectrum of genes, some of which code for cell envelop 
proteins (65;268). These studies suggest that low pH readily activates genes of a Gram-
negative bacterium which render the organism resistant. Although the question of 
whether pH-induced resistance of a Gram-negative involves the activation of genes that 
regulate and code for efflux pump constituents remains to be answered. Does the pH 
have a direct effect on the RND efflux pump family of E. coli? 
It is known that for the RND family: 
• The necessary energy to power extrusion of a compound is obtained directly 
from the trans-membrane proton gradient (211;212); 
• Maintenance of this gradient presumes the entrance of the protons from the 
periplasmic space through the pump, energizing it and the agent which is 
believed to be concentrated within the outer leaflet of the inner membrane is, in 
turn, extruded (269);  
• The proton is then released to the medial side of the plasma membrane (269);  
• The fusion proteins are believed to physically assist the extrusion of the agent 
(269).  
The PMF of the cell membrane is, in part, established by protons generated following 
the hydrolysis of ATP catalyzed by plasma membrane bound ATPases  (56;270-273) 
and by oxidative metabolism (54). The generation of these protons takes place at sites 
medial to the inner membrane of the Gram-negative bacterium. After, they are exported 
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to the periplasm by a variety of transport processes and most of which are then exported 
to the surface of the cell. The distribution of protons between the periplasm and the cell 
surface results in a proton gradient that is greatest at the surface of the cell and least in 
its periplasm.  
This distribution establishes a relative negative charged periplasmic space and positive 
charged surface of the cell and results in an electrochemical gradient. The resulting 
transmembrane difference in the electrochemical potential of hydrogen ions was at first 
seen to be the driving force behind the energy consuming enzymes and ATP synthase. It 
was defined as the proton motive force (274). 
Because of the largesse of the bulk water phase, the dissemination of protons from the 
surface of the cell would quickly eliminate the pH gradient across the cell envelope, and 
hence, the PMF and the energy it provides for driving efflux pumps would be 
eliminated (274). PMF is maintained by the bacterium when challenged by changes in 
the pH of the environment (259;260), and the concept was extended to include the 
distribution of protons on the surface of the cell which due to the components of the 
outer cell envelop, would be selectively concentrated and result in a pH of the medium 
immediately surrounding the surface of the cell that would be much lower than the pH 
of the bulk medium (55). This surface distribution of protons therefore assists the 
bacterial cell in maintaining a PMF that would not be significantly affected by the pH of 
the medium (52).  
The results presented in this thesis demonstrate that the pH of the milieu modulates the 
over-all activity of the intrinsic and over-expressed efflux pump system of E. coli. pH 
modulation of genes that code for ion transporters of E. coli has been previously 
demonstrated by others (275). However, this is the first demonstration that pH is shown 
to modulate the accumulation and extrusion of an efflux pump substrate such as EB. 
The effect of pH on the cell envelope, its constituents, genes that regulate growth and 
metabolism has been reported and reviewed in detail (275). As also shown in the current 
study, low and high pH reduces optimum growth demonstrable at pH 7. However, low 
pH is not a problem for E. coli inasmuch as its survival, regardless of a slower growth 
rate, is not significantly affected as evident from the success of an orally consumed E. 
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coli reaching and successfully colonizing the colon. The survival of the organism is 
dependent upon its ability to extrude noxious agents present in the digestive system of 
the host. Clearly, the ability to extrude a noxious agent is intrinsically present in wild-
type E. coli. The extrusion capability when over-expressed, make therapy of MDR E. 
coli infections problematic. 
The selection of pH affords the distinction between an efflux pump system immediately 
dependent on the PMF, such as a RND efflux pump, and one that is dependent upon 
metabolic energy and inhibited by verapamil. As shown in this thesis, extrusion of EB 
can be prevented at pH 8 by verapamil, an agent that is known to inhibit ABC 
transporters (276). Because the msbA gene of E. coli is similar to the ABC transporter 
gene efrAB of E. faecalis (277;278), the glucose dependent efflux at pH 8 noted in our 
study may be conducted by the putative MsbA transporter. Further studies have to be 
performed in order to identify the ABC transporter in this study. Nevertheless, an ABC 
type transporter system that has the capability to extrude the efflux pump substrate EB 
has now been demonstrated for the first time in E. coli. 
Consequently, it is widely held that the pH of the medium should not affect the activity 
of an RND efflux pump even though there is no evidence in support of this conclusion. 
However, work done with yeast showed that acidification of the medium during cellular 
growth triggers a decrease in cytosolic pH and this situation also leads to ATPase 
activation (258). If this observation can be also considered as true for E. coli, as it seems 
to be from the results presented on section 2.2 of the Results, the low pH (acidic) at the 
cytoplasmic side of the plasma membrane that results from the translocation of protons 
from the periplasm to the cytoplasm by the RND type transporter, promotes the 
synthesis of ATP. The synthesis of ATP therefore removes protons from the cytoplasm 
and the pH at the cytoplasmic side of the plasma membrane increases. This process not 
only maintains a relatively stable PMF but it also provides the ATP that is used by the 
ABC transporters that are then preferentially used by the cell for transport of nutrients 
into the cell. The hydrolysis of ATP by the ATP binding transporters is thus an ATPase 
like function that has been identified in yeast and which is surmised in this thesis to take 
place in a Gram-negative bacterium. This is the first time that the entire energy-proton-
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pH cycle has been described in a Gram-negative bacterium that is coupled to the pH of 
the medium (environment). 
The study of this dissertation supports the contention that the survival of a bacterium as 
it makes its way through the digestive system and eventual colonization of the colon, is 
assured by the activity of two types of efflux pump systems: one that operates directly 
from PMF derived energy and the other from a putative ABC transporter. It is supposed 
that when the bacterium reaches the duodenum, the toxicity presented by high 
concentrations of bile salts must be obviated and this is accomplished by the extrusion 
of these toxic substances by an RND efflux pump such as the AcrAB of E. coli. 
Because the results demonstrate that the intrinsic efflux pump system of wild-type E. 
coli is perfectly capable of extruding EB in glucose-free saline at pH 5, and this 
extrusion can be eliminated by an un-coupler of the PMF, it should be this PMF 
dependent pump system which protects the bacterium while passing through the 
duodenum. There is no need for an over-expressed PMF dependent efflux pump system. 
When the organism reaches the colon, bile salts, as well as many secreted agents 
produced by the normal flora, are present and are toxic to the organism. The pH of the 
colon is near 7 and because of the scarcity of protons in this bulk medium the 
concentration of surface bound protons must be affected, and is probably much lower 
than that at pH 5.  
If the RND pump is to operate under these conditions, the PMF must be maintained and 
the protons needed to activate the RND efflux pump must be available in the periplasm 
(269). Subsequent to the extrusion of the noxious agent the protons are released to the 
cytoplasm. Two general situations are expected from the activity of the RND efflux 
pump at pH 7 or higher:  
1) The consumption of protons from the periplasm reduces the PMF unless protons are 
replaced from the surface of the cell. The process of replacement is probably limited 
and inadequate for the maintenance of an RND efflux system under these conditions; 
2) The release of protons to the medial side of the cytoplasm membrane will decrease 
the pH and the synthesis of ATP by ATP-synthase is favoured (187;279). The 
utilization of protons for the synthesis of ATP insures that the pH gradient between the 
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periplasm and cytoplasmic side of the plasma membrane is maintained. The ATP 
generated is then bound by the ABC transporter, hydrolyzed and the energy from this 
process activates the ABC transporter to extrude the noxious agent. 
Metabolic energy also contributes to this process. In the toxic environment of the colon, 
it is supposed that the organism receives protection from the ABC type efflux pump 
system that relies primarily on metabolic energy, energy that is derived from the 
richness and practically unlimited supply of carbohydrates continuously replenished by 
the digestive processes of the human host. 
These observations are very important at clinical level since one must make a 
distinction between the process of an infection caused by Salmonella or E. coli strains 
and its colonisation of the colon that is made possible by the collaboration of PMF 
dependent efflux and ABC transporters from an infection by their MDR counterparts. 
When these MDR infections are efflux mediated, therapy which is normally ineffective 
may be improved by the co-administration of non-toxic compounds that inhibit the 
efflux pump machinery and hence, the previously inactive antibiotic can now reach its 
intended target. The following section therefore discusses the results obtained in Section 
2.3 of Results that demonstrated the effects of agents on the accumulation and efflux of 
EB by intrinsic and over-expressed efflux pumps.  
 
2.3 Role of efflux modulators 
 
The demonstration of pH modulated efflux pump activity is extremely significant for 
the design of agents that are to serve as efflux modulators. If the agent is to be an 
effective adjuvant to antibiotic therapy for the management of a food-borne infection 
caused by an efflux mediated MDR Gram-negative bacterium such as an E. coli strain, 
it must be active against the ABC transporter that is protecting the bacterium from the 
toxic agents of the colon, and during antibiotic therapy. Efflux modulators whose 
effectiveness is shown against RND type efflux pump systems may not be effective in 
the environment in which the offensive bacterium resides. Consequently, an efflux 
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modulator that is to serve as an adjunct to antibiotic therapy aimed at an efflux mediated 
MDR coliform infection should be evaluated for activity under physiological 
conditions, namely at a pH that favours the activity of RND and ABC type efflux pump 
systems.  In the following discussions, the results obtained in this thesis will present 
along new interpretive lines, considerations of efflux pumps that had not been 
previously considered.  
 
2.3.1 CCCP 
 
CCCP is a un-coupler that is known to destroy the PMF of the cell envelope by binding 
the surface bound protons of the bacterium (258). As per prior discussions, the pH of 
the medium is now known to be the major controller of surface bound protons of Gram-
negative and Gram-positive bacteria (54). Consequently, the question that was asked in 
this thesis was: Does CCCP has differential quantitative effects on the accumulation of 
EB when assessed by the semi-automated EB method at varying pH? As per the results 
obtained and described in Section 2.3.1 of Results, at pH 5 the concentration of CCCP 
needed to significantly increase the retention of EB is considerably greater than at pH 8. 
The interpretation of these results is that at pH 5 the concentration of protons on the 
surface of the cell is greater and exceeds the proton binding capacity of low 
concentrations of CCCP that are very effective at pH 8.  
The effectiveness of the over-expressed efflux pump is dependent upon the 
concentration of protons on the surface of the cell. At pH 8 due to the lower 
concentration of surface protons the available protons for the over-expressed pump is 
limited and rapidly depleted from the periplasm. If CCCP is then added, it produces a 
synergistic effect on the retention of EB. From the data presented in the CCCP section, 
it is readily seen that lower concentrations of CCCP are more effective in causing the 
retention of EB by over-expressed efflux pump cells at pH 8 than wild type cells 
containing the intrinsic level of efflux pump activity.  
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2.3.2 PAβN 
 
PAβN has been used as an EPI by many authors. However it was shown previously, at 
pH 7, that this agent causes accumulation of EB in a concentration dependent manner 
but does not influence efflux (187). Therefore the following question was asked: Is 
PAβN an EPI or competes with EB for a site of the efflux pump? To answer this 
question an assumption was tested: If PAβN is an EPI, the activity of the efflux pump at 
pH 5 should be reduced as a consequence of its binding to the transporter component of 
the pump (264;269;280;281). The data presented in the PAβN Section of the Results 
show that PAβN has no effect on the efflux of EB by the E. coli strain at pH 5, but 
causes an increase in its accumulation that is concentration dependent. These results 
support the previous contention that PAβN is not an EPI but a competitor with EB (280) 
for access to the substrate “active” site of the pump. In other words, efflux systems of E. 
coli extrude PAβN preferentially to EB. The preferential extrusion of PAβN is surmised 
from the effects of increasing concentrations of PAβN on the accumulation of EB when 
EB is maintained at 1 mg/L. Therefore, relative to this EB concentration, a KM for 
PAβN was calculated and yielded a value of 4.21 mg/L. It should be noted that if the 
PAβN is added after accumulation of EB, and the assay is allowed to take place for 
much longer periods, the effect of PAβN on accumulation will be noted (data not 
shown). The reason for this renewed accumulation of EB is due to the penetration of EB 
that is taking place continuously during the assay whereas PAβN is extruded 
preferentially. The approach used in this PAβN assay can be used for other efflux pump 
substrates that compete with EB and for which a similar KM may be calculated at pH 5 
and compared to the KM of other substrates. In this manner the relative binding of 
various efflux pump substrates to a given efflux pump transporter may be determined. 
More detailed kinetic and computational docking studies should be done to understand 
more clearly the mode of action of PAβN. Nevertheless, the results obtained are very 
important in the understanding of the mode of action of efflux modulators that could be 
used in therapy of infections caused by MDR strains. The results show that the 
commonly called EPIs – efflux pump inhibitors – do not have to inhibit directly the 
pump. In fact, it seems that the some of those compounds act in systems that interfere 
with the membrane organization as PMF or energy dependent pathways and by that way 
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cause less efflux of the antimicrobial agent. It was demonstrated that for the study of 
new “helper compounds” (20) its activity should be tested by a wide range of 
experiments including not only accumulation but also efflux assays. 
 
2.3.3  Verapamil 
 
Verapamil, known as an inhibitor of the ABC transporters was used in the assay in 
order to distinguish the role of the two main types of general efflux systems, at different 
pH. Since verapamil is an inhibitor of the ABC type of efflux pumps that is dependent 
upon immediate metabolic energy, and its inhibition is an indirect result of inhibiting 
access to calcium, when efflux is mainly due to an RND transporter, such as the AcrAB 
pump, verapamil should not alter the efflux of EB and no increase in EB accumulation 
should be observed. Conversely, if an efflux pump of the ABC family has an important 
role on the efflux of EB by the strain, then an effect of verapamil should be expected. 
The results obtained and described by the Verapamil Section of Results, indicate that 
the inhibitory effect of verapamil was mainly observed at pH 8 in a concentration 
dependent manner, indicating that, at pH 8 the extrusion of EB by E. coli is taking place 
by a metabolic energy dependent system. The genes efrA and efrB are responsible for 
the coding of the ABC transporter of Enterococcus faecalis, EfrAB, and have a 
homologue gene in E. coli, the msbA (278). The MsbA, which acts as a flippase and 
inserts the de novo synthesised Lipid A into the nascent LPS layer of the outer cell 
envelope (282;283), probably has a dual role, and can extrude EB at pH 8. But this 
remains to be proven.  
As previously observed in the preceding sections, at pH 8 ATPase preferentially 
hydrolysis ATP and contributes to the replenishment of protons and maintenance of the 
PMF. This idea is supported by the fact that at this pH the efflux that is dependent on an 
energy source is highly affected by verapamil Therefore transporters from the ABC 
superfamily are supposed to be the main extruders of noxious agents at pH 8. 
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Because verapamil is also known to limit the access of calcium to calcium dependent 
ATPases (108;277) and because calcium is an important ion in cell signalling (bacteria 
included) (220;258), the role of phenothiazines, inhibitors of calcium and potassium 
transporters (154), and calcium itself were also studied and the results obtained are 
discussed in the following sections. 
 
2.3.4 Phenothiazines 
 
Phenothiazines are calcium channel inhibitors that, at sub-inhibitory concentrations, 
were shown to reduce in vitro minimum inhibitory concentrations of some antibiotics 
against strains of E. coli (37), S. aureus (119), M, tuberculosis (186), etc. The effect of 
sub-inhibitory concentrations of TZ against Salmonella was also followed during 24h 
(267). Growth curves of different strains were followed in presence and absence of TZ 
and when this compound was present, the initial lag phase was increased in a 
concentration dependent manner (increase of TZ concentration promotes and increases 
lag phase duration). After that period of inhibition, adaptation takes place and growth of 
Salmonella strains is similar to that of unexposed controls. rtRT-PCR revealed that 
genes that regulate the expression of RND pumps were over-expressed just before the 
strain began to grow in the presence of TZ (267). When the TZ exposed strain attained 
full growth, only the acrB transporter gene was over-expressed. Interestingly, exposure 
of a salmonella strain to TZ in the semi-automated EB assay demonstrates a rapid 
accumulation of EB that is followed 30 to 60 minutes later by efflux (267). Because 
there is no metabolic energy in the assay, and because salmonella has a great ability to 
use its lipid metabolic pathway for generating energy (267), the role of a lipid such as 
palmitic acid was examined by the authors. As expected, the addition of this fatty acid 
resulted in the reduction of accumulation of EB (267) and therefore its efflux and those 
results support the proposal that a full examination of fatty acids (short versus long 
chained) should take place in order to establish the source of lipid derived energy. 
Moreover, one may conceive that by adding a lipid as a source of metabolic energy, 
genes that are activated may now be assessed by rtRT-PCR. 
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Therefore, the results obtained in this dissertation and presented in section 2.3.4 of 
Results showed that TZ and CPZ promote accumulation of EB and inhibit its efflux by 
E. coli AG100 but not by E. coli AG100TET8, and glucose decreases the activity of the 
phenothiazines. The inhibition of efflux was observed at pH 7 and 8. At pH 5 no 
inhibition was observed regardless of an energy source. These results again suggest that, 
for the parental strain, at pH 8, a putative ABC transporter plays an important role in 
efflux that is affected by TZ. However, in the adapted strain, because the RND systems 
are over-expressed, this influence is not that significant. 
The results obtained in the thesis relate TZ to genetic aspects that regulate efflux pumps 
as well as demonstrate that TZ itself increases accumulation and inhibits efflux at pH 7 
and 8 while having little effect at pH below 7. One may surmise that TZ targets at least 
two different systems that together provide protection against a noxious agent. Because 
phenothiazines affect access to calcium (154), and calcium is important for signalling 
(220) and activating genetic systems (220), the role of calcium alone and in 
combination with CPZ, at varying pH with and without metabolic energy was evaluated 
with the aid of the semi-automated EB method and is discussed in the following section. 
 
2.4 Role of Calcium 
 
Calcium is needed for a wide variety of metabolic and energy deriving pathways within 
the cell. Central to these pathways are ATPases that hydrolyse ATP and furnish protons 
for the activation of ABC type transporters. Although the medium employed in our 
study does not contain calcium, calcium is nevertheless present within the cell and is 
recycled as needed. The results presented in our study suggest that there are two general 
types of transporter systems in E. coli; one system that is dependent upon metabolic 
energy for the extrusion of the universal substrate EB and is evident at pH 8, and 
another general system that is readily demonstrable at pH 5 and which consists of 8 or 
more efflux pumps that accompany the main efflux pump of this organism, namely, the 
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AcrAB-TolC pump (65). These latter efflux pumps are dependent upon protons present 
in the periplasm for their activation, as discussed previously.  
The role of calcium was investigated in this thesis and described in Section 2.4 of the 
Results. Briefly, the addition of EDTA, a chelator of calcium, increases accumulation of 
EB and decreases its efflux. The addition of calcium inhibits the EDTA responses as 
well as the responses to CPZ. The addition of EDTA and CPZ has additive effects on 
the accumulation and efflux of EB. These results suggest that the activity of CPZ on 
accumulation and efflux is due to it having an effect on calcium. Because there is no 
calcium in the medium and there is no replication of cells during the assay period, the 
calcium that is being affected must be surface bound calcium that had been retained 
from the culture of the bacterium in complete MHB medium. 
Previous observations of ATPase activation made in yeast showed that extracellular 
calcium appeared to be essential for the CCCP-induced activation of ATPase, because 
pre-incubation of cells with EGTA (a calcium chelator equivalent to EDTA) completely 
inhibited this activation process. On the other hand, when an equimolecular calcium 
concentration was added together with EGTA, the CCCP-induced activation of the 
ATPase took place (258).  
The increase of EB accumulated and inhibition of EB efflux by CPZ at pH 8 and not at 
pH 5 is interpreted to result from an interference with access to calcium by ATPases 
that provide protons at pH 8. Because at pH 8 hydrolysis of ATP is favoured and 
contributes protons for the activation of ABC type transporters, CPZ is, at this time, 
suspected of having its effects on accumulation/efflux of EB by indirectly affecting 
ATPase activity. 
In conclusion, a phenothiazine such as CPZ or TZ has a variety of effects on the efflux 
machinery of the bacterium. These effects involve adaptive responses that are mediated 
by the activation of global and local regulator genes, stress genes and genes that code 
for the transporter component of the efflux pump AcrAB (267). In addition, the 
phenothiazines inhibit access to calcium more or less in the same manner they have 
been shown for eukaryotes (154;194). Because the EB assay is of short duration, one 
may say that the phenothiazine effects, noted via this assay, represent the earliest 
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response of the bacterium to the noxious phenothiazine. This early response allows the 
organism to survive while the genetic responses to the phenothiazine prepare the 
organism for long term survival in the presence of the agent.  
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3. Search for new active compounds against resistance 
 
As a consequence of new concepts introduced in the previous sections, a search for new 
compounds that modulate efflux has been undertaken. In this respect, because plants 
have been shown to contain such agents and previous studies indicated that one 
particular plant Carpobrotus edulis had properties that affected efflux, the isolation of 
active compounds from this plant was undertaken in this thesis. The isolation and 
characterisation of isolated compounds from plant sources is encouraged given the fact 
that such plants have a long history of medicinal use that suggest the presence of efflux 
pump modulators (example: plants that alleviated gastric reflux contain inhibitors of 
efflux pumps that secrete H+ and cause gastritis, etc. (284)). Because the therapy of 
MDR infections that are mediated by efflux pumps may eventually include agents that 
inhibit efflux activity of the clinical isolate, the compounds isolated from C. edulis were 
evaluated for activity against efflux by MDR bacteria that over express an efflux pump. 
Moreover, because medicinal use of some plants for cancers and other malignancies is 
widely reported and result in the isolation of compounds that inhibit the P-gp transporter 
of MDR cancer cells, the activity of the isolated compounds on the over-expressed P-gp 
transporter of MDR cancer cells was also investigated. 
Because of the results obtained in this thesis, attention has been focused on a variety of 
physiological factors that define conditions under which MDR bacteria and MDR 
cancer exist. Among these factors is pH. If a better understanding of the infection 
process and its relationship to efflux is to be gained, pH is an important and 
fundamental tool. However, the approach is first to conduct screening of isolated agents 
for effects on efflux by MDR bacteria and MDR cancer at pH 7 simply because all 
assays that evaluate the effects of an agent on efflux are conducted at this pH plus, if the 
isolated compound had been previously evaluated, the use of pH 7 provides a 
comparison between the data that is obtained by different methods versus those used in 
this work, such as the semi-automated EB method results. Active compounds may then 
be examined at varying pH in order to relate the activity at sites of infection or site of 
cancer that differ with respect to pH (examples: infection of the stomach by H. pylori or 
gastric MDR carcinoma, both of which take place at acidic pH). 
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Because the methanol extract of the plant C. edulis was shown to enhance the killing 
activity of infected macrophages and inhibit the ABC transporter in human mdr1 
transfected mouse lymphoma cells, this extract was investigated for its active 
compounds responsible for the reported activities. Moreover, this plant has also been 
described for many uses in traditional medicine. Consequently, the two main 
characteristics of a plant that support the isolation and evaluation of compound, namely, 
traditional medicinal use of the plant and activity of the plant extract are satisfied by C. 
edulis. The discussion of the results obtained for the purification and study of the 
activity of the isolated compounds are described below.   
 
3.1 Purification and identification of the compounds 
 
Methanol, as a semi-polar solvent, is appropriate for the extraction of constituents of a 
wide range of polarity. Moreover, previous activity of this plant was reported for the 
methanolic extract (175;176). Methanol was then chosen for the first solvent of the 
extraction. Extensive percolation with this solvent is a simple and effective method for 
the extraction because such extracts contain a wide scale of compounds (small 
molecular, hydrophobic, hydrophilic, polypeptides, etc). The fresh aerial parts (leaves) 
of C. edulis collected in November and January were extracted with methanol and the 
resulting aqueous was used in solvent-solvent partition.  
Solvent-solvent partition on the crude extract is a high capacity, economic technique, 
which is commonly used in natural product chemistry as the first separation step. The C. 
edulis crude extract was partitioned with hexane in order to obtain the fraction with the 
most apolar compounds of the plant leaves. This was followed by successive 
separations of the methanolic extract with chloroform and ethyl acetate, in an increasing 
order of polarity. 
Preparative-scale classical adsorption chromatography on silica is also a valuable 
method in the preliminary purification. This method has a very high capacity and is 
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cheap enough to be economic in the separation of samples in large amounts. After 
preliminary purification, a multistep procedure of combined chromatographic methods 
was followed for the isolation of active compounds. All of these chromatographic steps 
were monitored by using TLC, which is a simple and fast method. The TLC behaviour 
of the compounds helped in the choice of adequate solvent systems for the next 
isolation steps. In the end 5 more apolar compounds from the hexane/chloroform 
fraction and 3 more polar compounds from the ethylacetate fraction were obtained. 
The compounds isolated were identified by NMR as 3 flavonoids: catechin, epicatechin 
and procyanidin B5; 3 triterpenes: uvaol, oleanolic acid and β-amyrin, and a 
galactolipid: monogalactosyldiacylglycerol (MGDG). All of these compounds were 
isolated for the first time from C. edulis and for the Aizoaceae family. However, these 
compounds have also been isolated and characterised from other plants (222-229).  
Phenolic compounds such like catechin, epicatechin and its derivatives, mainly found in 
green tea, have been shown to act as anti-oxidants and provide protection from 
congestive heart failure (285), as anti-atherosclerotic (286), as chemopreventives (287), 
as anti-inflammatory agents (288) or as inhibitors of the gastric H+, K+-ATPase (289). 
Therefore these compounds could be the responsible for the successful use of C. edulis 
in traditional medicine for stomach problems and inflammatory pathologies 
(167;169;170). The results obtained and described in Section 3.6.2 of the Results show 
that epicatechin has no inhibitory effect on P-gp. These results are in agreement with 
others (290). However, some inhibitory effect has been reported with chemical 
derivatives of this compound (290). Procyanidin B5 dimmers were, also, demonstrated 
as potential chemopreventive agents against breast cancer by suppressing in situ 
estrogen biosynthesis (291).These flavonoids and related metabolites have been 
reported to exhibit mild activity towards mycobacteria, inhibiting its growth (148). Data 
from the literature also identify simple phenolic compounds such as epicatechin as 
antimicrobial compounds via a mechanism that disrupts the cell envelope (292). 
Catechin was also identified as an antimicrobial with MIC between 2 and 78 mg/L 
against a wide range of Gram-negative bacteria and 10 and 20 mg/L against Gram-
positive (293). In earlier investigations, catechin has been described to potentiate the 
action of streptomycin against M. tuberculosis infection in mice and decreases the 
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incidence of pulmonary tuberculosis fourfold, and that, this effect is probably due to 
their inhibitory effect on fatty acid and mycolic acid biosynthesis (150). This is an 
important result since C. edulis juice is used in the traditional medicine against TB 
infections. Other flavonoids were even shown to inhibit mycobacterial efflux pumps 
and potentiate the action of INH, but the mechanism is yet to be determined (150), or 
inhibit the efflux activity of NorA from MRSA strains (28).  
Other three of the isolated compounds belong to the class of the triterpenes. This class 
of compounds was also described to exhibit antimycobacterial activity. Uvaol, oleanolic 
acid and β-amyrin had an MIC of 8 mg/L (148;294), 28.7 mg/L (148;295) and 12.2 
mg/L (148;296) respectively, against M. tuberculosis determined by microplate alamar 
blue assay. By the same method oleanolic acid had an MIC of 25 mg/L against M. 
tuberculosis H37Rv and 50 mg/L against M. tuberculosis H37Rv strains individually 
resistant to streptomycin, isoniazid, rifampicin and ethambutol (297). These compounds 
and others from oleane and ursane skeleton triterpenes were also described with anti-
ulcer activity and other pharmacological properties such as anti-inflammatory, anti-
allergic, anti-nociceptive, anti-tumor and anti-viral activities (298). Antiproliferative 
and apoptosis-inducing effects of oleanolic acid on colon cancer cells were also reported 
(299). In 1995 Jiu Liu reported different properties of oleanolic acid and its use in 
human therapies such in liver failure and disorders, anti-inflammatory or anti-tumor 
activities, among others and no toxic effects were observed in rats or in humans. Those 
clinical trials also led to the patenting in Japan of the oleanolic acid as addictive to 
health drinks, hair tonics or topical used preparations for prevention of skin cancer 
(300). 
During bibliographic search for this thesis some biological activities were found for the 
galactolipid monogalactosyldiacylglycerol; anti-algal, anti-viral, anti-tumor and anti-
inflammatory activities reported for glycoglycerolipids isolated from cyanobacteria 
(301). This compound, together with digalactosyldiacylglycerol, represents ca. 75% of 
the total membrane lipids in plant leaves. They have special importance in membranes 
where photosynthesis occur and are not commonly found in animals (301).  
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3.2 Activity of C. edulis compounds against bacteria 
 
During this first screening for in vitro activity of the compounds against Gram-negative, 
Gram-positive and Mycobacteria, it was possible to observe that none of the compounds 
were active against Gram-negative bacteria but some of them were very active against 
certain Gram-positive bacteria and had moderate activity against Mycobacteria. 
The results for the MRSA COLOXA strain and S. aureus HPV 107 are of significant 
importance. Susceptibility/resistance of given bacteria is defined by critical 
concentrations and regression analysis of Kirby-Bauer data (29). The application of this 
approach for defining susceptibility/resistance is beyond the scope of this thesis. 
However, if we employ the MIC results in terms of mg/L, some comparison can be 
made between the activity of the compounds isolated against given bacteria and that by 
conventional antibiotics. Oleanolic acid can be considered to exhibit high activity 
against the E. faecalis strain inasmuch as its MIC 6 mg/L comparing to the 
susceptibility of this strain to common antibiotics (189). Similarly, results obtained to 
the M. tuberculosis H37Rv strain are good and in correlation with data from the 
literature to the oleanolic acid  (297). 
Previous results showed that the methanolic extract could reduce or reverse the activity 
of antibiotics against specific bacteria (175). Therefore the compounds isolated were 
evaluated for that property. None of the compounds reduced the resistance of S. 
enteritidis 104CIP and MRSA strains to antibiotics to which they were resistant. This 
suggests that these compounds did not affect the efflux system of these organisms. 
However, some of the compounds reduced or reversed resistance to some antibiotics in 
other strains. Among these compounds, uvaol was the compound that had the greatest 
ability to reduce resistance of MDR Gram-negative and MDR Gram-positive strains to 
antibiotics to which they were initially resistant. These MDR bacterial strains owed 
their MDR phenotypes to over-expressed efflux pump systems. Uvaol also reversed 
resistance of MDR cancer cells; therefore it is this compound that has promise as a 
modulator of efflux by MDR bacteria and MDR cancer cells and should be furthered 
studied.  
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However, when tested for the modulation of activity against bacteria by the semi-
automated EB method, uvaol did not increase the accumulation of EB inside Gram-
negative strains (E. coli AG100 and E. coli AG100TET8). However, it did increase 
accumulation of EB by the MRSA strain (S. aureus COLOXA). This increased 
accumulation was influenced by glucose. This glucose influence was demonstrable by 
the rates of accumulation; whereas in the absence of glucose the rate of accumulation 
was steady per unit period of time; in the presence of glucose accumulation was much 
steeper. These results suggest that uvaol may penetrate the bacterium via a glucose 
controlled pathway. Once it penetrates it may then act on the efflux pump system.  
MGDG was the other compound that promotes increases of accumulation of EB by the 
MRSA COLOXA strain but only in the absence of glucose. This may be due to a glucose 
dependent efflux pump system that extrudes the MGDG and that accumulation of EB is 
very much similar to the effects of PAβN, namely, MGDG competes with EB. However 
complementary studies should be done to understand its mechanism of action. 
Oleanolic acid, a compound with a similar skeleton to uvaol, was, together with 
catechin and epicatechin, modestly active in the modulation of accumulation and efflux 
of EB by E. coli strains. Oleanolic acid is known as an inhibitor of protein kinase, while 
flavonoids were shown to inhibit the transport of glucose. These two mechanisms 
prevent the derivation of energy needed for efflux pump activity, therefore 
accumulation takes place. In the presence of glucose, the capacity for inhibition by the 
compounds is not very significant and therefore less accumulation is observed. 
However as the effects were not considerably higher as the ones observed previously for 
other compounds such as verapamil or phenothiazines whose sites of action are more 
directly related with the efflux pumps itself, it can be thought that for inhibition of 
efflux activity, the compounds should inhibit key physiological pathways that are more 
proximal to the efflux pumps. 
The compounds were then tested for their ex-vivo activity against the model strains S. 
aureus ATCC and MRSA. Again, uvaol was the compound that increases the killing 
activity of the macrophages when infected with either one of the two strains. Oleanolic 
acid, catechin and MGDG were also active but only when infected with the ATCC 
strain (first two) or the MRSA (MGDG). At this time we cannot say that the 
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enhancement of killing by non-killing macrophages is due to accumulation of the 
compounds to levels compatible with in vitro bactericidal levels (152) or by direct 
interaction with the phagolysosomal system of the macrophage itself (194).  
The activity of uvaol is again the most promising for future studies in Mycobacterium 
tuberculosis infection of macrophages. This compound apparently has activity against a 
wide range of efflux pump families. 
 
3.3 Anticancer activity 
 
From the results obtained, although all of the compounds had anti-proliferative activity 
against parental (PAR) and its mdr1 transfected progeny, only MGDG had major 
activity against the MDR cell line while uvaol and oleanolic acid were more effective 
against the PAR cell. The remainder of the compounds, although effective, did not 
discriminate among the two cell lines with respect to activity. Nevertheless it must be 
remembered that both cell lines are cancer cells and therefore the discrimination 
between the cancer cell lines by some of the compounds has clinical significance. 
Previous authors showed that the MGDG compound could decrease the biosynthesis of 
cholesterol by inhibiting the human enzyme lanosterol synthase (228). This result, 
together with the lipophilicity of MGDG, can explain that the compound MGDG 
interacts with the MDR cell line in a more specific manner, and hence is more effective 
against the more sensitive MDR cell line.  
Uvaol exhibited a significant effect on the inhibition of the P-gp that resulted in the 
accumulation of rhodamine 123 inside the MDR mouse lymphoma cells. This 
compound also showed a concentration dependent activity with an increase of the FAR 
values for the higher concentrations. Oleanolic acid has very weak activity and β-
amyrin, MGDG, catechin, epicatechin and procyanidin B5 were not effective. These 
results were confirmed by the ones obtained by the semi-automated EB method adapted 
for the evaluation of activity against the P-gp transporter of these cancer cell lines. 
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Uvaol also promotes an increase in concentration of EB; the oleanolic acid is less 
effective. By this technique, EB accumulation promoted by MGDG was also observed. 
Of the compounds isolated from C. edulis, uvaol was the most effective in inhibiting the 
extrusion of rhodamine 123 and EB by the MDR mouse lymphoma cells as evident 
from the accumulation of these P-gp substrates, demonstrated by two distinctly different 
methods, flow cytometry and the semi-automated EB method, respectively. Because 
this compound does not produce toxicity at the concentrations employed, it may have 
potential as an adjuvant for the therapy of MDR cancer that is refractory to therapy. 
The structural difference between uvaol and β-amyrin or oleanolic acid is the methyl 
group at position C-29 (Figure 51 – 1, 2 and 3) and seems to play an important role in 
the activity of this class of compounds. Further studies should be conducted in order to 
study in more detail the structure-activity relationship. Furthermore, members of the 
triterpenes group may serve as lead compounds for the synthesis of new compounds that 
may prove even more effective as inhibitors of P-gp than those isolated from C. edulis; 
hence, they may serve as adjuvants in cancer chemotherapy.  
 
3.4 Structure activity relationship 
 
During this dissertation work, a group of compounds were tested for their activity as 
modulators of efflux. Figure 50 shows the structure of the compounds used in this work 
and that were previous characterized as efflux modulators or EPIs against MDR bacteria 
and cancer. Figure 51 shows the structure of the active compounds obtained in this 
thesis from the plant C. edulis. The compounds oleanolic acid, uvaol, catechin, 
epicatechin and MGDG presented activity against bacterial efflux pumps, showed by 
the reduction of antibiotic MIC whose resistance was acquired by over-expression of 
EP. When reduction of MIC was observed, the compound uvaol was the one that always 
showed activity. Compound uvaol also significantly inhibits the P-gp pump of the tested 
cancer cell line, followed by oleanolic acid whose activity was much lower. 
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Figure 50 – Structures of the commonly used efflux modulators. 
(1) Verapamil; (2) PAβN; (3) CCCP; (4) chlorpromazine; and (5) thioridazine. 
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Figure 51 - Structures of the isolated compounds from the methanolic extract of C. edulis 
(1) β-amyrin; (2) oleanolic acid; (3) uvaol; (4) monogalactosyldiacylglycerol (MGDG); (5) catechin; (6) 
epicatechin; and (7) procyanidin B5. 
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In this work it is not possible to make a detailed study about structure activity 
relationship (QSAR) of the tested compounds. For this kind of study, a greater number 
of compounds from the same structural family are needed, in other words with the same 
structural core, or exactly with the same activity assay, in order of a possible correlation 
between the structure (2D and 3D) and the activity observed. However, from the 
structures presented in the previous figures and others that can be found in the literature, 
no inference of structure to activity is at this time possible. The wide variety of EPs, 
together with the differences on the cellular envelope of Gram-positive and Gram-
negative bacteria, Mycobacteria and all kinds of Eukaryotic cells, makes this “job” very 
difficult. However, compounds that influence the energy systems of the cell, specifically 
those that block common constituents of the majority of efflux pumps or interact with 
the membrane of the cells, can be promising agents for the use as adjuvants in therapy. 
It is also important that the referred compounds specifically interact with bacterial cells, 
if for use against bacterial infections or the cancer cells, if adjuvants in chemotherapy, 
but not active on healthy human cells.  
The presented work gave an important contribution to the study of the mechanisms of 
efflux, as well as for the discovery/synthesis of new compounds that could fill the 
requests cited previously and then, be used in therapy for reversion of multi-drug 
resistance. 
  
 
 
 
 
 
 
 
 
 
 
 
 
VI. FINAL REMARKS AND FUTURE PERSPECTIVES 
 
  
 
Final Remarks 
From the work conducted for this thesis, important conclusions can be taken according 
to the physiology and modulation of efflux and the activity of C. edulis isolated 
compounds. The conclusions of this dissertation are summarized below. 
 
1. Physiology and modulation of efflux 
 
• The cell envelope of bacteria is fundamental to their survival and response to the 
changes in the environment; 
• In vitro antibiotic pressure to drug resistance strains results in the acquisition of 
an MDR phenotype mimic what happens in vivo during chemotherapy; 
• Efflux of EB by Gram-negative bacteria, namely E. coli is dependent on the pH 
of the environment of the cell (media); 
• The efflux response is independent on the pH of growth of the bacteria; 
• Energy dependent efflux mechanisms vary upon the pH and the conjunction of 
pH and glucose is an important tool in the study and understanding of the 
physiology and mechanisms of efflux; 
• Efflux pumps belonging to the ABC superfamily have an important role in 
efflux at pH 8 as shown by the assays with CCCP, Verapamil, EDTA, CPZ and 
Calcium; 
• PMF is essential for RND family mediated efflux as per the results obtained at 
pH 5; 
• CCCP is an important molecule to use at different pH in order to distinguish the 
role of protons on the efflux and consequently the PMF due to its capacity of 
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binding protons. Together with pH, it helps to distinguish which should be the 
main types of efflux transporters that are working at the different conditions; 
• PAβN modulates efflux of EB by competing with EB for the site of extrusion of 
the pump and a KM was determined; 
• A proposal of regulation of the efflux mediated by pH and energy is presented in 
the following figures: 
 
 
Figure 52 - Representation of the proposed efflux mechanisms at pH 5. 
The relevant mechanisms that occur at pH 5 and influence the efflux activity of bacteria are colored while 
grey pathways, unless present, have a minor contribution for the efflux at this pH. At pH 5 the essential 
aspects of efflux are carried out by the RND efflux pump system of Gram-negative bacteria. This system, 
as noted, is dependent upon the establishing and maintenance of the PMF which results from the 
metabolism (catabolism) of glucose and the production of H+ that are handled by two related 
mechanisms: production of ATP and transport to surface of cell. The equilibrium may be presented as 
follows:  2H++ pi + ADP → ATP /2H+ → surface.  The balance is affected by efflux pump activity.  
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Figure 53 - Representation of the proposed efflux mechanisms at pH 8. 
The relevant mechanisms that occur at pH 8 and influence the efflux activity of bacteria are colored while 
grey pathways, unless present, have a minor contribution for the efflux at this pH. At pH 8 the essential 
aspects of efflux are carried out by the ABC transporter system of Gram-negative bacteria. This system, 
as noted, is dependent upon glucose as source of energy (ATP) and much less dependent upon PMF than 
at pH 5. ATPase and ETC (electron transporter chain) play an important role in pumping out the protons 
to maintain the membrane PMF. 
 
• Some studies on docking of efflux pumps and efflux modulator compounds 
should be done considering the conditions used in the assays described in this 
thesis to allow a better understanding of the possible interactions; 
• Similar work should be done with Gram-positive strains. The results of such 
kind of assay should also improve the knowledge about the role of the different 
structures of the Gram-negative and Gram-positive cell envelope on efflux 
regulation; 
• The term EPI, efflux pump inhibitor, is not adequate in the majority of the 
situations when a compound interfere with the efflux of an agent. Some 
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compounds seem to modulate or inhibit efflux through other processes than 
direct inhibition of the pump. 
 
2. Activity of C. edulis isolated compounds 
 
• This was the first time that compounds β-amyrin, oleanolic acid, uvaol, MGDG, 
catechin, epicatechin and procyanidin B5 were isolated from the plant C. edulis 
and from the Aizoaceae family. 
• The majority of the compounds isolated from C. edulis are active as 
antimicrobial agent or efflux pump inhibitor. Oleanolic acid presented in this 
study a high antibacterial activity against a higher number of bacterial strains. Its 
activity against E. aerogenes is of great significance so that it is suggested to be 
studied, in the future, in more detail how oleanolic acid interferes with the 
growth of this strain;  
• The triterpene uvaol was the most active compound as efflux modulator in 
bacteria and cancer cells. In the future, its activity on bacterial efflux pumps 
could be studied under different conditions such as pH, glucose availability and 
influence on the efflux of EB with the addiction of the compound after a period 
of EB accumulation, as described in the previous section in order to understand 
its mechanism of action; 
• Triterpenes could be the family of compounds responsible for the activity of C. 
edulis in the reversal of resistance in the studied cancer cell line. However, their 
activity could be dependent on the substituent of the molecule which facilitates 
the interaction of the compound with the efflux pump;  
• Promising studies could be done in the structure / activity relation of triterpene 
molecules in order to use them as efflux modulators in cancer chemotherapy and 
therapy of infections with MDR strains; 
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• The use of some of this compound as adjuvants in TB therapy is also promising. 
However, the next step of the work should be the use of MDR M. tuberculosis 
strains as test its modulation of resistance in presence of the compounds, namely 
oleanolic acid and uvaol. At the time of the writing of this thesis additional work 
to verify this premises was ongoing. 
• C. edulis plant also seems to be a promising plant to search of more effective 
compounds. Its availability and not specially requirements in the growth is an 
advantage to the use of this plant in extraction of active compounds in sufficient 
amount. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
VII. REFERENCES 
 
 
   
 
References 
1. Merck. 1987. The Merck Manual. Merck Sharp and Dohme International, 
Rahway, N.J.  
2. Langenscheidt. 2002. Langenscheidt's Pocket Merriam-Webster Medical 
Dictionary. Langenscheidt Publishing Group. 
3. Fleming, A. 1945. Penicillin. Nobel Prize Lecture.  
http://nobelprize.org/nobel_prizes 
4. Zuzhetskyy, A., S. Pelzer, and A. Bechthold. 2007. The future of natural 
products as a source of new antibiotics. Curr. Opin. Investig. Drugs 8:608-613. 
5. Schatz, A., Bugie, E., Waksman, S., and Hanssen, A. 1944. Streptomycin, a 
Substance Exhibiting Antibiotic Activity against Gram-Positive and Gram-
Negative Bacteria. Proc. Soc. Exp. Biol. Med. 55:66-69. 
6. Duggar BM. 1948. Aureomycin: a product of the continuing search for new 
antibiotics. Ann N Y Acad Sci. 51:177-181. 
7. Conover, L.H. January 1955. Tetracycline. U.S. Patent 385041(2699054). 
8. Reynolds J. E. F. (ed.). 1996. Antibacterial Agents, p. 129-170. In: Martindale - 
The Extra Pharmacopoeia. Royal Pharmaceutical Society, London. 
9. Watanabe, T. 1963. Infective heredity of multiple drug resistance in bacteria. 
Bacteriol. Rev. 27:87-115. 
10. Butler, M. S. and A. D. Buss. 2006. Natural products - The future scaffolds for 
novel antibiotics? Biochem. Pharmacol. 71:919-929. 
11. World Health Organization. 2000. Overcoming Antimicrobial Resistance  
World Health Report on Infectious Diseases 2000. 
12. Gottesman, M. M., T. Fojo, and S. E. Bates. 2002. Multidrug resistance in 
cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2:48-58. 
13. Kaye, S. B. 1998. Multidrug resistance: Clinical relevance in solid tumours and 
strategies for circumvention. Curr. Opin. Oncol. 10:S15-S19. 
14. Sayed-Ahmed, M. M. 2007. Multidrug resistance to cancer chemotherapy: 
Genes involved and blockers. Saudi Pharmaceutical Journal 15:161-175. 
199 
References 
15. Sikic, B. I. 1997. Modulation and prevention of multidrug resistance by 
inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol. 40:S13-S19. 
16. Gibbons, S. 2008. Phytochemicals for baterial Resistance - Strengths, 
weaknesses and opportunities. Planta Med. 74:594-602. 
17. Kaatz, G.W. 2005. Bacterial efflux pump inhibition. Curr. Opin. Investig. 
Drugs 6:191-198. 
18. Kamicker, B. J., M. T. Sweeney, F. Kaczmarek, F. Dib-Hajj, W. Shang, K. 
Crimin, J. Duignan, and T. D. Goot. 2008. Bacterial efflux pumps inhibitors. 
Methods Mol. Med. 142:187-204. 
19. Marquez, B. 2005. Bacterial efflux systems and efflux pumps inhibitors. 
Biochimie 87:1137-1147. 
20. Martins, M., S. D. Dastidar, S. Fanning, J. E. Kristiansen, J. Molnár, J. M. 
Pagès, Z. Schelz, G. Spengler, M. Viveiros, and L. Amaral. 2008. Potential 
role of non-antibiotics (helper compounds) in the treatment of multidrug-
resistant Gram-negative infections: mechanisms for their direct and indirect 
activities. Int. J. Antimicrob. Agents 31:198-208. 
21. Werle, M., H. Takeuchi, and A. Bernkop-Schnurch. 2008. New-generation 
efflux pump inhibitors. Expert Review of Clinical Pharmacology 1:429-440. 
22. Dutta, N.K., S. Annadurai, K. Mazumdar, S. G. Dastidar, J. E. Kristiansen, 
J. Molnár, M. Martins, and L. Amaral. 2007. Potential management of 
resistant microbial infections with a novel non-antibiotic: the anti-inflammatory 
drug diclofenac sodium. Int. J. Antimicrob. Agents 30:242-249. 
23. Nikaido, H. 2003. Molecular basis of bacterial outer membrane permeability 
revisited. Microb. Mol. Biol. Rev. 67:593-656. 
24. Poole, K. 2002. Mechanisms of Bacterial biocide and antibiotic resistance. J. 
Appl. Microbiol. 92:55s-64s. 
25. Hogan, D., and R. Kolter. 2002. Why are bacteria refractory to antimicrobials? 
Curr. Opin. Microbiol. 5:472-477. 
26. McManus, M. C. 1997. Mechanisms of bacterial resistance to antimicrobial 
agents. Am. J. Health Syst. Pharm. 54:140-143. 
200 
References 
27. Wilcox, S. 2004. Cationic peptides: a new hope. The science creative quarterly. 
www.scq.ubc.ca/cationic-peptides-a-new-hope/. 
28. Stavri, M., L. J. V. Piddock, and S. Gibbons. 2007. Bacterial efflux pump 
inhibitors from natural sources. J. Antimicrob. Chemother. 59:1247-1260. 
29. Lorian, V. 2009. Antibiotics in laboratory medicine. Williams & Wilkins, 
Baltimore. 
30. Rosenshine, I., T. Zusman, R. Werczberger, and M. Mevarech. 1987. 
Amplification of specific DNA sequences correlates with resistance of the 
archaebacterium Halobacterium volcanii to the dihydrofolate reductase 
inhibitors trimethoprim and methotrexate. Molecular and General Genetics 
208:518-522. 
31. Hooper, D. 2008. Target modification as mechanism of antimicrobial resistance, 
p. 133-167. In: K. Lewis, A. Sayers, H. Taber, and T. Wax (eds.), Bacterial 
Resistance to Antimicrobials. Marcel Dekker, New York. 
32. Swedberg, G., and O. Sköld. 1983. Plasmid-borne sulfonamide resistance 
determinants studied by restriction enzyme analysis. J. Bacteriol. 153:1228-
1237. 
33. Dupont, M., C. E. James, J. Chevalier, and J. M. Pagès. 2007. An early 
response to environmental stress involves regulation of OmpX and OmpF, two 
enterobacterial outer membrane pore-forming proteins. Antimicrob. Agents 
Chemother. 51:3190-3198. 
34. Ceccarelli, M. and P. Ruggerone. 2008. Physical insights into permeation of 
and resistance to antibiotics in bacteria. Curr. Drug Targets 9:779-788. 
35. Li, X. Z. and H. Nikaido. 2004. Efflux-mediated drug resistance in bacteria. 
Drugs 64:159-204. 
36. Webber, M. A., and L. J. V. Piddock. 2003. The importance of efflux pumps 
in bacterial antibiotic resistance. J. Antimicrob. Chemother. 51:9-11. 
37. Viveiros, M., A. Jesus, M. Brito, C. Leandro, M. Martins, D. Ordway, A. M. 
Molnár, J. Molnár, and L. Amaral. 2005. Inducement and reversal of 
tetracycline resistance in Escherichia coli K-12 and expression of proton 
201 
References 
gradient-dependent multidrug efflux pump genes. Antimicrob. Agents 
Chemother. 49:3578-3582. 
38. Stephan, J., C. Mailaender, G. Etienne, M. Daffé, and M. Niederweis. 2004. 
Multidrug resistance of a porin deletion mutant of Mycobacterium smegmatis. 
Antimicrob. Agents Chemother. 48:4163-4170. 
39. Baird, R. D., and S. B. Kaye. 2003. Drug resistance reversal - are we getting 
closer? Eur. J. Cancer 39:2450-2461. 
40. Ling, V. 1997. Multidrug resistance: molecular mechanisms and clinical 
relevance. Cancer Chemother. Pharmacol. 40:S3-S8. 
41. Meijerman, I., J. H. Beijnen, and J. H. M. Schellens. 2008. Combined action 
and regulation of phase II enzymes and multidrug resistance proteins in 
multidrug resistance in cancer. Cancer Treat. Rev. 34:505-520. 
42. Paustian, T. and G. Roberts. 2009. Through the Microscope. Textbook 
Consortia. http://www.microbiologytext.com/ 
43. Angert, E. 2009. Low G + C Gram positive bacteria. Department of 
Microbiology, Cornell University. Accessed on 18-9-2009. 
www.micro.cornell.edu 
44. Park, S. H. and A. Bendelac. 2000. CD1-restricted T-cell responses and 
microbial infection. Nature 406:788-792. 
45. Gill, S. R. and D. E. Fouts. 2005. Insights on Evolution of virulence and 
resistance from the complete genome analysis of an early methicillin-resistance 
Staphilicoccus aureus and a biofilm-producing methicillin-resistance 
Staphylococcus epidermis strain. J. Bacteriol. 187:2426-2438. 
46. Couto I, Costa SS, Miguel V, Martins M, and Amaral L. 2008. Efflux-
mediated response of Staphilococcus aureus exposed to ethidium bromide. 
J.Antimicrob.Chemother. 62:504-513. 
47. Langton, K., P. Henderson, and R. Herbert. 2005. Antibiotic resistance: 
multidrug efflux proteins, a common transport mechanism? Nat. Prod. Rep. 
22:439-451. 
202 
References 
48. Pumbwe, L., L. P. Randall, M. J. Woodward, and L. J. V. Piddock. 2004. 
Expression of the efflux pump genes cmeB, cmeF and the porin gene porA in 
multiple-antibiotic-resistant Campylobacter jejuni. J. Antimicrob. Chemother. 
54:341-347. 
49. Liu, J., E. Y. Rosenberg, and H. Nikaido. 1995. Fluidity of the lipid domain of 
cell wall from Mycobacterium chelonae. Proc. Natl. Acad. Sci. USA 92:11254-
11258. 
50. Salmi, C., C. Loncle, N. Vidal, Y. Letourneux, J. Fantini, M. Maresca, N. 
Taïeb, J. M. Pagès, and J. M. Brunel. 2008. Squalamine: An appropriate 
strategy against the emergence of multidrug resistant gram-negative bacteria? 
PLoS ONE 3:e2765. 
51. Nikaido, H. 2005. Restoring permeability barrier function to outer membrane. 
Chem. Biol. 12:507-509. 
52. Gunn, J. S. 2008. The Salmonella PmrAB regulon: lipopolysaccharide 
modifications, antimicrobial peptide resistance and more. Trends Microbiol. 
16:284-290.  
53. Murata, T., W. Tseng, T. Guina, S. I. Miller, and H. Nikaido. 2007. PhoPQ-
mediated regulation produces a more robust permeability barrier in the outer 
membrane of Salmonella enterica serovar Typhimurium. J. Bacteriol 189:7213-
7222. 
54. Mulkidjanian, A. Y., J. Heberle, and D. A. Cherepanov. 2006. Protons @ 
interfaces: Implications for biological energy conversion. Biochim. Biophys. 
Acta 1757:913-930. 
55. Cherepanov, D.A., W. Junge, and A. Y. Mulkidjanian. 2004. Proton transfer 
dynamics at the membrane/water interface: dependence on the fixed and mobile 
pH buffers, on the size and form of membrane particles, and on the interfacial 
potential barrier. Biophys. J. 86:665-680. 
56. Turina, P., A. Rebecchi, M. D'Alessandro, S. Anefors, and B. A. Melandri. 
2006. Modulation of proton pumping efficiency in bacterial ATP synthases. 
Biochim. Biophys. Acta - Bioenergetics 1757:320-325. 
203 
References 
57. Ambler, R. P. 1980. The Structure of beta-Lactamases. Philos. Trans. R. Soc. 
Lond. B Biol. Sci. 289:321-331. 
58. Georgopapadakou, N. H. 1993. Penicillin-binding proteins and bacterial 
resistance to beta-lactams. Antimicrob. Agents Chemother. 37:2045-2053. 
59. Weingart, H., M. Petrescu, and M. Winterhalter. 2008. Biophysical 
characterization of in- and efflux in Gram-negative bacteria. Curr. Drug Targets 
9:789-796. 
60. Klitgaard, J. K., M. N. Skov, B. H. Kallipolitis, and H. J. Kolmos. 2008. 
Reversal of methicillin resistance in Staphylococcus aureus by thioridazine. J. 
Antimicrob. Chemother. 62:1215-1221.  
61. Cowan, S. W., T. Schirmer, G. Rummel, M. Steiert, R. Ghosh, R. A. 
Pauptit, J. N. Jansonius, and J. P. Rosenbusch. 1992. Crystal structures 
explain functional properties of two E. coli porins. Nature 358:727-733. 
62. Davin-Regli, A., J. M. Bolla, C. E. James, J. P. Lavigne, J. Chevalier, E. 
Garnotel, A. Molitor, and J. M. Pagès. 2008. Membrane permeability and 
regulation of drug influx and efflux in Enterobacterial pathogens. Curr. Drug 
Targets 9:750-759. 
63. Pagès, J. M. 2004. Porines bactériennes et sensibilité aux antibiotiques. 
Medicine/sciences 20:346-351. 
64. Pagès, J. M., C. E. James, and M. Winterhalter. 2008. The porin and the 
permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. 
Nat. Rev. Microbiol. 6:893-903. 
65. Viveiros, M., M. Dupont, L. Rodrigues, I. Couto, A. Davin-Regli, M. 
Martins, J. M. Pagès, and L. Amaral. 2007. Antibiotic stress, genetic response 
and altered permeability of E. coli. PLoS ONE 2:e365. 
66. Chen, S., A. Zhang, L. B. Blyn, and G. Storz. 2004. MicC, a second small-
RNA regulator of Omp protein expression in Escherichia coli. J.Bacteriol. 
186:6689-6697. 
67. VanBambeke, F., E. Balzi, and P. M. Tulkens. 2000. Antibiotic efflux pumps. 
Biochem. Pharmacol. 60:457-470. 
204 
References 
68. Piddock, L. J. V. 2006. Multidrug-resistance efflux pumps - not just for 
resistance. Microbiology 4:629-636. 
69. VanBambeke, F., Y. Glupczynski, P. Plésiat, J. C. Pechère, and P. M. 
Tulkens. 2003. Antibiotic efflux pumps in prokaryotic cells: occurrence, impact 
on resistance and strategies for the future of antimicrobial theraphy. J. 
Antimicrob. Chemother. 51:1055-1065.  
70. Moussatova, A., C. Kandt, M. L. O'Mara, and D. P. Tieleman. 2008. ATP-
binding cassette transporters in Escherichia coli. Biochim. Biophys. Acta - 
Biomembranes 1778:1757-1771. 
71. Higgins, C. F. 1992. ABC Transporters: from microorganisms to man. Annual 
Review of Cell Biology 8:67-113. 
72. Kumar, A. and H. P. Schweizer. 2005. Bacterial resistance to antibiotics: 
Active efflux and reduced uptake. Adv. Drug Deliv. Rev. 57:1486-1513. 
73. Dean, M., A. Rzhetsky, and R. Allikmets. 2001. The human ATP-Binding 
cassette (ABC) transporter superfamily. Genome Res. 11:1156-1166. 
74. VanBambeke, F., J. M. Michot, and P. M. Tulkens. 2003. Antibiotic efflux 
pumps in eukaryotic cells: occurrence and impact on antibiotic cellular 
pharmacokinetics, pharmacodynamics and toxicodynamics. J. Antimicrob. 
Chemother. 51:1067-1077. 
75. Vila, J., S. Marti, and J. Sanchez-Cespedes. 2007. Porins, efflux pumps and 
multidrug resistance in Acinetobacter baumannii. J. Antimicrob. Chemother. 
59:1210-1215. 
76. Poole, K. 2000. Efflux-mediated resistance to fluoroquinolones in gram-
negative bacteria. Antimicrob. Agents Chemother. 44:2233-2241. 
77. Tseng, T.-T., K. S. Gratwick, J. Kollman, D. Park, N. H. Nies, A. Goffeau, 
and M. H. Saier Jr. 1999. The RND permease superfamily, an ancient, 
ubiquitous and diverse family that includes Human disease and development 
proteins. J. Mol. Microbiol. Biotechnol. 1:107-125. 
78. Pagès, J. M., M. Masi, and J. Barbe. 2005. Inhibitors of efflux pumps in 
Gram-negative bacteria. Trends Mol. Med. 11:382-389. 
205 
References 
79. Brown, M. 2009. Multidrug resistance in bacteria. Flinders University. 18-9-
2009. http://www.flinders.edu.au/ 
80. Tuberculosis. 2008. Robert Koch and Tuberculosis. Nobel Prize. 
http://nobelprize.org/ 
81. Todar, K. 2008. Todar's Online texbook of Bacteriology. 
http://textbookofbacteriology.net 
82. World Health Organization. WHO Global InfoBase. World Health 
Organization. 
83. Russell,  D. G. 2001. TB comes to a sticky beginning. Nat. Med. 7:894-895. 
84. World Health Organization. 1997. Anti-Tuberculosis drug resistance in the 
world - The WHO/IUATLD Global project on Anti-tuberculosis drug resistance 
surveillance. WHO.  
85. World Health Organization. 2008. The Global TDR-TB and XDR-TB 
Response Plan 2007-2008. WHO.  
86. Perdigão, J., R. Macedo, I. João, E. Fernandes, L. Brum, and I. Portugal. 
2008. Multidrug-resistant tuberculosis in Lisbon, Portugal: A molecular 
epidemiological perspective. Microb. Drug Res. 14:133-143. 
87. Rossi, E. D., J. A. Ainsa, and G. Riccardi. 2006. Role of mycobacterial efflux 
transporters in drug resistance: an unsolved question. FEMS Microbiol. Rev. 
30:36-52. 
88. Nikaido, H. 2001. Preventing drug access to targets: cell surface permeability 
barriers and active efflux in bacteria. Semin. Cell Dev. Biol. 12:215-223. 
89. Paulensen, I. T. 2008 Transport DB: Genomic comparisons of membrane 
transport systems. Transport DB. http://www.membranetransport.org/. 
90. Escribano, I., J. C. Rodríguez, B. Llorca, E. García-Pachon, M. Ruiz, and 
G. Royo. 2007. Importance of the Efflux Pump Systems in the Resistance of 
Mycobacterium tuberculosis to Fluoroquinolones and Linezolid. Chemotherapy 
53:397-401. 
91. Jiang X, Zhang W, Zhang Y, Gao F, Lu C, Zhang X, and Wang H. 2008. 
Assessment of efflux pump gene expression in a clinical isolate Mycobaterium 
206 
References 
tuberculosis by real time reverse transcription PCR. Microb. Drug Resist. 14:7-
11. 
92. Piddock, L. J. V. 2006. Clinically relevant chromosomally encoded multidrug 
resistance efflux pumps in bacteria. Clin. Microbiol. Rev. 19:382-402. 
93. Arentz, M., and T. R. Hawn. 2007. Tuberculosis infection: Insight from 
immunogenomics. Drug Discov. Today Dis. Mech. 4:231-236. 
94. Vandal, O. H., L. M. Pierini, D. Schnappinger, C. F. Nathan, and S. Ehrt. 
2008. A membrane protein preserves intrabacterial pH in intraphagosomal 
Mycobacterium tuberculosis. Nat. Med. 14:849-854. 
95. Martins, M., M. Viveiros, I. Couto, and L. Amaral. 2009. Targeting human 
macrophages for enhanced killing of intracellular XDR-TB and MDR-TB. Int. J. 
Tuberc. Lung Dis. 13:569-573. 
96. Danaei, G., S. Vander Hoorn, A. D. Lopez, C. J. Murray, and M. Ezzati. 
Causes of cancer in the world: comparative risk assessment of nine behavioural 
and environmental risk factors. The Lancet 366:1784-1793. 
97. Fragoulia, A., X. G. Kondakis, and I. Dimopoulos. 1989. Is natural infection 
with M. tuberculosis protective against cancer? Eur. J. Epidemiol. 5:234-238. 
98. Song, L., W. Yan, T. Zhao, M. Deng, S. Song, J. Zhang, and M. Zhu. 2005. 
Mycobacterium tuberculosis infection and FHIT gene alterations in lung cancer. 
Cancer Lett. 219:155-162. 
99. World Health Organization. 2008. Cancer Home: treatment. WHO. 
100. Volm, M. 1998. Multidrug resistance and its reversal. Anticancer Res. 18:2905-
2917. 
101. Persidis A. 2000. Cancer multidrug resistance. Nature Biotechnology 18:IT18-
IT20. 
102. Filipits, M. 2004. Mechanisms of cancer: multidrug resistance. Drug Discov. 
Today Dis. Mech. 1:229-234. 
103. Kars, M. D., O. D. Iseri, U. Gündüz, A. U. Ural, F. Arpaci, and J. Molnár. 
2006. Development of rational in vitro models for drug resistance in breast 
207 
References 
cancer and modulation of MDR by selected compounds. Anticancer Res. 
26:4559-4568. 
104. Sarkadi, B., L. Homolya, G. Szakacs, and A. Varadi. 2006. Human multidrug 
resistance ABCB and ABCG transporters: participation in a chemoimmunity 
defense system. Physiol. Rev. 86:1179-1236. 
105. Kuo, M. T. 2007. Roles of multidrug resistance genes in breast cancer 
chemoresistance. Adv. Exp. Med. Biol. 608:23-30. 
106. Riordan, J., and V. Ling. 1979. Purification of P-glycoprotein from plasma 
membrane vesicles of Chinese hamster ovary cell mutants with reduced 
colchicine permeability. J. Biol. Chem. 25:12701-12705. 
107. Ferry, D.R. and D. J. Kerr. 1994. Multidrug resistance in cancer. BMJ 
308:148-149. 
108. Endicott, J. A. and V. Ling. 1989. The biochemistry of P-glycoprotein-
mediated multidrug resistance. Annu. Rev. Biochem. 58:137-171. 
109. Tsuruo, T., H. Iida, Y. Kitatani, K. Yokota, S. Tsukagoshi, and Y. Sakrai. 
1984. Effects of quinidine and related compounds on cytotoxicity and cellular 
accumulation of vincristine and adriamycin in drug resistant tumor cells. Cancer 
Res 44:4303-4307. 
110. Miller, T. P., T. M. Grogan, W. S. Dalton, C. M. Spier, R. J. Scheper, and S. 
E. Salmon. 1991. P glycoprotein expression in malignant lymphoma and 
reversal of clinical drug resistance with chemotherapy plus high dose verapamil. 
J. Clin. Oncol. 9:17-24. 
111. Teodori, E., S. Dei, C. Martelli, S. Scapecchi, and F. Gualtieri. 2006. The 
functions and structure of ABC transporters: Implications for the design of new 
inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr. Drug 
Targets 7:893-909. 
112. Hohmann, J., J. Molnár, D. Rédei, F. Evanics, P. Forgo, A. Kálmán, G. 
Argay, and P. Szabó. 2002. Discovery and biological evaluation of a new 
family of potent modulators of multidrug resistance: reversal of multidrug 
208 
References 
resistance of mouse lymphoma cells by new natural jatrophane diterpenoids 
isolated from Euphorbia species. J. Med. Chem. 45:2425-2431. 
113. Lomovskaya, O., M. Warren, A. Lee, J. Galazzo, R. Fronko, M. Lee, J. 
Blais, D. Cho, S. Chamberland, T. Renau, R. Leger, S. Hecker, W. Watkins, 
K. Hoshino, H. Ishida, and V. J. Lee. 2001. Identification and characterization 
of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: 
Novel agents for combination therapy. Antimicrob. Agents Chemother. 45:105-
116. 
114. Molnár, J., N. Gyémánt, M. Tanaka, J. Hohmann, E. Bergmann-Leitner, P. 
Molnár, J. Deli, R. Disiziapetris, and M. J. U. Ferreira. 2006. Inhibition of 
multidrug resistance of cancer cells by natural diterpenes, triterpenes and 
carotenoids. Curr. Pharm. Des. 12:287-311.  
115. Hohmann, J., D. Rédei, P. Forgo, J. Molnár, G. Dombi, and T. Zorig. 2008. 
Jatrophane diterpenoids from Euphorbia mongolica as modulators of the 
multidrug resistance of L5128 mouse lymphoma cells. J. Nat. Prod. 66:976-979.  
116. Madureira, A. M., M. J. U. Ferreira, N. Gyémánt, K. Ugocsai, J. R. 
Ascenso, P. M. Abreu, J. Hohmann, and J. Molnár. 2004. Rearranged 
Jatrophane-type diterpenes from Euphorbia species: evaluation of their effects 
on the reversal of multidrug resistance. Planta Med. 70:45-49. 
117. Amaral, L., M. Martins, M. Viveiros, J. Molnár, and J. E. Kristiansen. 
2008. Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of 
bacterial efflux pumps. Curr. Drug Targets 9:816-819. 
118. Kaatz, G.W., V. V. Moudgal, S. M. Seo, and J. E. Kristiansen. 2003. 
Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in 
Staphylococcus aureus. Antimicrob. Agents Chemother. 47:719-726.  
119. Kristiansen, M., C. Leandro, D. Ordway, M. Martins, M. Viveiros, T. 
Pacheco, J. E. Kristiansen, and L. Amaral. 2003. Phenothiazines alter 
resistance of methicillin-resistant strains of Staphylococcus aureus (MRSA) to 
oxacillin in vitro. Int. J. Antimicrob. Agents 22:250-253. 
120. Schmitz, F-J., A. C. Fluit, M. Lückefahr, B. Engler, B. Hofmann, J. 
Verhoef, H-P. Heinz, U. Hadding, and M. E. Jones. 1998. The effect of 
209 
References 
reserpine, an inhibitor of multidrug efflux pumps, on the in vitro activities of 
ciprofloxacin and moxifloxacin against clinical isolates of Staphylococcus 
aureus. J. Antimicrob. Chemother. 42:807-810. 
121. Zloh, M., and S. Gibbons. 2007. The role of small molecule-small molecule 
interactions in overcoming biological barriers for antibacterial drug action. 
Theor. Chem. Acc. 117:231-238. 
122. McKeegan, K., M. Borges-Walmsley, and A. Walmesley. 2004. Structural 
understanding of efflux-mediated drug resistance: potential routes to efflux 
inhibition. Curr. Opin. Phamacol. 4:479-486. 
123. Zloh, M., and S. Gibbons. 2004. Molecular similarity of MDR inhibitors. Int. J. 
Mol. Sci. 5:37-47. 
124. Lynch, A. 2006. Efflux systems in bacterial pathogens: An opportunity for 
therapeutic intervention? An industry view. Biochem. Pharmacol. 71:949-956. 
125. Liu, C.-I., G. Liu, Y. Song, F. Yin, M. Hensler, W.-Y. Jeng, V. Nizet, A.-J. 
Hang, and E. Oldfield. 2008. A cholesterol biosynthesis inhibitor bolcks 
Staphylococcus aureus virulence. Science 319:1391-1394. 
126. Saha, S., P. B. Savage, and M. Bal. 2008. Enhancement of the efficacy of 
erythromycin in multiple antibiotic-resistant gram-negative bacterial pathogens. 
J. Appl. Microbiol. 105:822-828. 
127. Pelz, A., K. P. Wieland, K. Putzbach, P. Hentschel, K. Albert, and F. Gotz. 
2005. Structure and biosynthesis of staphyloxanthin from Staphylococcus 
aureus. J. Biol. Chem. 280:32493-32498. 
128. Som, A., S. Vemparala, I. Ivanov, and G. N. Tew. 2008. Synthetic mimics of 
antimicrobial peptides. Biopolymers - Peptide Science Section 90:83-93. 
129. Giuliani, A., G. Pirri, A. Bozzi, A. di Giulio, M. Aschi, and A. C. Rinaldi. 
2008. Antimicrobial peptides: Natural templates for synthetic membrane-active 
compounds. Cell. Mol. Life Sci. 65:2450-2460.  
130. Méndez-Samperio, P. 2008. Role of antimicrobial peptides in host defense 
against mycobactrial infections. Peptides. 29:1836-1841.  
210 
References 
131. Wildman, K., D.-K. Lee, and A. Ramamoorthy. 2003. Mechanism of lipid 
bilayer disruption by human antimicrobial peptide, LL-37. Biochemistry 
42:6545-6558. 
132. Wang, Z., and G. Wang. 2009. APD: the antimicrobial peptide database. 
Eppley Institute, UNMC. http://aps.unmc.edu/AP/main.php 
133. Wang, Z., and G. Wang. 2004. APD: the antimicrobial peptide database. 
Nucleic Acids Res. 332:D590-D592. 
134. Heinrich, M., J. Barnes, S. Gibbons, and E. M. Williamson. 2004. 
Fundamentals of pharmacognosy and phytotherapy. Churchill Livingstone. 
Elsevier Science Limited. London. 
135. World Health Organization. 1989. Medicinal Plants in China. WHO Regional 
Office for the Western Pacific, Manila. 
136. World Health Organization. 1998. Medicinal Plants in the South Pacific. 
WHO Regional Office for the Western Pacific, Manila. 
137. Nies, D. H. 2000. African Traditional Medicine - A dictionary of plant use and 
applications. Neuwinger H. D. (ed) Medpharm Scientific Publishers, Stuttgart. 
138. Hemaiswarya, S., A. K. Kruthiventi, and M. Doble. 2008. Synergism between 
natural products and antibiotics against infectious diseases. Phytomedicine 
15:639-652. 
139. Kanokmedhakul, S., K. Kanokmedhakul, T. Prajuabsuk, K. Soytong, P. 
Kongsaeree, and A. Suksamrarn. 2003. A bioactive triterpenoid and vulpinic 
acid derivatives from the mushroom Scleroderma citrinum. Planta Med. 69:568-
571. 
140. Kokubun, T., W. K. P. Shiu, and S. Gibbons. 2007. Inhibitory activities of 
lichen-derived compounds against methicillin- and multidrug-resistant 
Staphylococcus aureus. Planta Med. 73:176-179. 
141. Martini, N. D., D. R. P. Katerere, and J. N. Eloff. 2004. Biological activity of 
five antibacterial flavonoids from Combretum erythrophyllum (Combretaceae). 
J. Ethnopharmacol. 93:207-212. 
211 
References 
142. Martini, N. D., D. R. Katerere, and J. N. Eloff. 2004. Seven flavonoids with 
antibacterial activity isolated from Combretum erythrophyllum. South African 
Journal of Botany 70:310-312. 
143. Katerere, D. R., A. I. Gray, R. J. Nash, and R. D. Waigh. 2003. 
Antimicrobial activity of pentacyclic triterpenes isolated from African 
Combretaceae. Phytochemistry 63:81-88. 
144. Pauli, G. F., R. J. Case, T. Inui, Y. Wang, S. Cho, N. H. Fischer, and S. G. 
Franzblau. 2005. New perspectives on natural products in TB drug research. 
Life Sci. 78:485-494.  
145. Okunade, A. L., M. P. F. Elvin-Lewis, and W. H. Lewis. 2004. Natural 
antimycobacterial metabolites: Current status. Phytochemistry 65:1017-1032. 
146. de Souza, M.V. 2005. Plants and fungal products with activity against 
tuberculosis. Scientific World Journal 5:609-628. 
147. Gibbons, S. 2005. Plants as a source of bacterial resistance modulators and anti-
infective agents. Phytochem. Rev. 4:63-78. 
148. Copp, B. R., and A. N. Pearce. 2007. Natural product growth inhibitors of 
Mycobacterium tuberculosis. Nat. Prod. Rep. 24:278-297. 
149. Copp, B. R. 2003. Antimycobacterial natural products. Nat. Prod. Rep. 20:535-
557. 
150. Lechner, D., S. Gibbons, and F. Bucar. 2008. Modulation of isoniazid 
susceptibility by flavonoids in Mycobacterium. Phytochemistry Letters 1:71-75. 
151. Lechner, D., S. Gibbons, and F. Bucar. 2008. Plant phenolic compounds as 
ethidium bromide efflux inhibitors in Mycobacterium smegmatis. J. Antimicrob. 
Chemother. 62:345-348. 
152. Martins, M., Z. Schelz, A. Martins, J. Molnár, G. Hajös, Z. Riedl, M. 
Viveiros, I. Yalcin, E. Aki-Sener, and L. Amaral. 2007. In vitro and ex vivo 
activity of thioridazine derivatives against Mycobacterium tuberculosis. Int. J. 
Antimicrob. Agents 29:338-340. 
212 
References 
153. Martins, M., M. Viveiros, and L. Amaral. 2008. The TB laboratory of the 
future: macrophage-based selection of XDR-TB therapeutics. Future 
Microbiology 3:135-144. 
154. Martins, M., M. Viveiros, and L. Amaral. 2008. Inhibitors of Ca2+ and K+ 
transport enhance intracellular killing of M. tuberculosis by non-killing 
macrophages. In Vivo 22:69-75. 
155. Anand, P.K., D. Kaul, and M. Sharma. 2006. Green tea polyphenol inhibits 
Mycobacterium tuberculosis survival within human macrophages. Int. J. 
Biochem. Cell Biol. 38:600-609. 
156. Gibbons, S., E. Moser, and G. W. Kaatz. 2004. Catechin gallates inhibit 
multidrug resistance (MDR) in Staphylococcus aureus. Planta Med. 70:1240-
1242. 
157. Kumar, A., I. A. Khan, S. Koul, J. L. Koul, S. C. Taneja, I. Ali, S. Sharma, 
Z. M. Mirza, M. Kumar, P. L. Sangwan, P. Gupta, N. Thota, and G. N. 
Qazi. 2008. Novel structural analogues of piperine as inhibitors of the NorA 
efflux pump of Staphylococcus aureus. J. Antimicrob. Chemother. 61:1270-
1276. 
158. Poisson, J., A. LeHir, R. Goutarel, and M. M. Janot. 1954. Isolation of 
reserpine from roots of Rauwolfia vomitoria Afz. C. R. Hebd. Seances Acad. 
Sci. 238:1607-1609. 
159. Smith, E. C. J., G. W. Kaatz, S. M. Seo, N. Wareham, E. M. Williamson, 
and S. Gibbons. 2007. The phenolic diterpene totarol inhibits multidrug efflux 
pump activity in Staphylococcus aureus. Antimicrob. Agents Chemother. 
51:4480-4483. 
160. Boumendjel, A., A. Di Pietro, C. Dumontet, and D. Barron. 2002. Recent 
advances in the discovery of flavonoids and analogs with high-affinity binding 
to P-glycoprotein responsible for cancer cell multidrug resistance. Med. Res. 
Rev. 22:512-529. 
161. Nabekura, T., T. Yamaki, K. Ueno, and S. Kitagawa. 2008. Inhibition of P-
glycoprotein and multidrug resistance protein 1 by dietary phytochemicals. 
Cancer Chemother. Pharmacol. 62:867-873. 
213 
References 
162. Kovács, A., A. Vasas, and J. Hohmann. 2008. Natural phenanthrenes and their 
biological activity. Phytochemistry 69:1084-1110. 
163. Fouche, G., G. M. Cragg, P. Pillay, and N. Kolesnikova. 2008. In vitro 
anticancer screening of South African plants. J. Ethnopharmacol. 119:455-461. 
164. Frum, Y., and A. M. Viljoen. 2006. In vitro 5-lipoxygenase and anti-oxidant 
activities of South African medicinal plants commonly used topically for skin 
diseases. Skin Pharmacol. Physiol. 19:329-335. 
165. Scherrer, A. M., Motti, R., and Weckerle, C. S. 2005. Traditional plant use in 
the areas of Monte Vesole and Ascea, Cilento National Park (Campania, 
Southern Italy). J. Ethnopharm. 97:129-143. 
166. Scott, G., and M. L. Hewett. 2008. Pioneers in ethnopharmacology: The Dutch 
East India Company (VOC) at the Cape from 1650 to 1800. J. Ethnopharmacol. 
115:339-360. 
167. Springfield, E. P., G. Amabeoku, F. Weitz, W. Mabusela, and Q. Johnson. 
2003. An assessment of two Carpobrotus species extracts as potential 
antimicrobial agents. Phytomedicine 10:434-439. 
168. Springfield, E. P. and F. Weitz. 2006. The scientific merit of Carpobrotus 
mellei L. based on antimicrobial activity and chemical profiling. African J. 
Biotechnol. 5:1289-1293. 
169. Thring, T. S. A., and F. M. Weitz. 2006. Medicinal plant use in the 
Bredasdorp/Elim region of the Southern Overberg in the Western Cape Province 
of South Africa. Journal of Ethnopharmacology 103:261-275. 
170. Watt, E., and J. C. Pretorius. 2001. Purification and identification of active 
antibacterial components in Carpobrotus edulis. J. Ethnopharmacol. 76:87-91. 
171. Mulder, Ch. 2003. Aizoaceae. Review of Palaeobotany and Palynology 123:41-
45. 
172. Underwood, E.C., S. L. Ustin, and C. M. Ramirez. 2007. A comparison of 
spatial and spectral image resolutions for mapping invasive plants in coastal 
California. Environ Manage 39:63-83. 
214 
References 
173. Suehs, C. M., L. Affre, and F. Médail. 2004. Invasion dynamics of two alien 
Carpobrotus (Aizoaceae) taxa on a Mediterranean island: I. Genetic diversity 
and introgression. Heredity 92:31-40. 
174. Mathabe, M. C., R. V. Nikolova, N. Lall, and N. Z. Nyazema. 2006. 
Antibacterial activities of medicinal plants used for treatment of diarrhoea in 
Limpopo Province, South Africa. J. Ethnopharmacol. 105:286-293. 
175. Ordway, D., J. Hohmann, M. Viveiros, A. Viveiros, J. Molnár, C. Leandro, 
M. J. Arroz, M. A. Grácio, and L. Amaral. 2003. Carpobrotus edulis 
methanol extract inhibits the MDR efflux pumps, enhances killing of 
phagocytosed S. aureus and promotes immune modulation. Phytother. Res. 
15:512-519. 
176. Martins, M., D. Ordway, M. Kristiansen, M. Viveiros, C. Leandro, J. 
Molnár, and L. Amaral. 2005. Inhibition of the Carpobrotus edulis methanol 
extract on the growth of phagocytosed multidrug-resistant Mycobacterium 
tuberculosis and methicillin-resistant Staphylococcus aureus. Fitoterapia 76:96-
99. 
177. Sanches, I. S., M. Aires de Sousa, L. Sobral, I. Calheiros, L. Felicio, I. 
Pedra, and H. de Lencastre. 1995. Multidrug-resistant Iberian epidemic clone 
of methicillin-resistant Staphylococcus aureus endemic in a hospital in northern 
Portugal. Microb. Drug Resist. 1:299-306. 
178. Oliveira, D. C., A. Tomasz, and H. de Lencastre. 2001. The evolution of 
pandemic clones of methicillin-resistant Staphylococcus aureus: Identification 
of two ancestral genetic backgrounds and the associated mec elements. Microb. 
Drug Resist. 7:349-361. 
179. Oliveira, D. C. and H. de Lencastre. 2002. Multiplex PCR strategy for rapid 
identification of structural types and variants of the mec element in methicillin-
resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46:2155-2161. 
180. Crisóstomo, M. I., H. Westh, A. Tomasz, M. Chung, D. C. Oliveira, and H. 
de Lencastre. 2001. The evolution of methicillin resistance in Staphylococcus 
aureus: Similarity of genetic backgrounds in historically early methicillin-
215 
References 
susceptible and -resistant isolates and contemporary epidemic clones. Proc. Natl. 
Acad. Sci. USA 98:9865-9870. 
181. Martins, A., I. Couto, L. Aagaard, M. Martins, M. Viveiros, J. E. 
Kristiansen, and Amaral L. 2007. Prolonged exposure of methicillin-resistant 
Staphylococcus aureus (MRSA) COL strain to increasing concentrations of 
oxacillin results in a multidrug-resistant phenotype. Int. J. Antimicrob. Agents 
29:302-305. 
182. Chollet, R., J. Chevalier, A. Bryskier, and J. M. Pagès. 2004. The AcrAB-
TolC pump is involved in macrolide resistance but not in telithromycin efflux in 
Enterobacter aerogenes and Escherichia coli. Antimicrob. Agents Chemother. 
48:3621-3624. 
183. Okusu, H., D. Ma, and H. Nikaido. 1996. AcrAB efflux pump plays a major 
role in the antibiotic resistance phenotype of Escherichia coli multiple-
antibiotic-resistance (Mar) mutants. J. Bacteriol. 178:306-308. 
184. Espinel-Ingroff, A., A. Fothergill, M. Ghannoum, E. Manavathu, L. 
Ostrosky-Zeichner, M. A. Pfaller, M. G. Rinaldi, W. Schell, and T. J. 
Walsh. 2007. Quality control and reference guidelines for CLSI broth 
microdilution method (M38-A Document) for susceptibility testing of 
anidulafungin against molds. J. Clin. Microbiol. 45:2180-2182. 
185. Pfyffer, G. E., D. A. Bonato, A. Ebrahimzadeh, W. Gross, J. Hotaling, J. 
Kornblum, A. Laszlo, G. Roberts, M. Salfinger, F. Wittwer, and S. Siddiqi. 
1999. Multicenter laboratory validation of susceptibility testing of 
Mycobacterium tuberculosis against classical second-line and newer 
antimicrobial drugs by using the radiometric BACTEC 460 technique and the 
proportion method with solid media. J. Clin. Microbiol. 37:3179-3186. 
186. Viveiros, M. and L. Amaral. 2001. Enhancement of antibiotic activity against 
poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int. J. 
Antimicrob. Agents 17:225-228. 
187. Viveiros, M., A. Martins, L. Paixão, L. Rodrigues, M. Martins, I. Couto, E. 
Fähnrich, W. V. Kern, and L. Amaral. 2008. Demonstration of intrinsic efflux 
216 
References 
activity of Escherichia coli K-12 AG100 by an automated ethidium bromide 
method. Int. J. Antimicrob. Agents 31:458-462. 
188. Amaral, L., J.E. Kristiansen, V. Frolund Thomsen, and B. Markovich. 
2000. The effects of chlorpromazine on the outer cell wall of Salmonella 
typhimurium in ensuring resistance to the drug. Int. J. Antimicrob. Agents 
14:225-229. 
189. Clinical and Laboratory Standards Institute. 2007. Performance standards 
for antimicrobial susceptibility testing; seventeenth informational supplement. 
CLSI document 27:M100-S17. 
190. Ordway, D., M. Viveiros, C. Leandro, R. Bettencourtt, J. Almeida, M. 
Martins, J. E. Kristiansen, J. Molnár, and L. Amaral. 2003. Clinical 
concentrations of thioridazine kill intracellular multidrug-resistant 
Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:917-922. 
191. Pastan, I., M. M. Gottesman, K. Ueda, E. Lovelace, A. V. Rutherford, and 
M. C. Willingham. 1988. A retrovirus carrying an MDR1 cDNA confers 
multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. 
Proc. Natl. Acad. Sci. USA. 85:4486-4490. 
192. Choi, K., T. O. Frommel, R. K. Stern, C. F. Perez, M. Kriegler, T. Tsuruo, 
and I. B. Roninson. 1991. Multidrug resistance after retroviral transfer of the 
human MDR1 gene correlates with P-glycoprotein density in the plasma 
membrane and is not affected by cytotoxic selection. Proc. Natl. Acad. Sci. USA 
88:7386-7390. 
193. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: 
Application to proliferation and cytotoxicity assays. J. Immunol. Methods 
65:55-63. 
194. Amaral, L., M. Martins, and M. Viveiros. 2007. Enhanced killing of 
intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that 
affect the activity of efflux pumps. J. Antimicrob. Chemother. 59:1237-1246. 
195. Amaral, L., H. Engi, M. Viveiros, and J. Molnár. 2007. Comparison of 
multidrug resistant efflux pumps of cancer and bacterial cells with respect to the 
same inhibitory agents. In Vivo 21:237-244. 
217 
References 
196. Liu, X. and T. Ferenci. 1998. Regulation of porin-mediated outer membrane 
permeability by nutrient limitation in Escherichia coli. J. Bacteriol. 180:3917-
3922. 
197. Harder, K. J., H. Nikaido, and M. Matsuhashi. 1981. Mutants of Escherichia 
coli that are resistant to certain beta-lactam compounds lack the ompF porin. 
Antimicrob. Agents Chemother. 20:549-552. 
198. Charrel, R. N., J. M. Pagès, P. de Micco, and M. Mallea. 1996. Prevalence of 
outer membrane porin alteration in beta-lactam-antibiotic- resistant Enterobacter 
aerogenes. Antimicrob. Agents Chemother. 40:2854-2858. 
199. Mallea, M., J. Chevalier, C. Bornet, A. Eyraud, A. vin-Regli, C. Bollet, and 
J. M. Pagès. 1998. Porin alteration and active efflux: two in vivo drug resistance 
strategies used by Enterobacter aerogenes. Microbiology 144:3003-3009. 
200. Falagas, M. E., P. K. Koletsi, and I. A. Bliziotis. 2006. The diversity of 
definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) 
Acinetobacter baumannii and Pseudomonas aeruginosa. J. Med. Microbiol. 
55:1619-1629. 
201. Ritz, M., M. Freulet, N. Orange, and M. Federighi. 2000. Effects of high 
hydrostatic pressure on membrane proteins of Salmonella typhimurium. Int. J. 
Food Microbiol. 55:115-119. 
202. O'Regan, E., T. Quinn, J. M. Pagès, M. McCusker, L. Piddock, and S. 
Fanning. 2009. Multiple regulatory pathways associated with high-level 
ciprofloxacin and multidrug resistance in Salmonella enterica serovar 
Enteritidis: Involvement of ramA and other global regulators. Antimicrob. 
Agents Chemother. 53:1080-1087. 
203. Pagès, J. M. Personal communication. 2008. 
204. Foulaki, K., W. Gruber, and S. Schlecht. 1989. Isolation and immunological 
characterization of a 55-kilodalton surface protein from Salmonella 
typhimurium. Infect. Immun. 57:1399-1404. 
205. Viveiros, M., I. Portugal, R. Bettencourt, T. C. Victor, A. M. Jordaan, C. 
Leandro, D. Ordway, and L. Amaral. 2002. Isoniazid-induced transient high-
218 
References 
level resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 
46:2804-2810. 
206. Martins, A., G. Spengler, L. Rodrigues, M. Viveiros, J. Ramos, M. Martins, 
I. Couto, S. Fanning, J. M. Pagès, J. M. Bolla, J. Molnár, and L. Amaral. 
2009. pH modulation of efflux pump activity of multi-drug resistant Escherichia 
coli: protection during its passage and eventual colonization of the colon. PLoS 
ONE 4:e6656. 
207. Martins, M., B. Santos, A. Martins, M. Viveiros, I. Couto, A. Cruz, J. M. 
Pagès, J. Molnár, S. Fanning, and L. Amaral. 2006. An instrument-free 
method for the demonstration of efflux pump activity of bacteria. In Vivo 
20:657-664. 
208. Schumacher, A., R. Trittler, J. A. Bohnert, K. Kummerer, J. M. Pagès, and 
W. V. Kern. 2007. Intracellular accumulation of linezolid in Escherichia coli, 
Citrobacter freundii and Enterobacter aerogenes: role of enhanced efflux pump 
activity and inactivation. J. Antimicrob. Chemother. 59:1261-1264. 
209. Borges-Walmsley, M. I., K. S. McKeegan, and A. R. Walmsley. 2003. 
Structure and function of efflux pumps that confer resistance to drugs. Biochem. 
J. 376:313-338. 
210. German, N., P. Wei, G. W. Kaatz, and R. J. Kerns. 2008. Synthesis and 
evaluation of fluoroquinolone derivatives as substrate-based inhibitors of 
bacterial efflux pumps. Eur. J. Med. Chem. 43:2453-2463. 
211. Elkins, C. A. and H. Nikaido. 2003. 3D structure of AcrB: the archetypal 
multidrug efflux transporter of Escherichia coli likely captures substrates from 
periplasm. Drug Resist. Updat. 6:9-13. 
212. Nikaido, H. 1996. Multidrug efflux pumps of gram-negative bacteria. J. 
Bacteriol. 178:5853-5859. 
213. Thanassi, D. G., L. W. Cheng, and H. Nikaido. 1997. Active efflux of bile 
salts by Escherichia coli. J. Bacteriol. 179:2512-2518. 
214. Rees, D. C., E. Johnson, and O. Lewinson. 2009. ABC transporters: the power 
to change. Nat. Rev. Mol. Cell Biol. 10:218-227. 
219 
References 
215. Lomovskaya, O., H. I. Zgurskaya, M. Totrov, and W. J. Watkins. 2007. 
Waltzing transporters and 'the dance macabre' between humans and bacteria. 
Nat. Rev. Drug Discov. 6:56-65. 
216. Su, C. C., M. Li, R. Gu, Y. Takatsuka, G. McDermott, H. Nikaido, and E. 
W. Yu. 2006. Conformation of the AcrB multidrug efflux pump in mutants of 
the putative proton relay pathway. J. Bacteriol. 188:7290-7296. 
217. Thota, N., S. Koul, M. V. Reddy, P. L. Sangwan, I. A. Khan, A. Kumar, A. 
F. Raja, S. S. Andotra, and G. N. Qazi. 2008. Citral derived amides as potent 
bacterial NorA efflux pump inhibitors. Bioorg. Med. Chem. 16:6535-6543. 
218. Rodrigues, L., D. Wagner, M. Viveiros, D. Sampaio, I. Couto, M. Vavra, W. 
V. Kern, and L. Amaral. 2008. Thioridazine and chlorpromazine inhibition of 
ethidium bromide efflux in Mycobacterium avium and Mycobacterium 
smegmatis. J. Antimicrob. Chemother. 61:1076-1082. 
219. Naseem, R., K. T. Wann, I. B. Holland, and A. K. Campbell. 2009. ATP 
regulates calcium efflux and growth in E. coli. J. Mol. Biol. 391:42-56. 
220. Norris, V., S. Grant, P. Freestone, J. Canvin, F. N. Sheikh, I. Toth, M. 
Trinei, K. Modha, and R. I. Norman. 1996. Calcium signalling in bacteria. J. 
Bacteriol. 178:3677-3682. 
221. de Souza, L. M., T. R. Cipriani, M. Iacomini, P. A. J. Gorin, and G. L. 
Sassaki. 2008. HPLC/ESI-MS and NMR analysis of flavonoids and tannins in 
bioactive extract from leaves of Maytenus ilicifolia. J. Pharm. Biomed. Anal. 
47:59-67. 
222. Bilia, A.R., I. Morelli, M. Hamburger, and K. Hostettmann. 1996. Flavans 
and A-type proanthocyanidins from Prunus prostata. Phytochemistry 43:887-
892. 
223. Agerbirk, N., C. E. Olsen, B. M. Bibby, H. O. Frandsen, L. D. Brown, J. K. 
Nielsen, and J. A. Renwick. 2003. A saponin correlated with variable 
resistance of Barbarea vulgaris to the diamondback moth Plutella xylostella. 
Journal of Chemical Ecology 29:1417-1433. 
220 
References 
224. Chung, M.-I., M.-H. Lai, M.-H. Yen, R.-R. Wu, and C.-N. Lin. 1997. 
Phenolics from Hypericum geminiflorum. Phytochemistry 44:943-947. 
225. Cui, C.B., Y. Tezuka, T. Kikuchi, H. Nakano, T. Tamaoki, and J. H. Park. 
1992. Constituents of a fern, Davallia mariesii Moore. II. Identification and 1H- 
and 13C-nuclear magnetic resonance spectra of procyanidin B-5, epicatechin-
(4β-8)-epicatechin-(4β-6)-epicatechin, and epicatechin-(4β-6)—epicatechin-(4β-
8)-epicatechin-(4β-6)-epicatechin. Chem. Pharm. Bull. (Tokyo) 40:889-898. 
226. Kushiro, T., M. Shibuya, and Y. Ebizuka. 1998. Beta-amyrin synthase--
cloning of oxidosqualene cyclase that catalyzes the formation of the most 
popular triterpene among higher plants. Eur. J. Biochem. 256:238-244. 
227. Mahato, S. B. and A. P. Kundu. 1994. 13C NMR spectra of pentacyclic 
triterpenoids – A compilation and some salient features. Phytochemistry 
37:1517-1575. 
228. Sakano, Y., M. Mutsuga, R. Tanaka, H. Suganuma, T. Inakuma, M. 
Toyoda, Y. Goda, M. Shibuya, and Y. Ebizuka. 2005. Inhibition of human 
lanosteri synthase by the constituents of Colocasia esculenta (Taro). Biol. 
Pharm. Bull. 28:299-304 
229. Siddiqui, S., T. Mahmood, B. S. Siddiqui, and S. Faizi. 2004. Two new 
tetranortriterpenoids from Azadirachta indica. J. Nat. Prod. 49:1068-1073. 
230. Hussain, Z., L. Stoakes, V. Massey, D. Diagre, V. Fitzgerald, S. El Sayed, 
and R. Lannigan. 2000. Correlation of oxacillin MIC with mecA gene carriage 
in coagulase-negative Staphylococci. J. Clin. Microbiol. 38:752-754. 
231. Severin, A., K. Tabei, F. Tenover, M. Chung, N. Clarke, and A. Tomasz. 
2004. High level oxacillin and vancomycin resistance and altered cell wall 
composition in Staphylococcus aureus carrying the Staphylococcal mecA and 
the Enterococcal vanA gene complex. J. Biol. Chem. 279:3398-3407. 
232. Adhikari, R. P., G. C. Scales, K. Kobayashi, J. M. B. Smith, B. Berger-
Bachi, and G. M. Cook. 2004. Vancomycin-induced deletion of the methicillin 
resistance gene mecA in Staphylococcus aureus. J. Antimicrob. Chemother. 
54:360-363. 
221 
References 
233. Martins, M., M. Viveiros, J. Ramos, I. Couto, J. Molnár, M. Boeree, and L. 
Amaral. 2009. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances 
the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB). Int. 
J. Antimicrob. Agents 33:479-482. 
234. Spengler, G., M. Viveiros, M. Martins, L. Rodrigues, A. Martins, J. Molnár, 
I. Couto, and L. Amaral. 2009. Demonstration of the activity of P-glycoprotein 
by a semi-automated fluorometric method. Anticancer Res. 29:2173-2177. 
235. Amaral, L., and V. Lorian. 1991. Effects of chlorpromazine on the cell 
envelope proteins of Escherichia coli. Antimicrob. Agents Chemother. 35:1923-
1924.  
236. Lounatmaa, K., P. H. Makela, and M. Sarvas. 1976. Effect of polymyxin on 
the ultrastructure of the outer membrane of wild-type and polymyxin-resistant 
strain of Salmonella. J. Bacteriol. 127:1400-1407. 
237. Moreno Switt, A. I., Y. Soyer, L. D. Warnick, and M. Wiedmann. 2009. 
Emergence, distribution, and molecular and phenotypic characteristics of 
Salmonella enterica Serotype 4,5,12:i. Foodborne Pathog. Dis. 6:407-415. 
238. Little, C. L. and I. A. Gillespie. 2008. Prepared salads and public health. J. 
Appl. Microbiol. 105:1729-1743. 
239. Ricke, S. C., M. M. Kundinger, D. R. Miller, and J. T. Keeton. 2005. 
Alternatives to antibiotics: chemical and physical antimicrobial interventions 
and foodborne pathogen response. Poult. Sci. 84:667-675. 
240. Cheftel, J. C. 1995. Review: High-pressure, microbial inactivation and food 
preservation / Revision: Alta-presion, inactivacion microbiologica y 
conservacion de alimentos. Food Science and Technology International 1:75-90. 
241. Dastidar, S. G., A. Chaudhury, S. Annadurai, S. Roy, M. Mookerjee, and A. 
N. Chakrabarty. 1995. In vitro and in vivo antimicrobial action of 
fluphenazine. J. Chemother. 7:201-206. 
242. Mazumder R, Chaudhuri SR, and Mazumder A. 2002. Antimicrobial 
potentiality of a phenothiazine group of antipsychotic drug-prochlorperazine. 
Indian J. Exp. Biol. 40:828-830. 
222 
References 
243. Purdy, G. E., M. Niederweis, and D. G. Russell. 2009. Decreased outer 
membrane permeability protects mycobacteria from killing by ubiquitin-derived 
peptides. Mol. Microbiol. 73:844-857. 
244. Ramon-Garcia, S., C. Martin, C. J. Thompson, and J. A. Ainsa. 2009. Role 
of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, 
oxidative stress responses, and growth. Antimicrob. Agents Chemother. 
53:3675-3682. 
245. Guina, T., E. C. Yi, H. Wang, M. Hackett, and S. I. Miller. 2000. A PhoP-
regulated outer membrane protease of Salmonella enterica serovar 
Typhimurium promotes resistance to alpha-helical antimicrobial peptides. J. 
Bacteriol. 182:4077-4086. 
246. Nicasio, A. M., J. L. Kuti, and D. P. Nicolau. 2008. The current state of 
multidrug-resistant gram-negative bacilli in Norht America. Pharmacotherapy 
28:235-249. 
247. Brazas, M.D., and R.E. Hancock. 2005. Using microarray gene signatures to 
elucidate mechanisms of antibiotic action and resistance. Drug Discov. Today 
10:1245-1252. 
248. Poole, K. 2007. Efflux pumps as antimicrobial resistance mechanisms. Ann. 
Med. 39:162-176.  
249. Vila, J. and J. L. Martinez. 2008. Clinical impact of the over-expression of 
efflux pump in nonfermentative Gram-Negative bacilli, development of efflux 
pump inhibitors. Curr. Drug Targets 9:797-807.  
250. Sobral, R. G., A. M. Ludovice, S. Gardete, K. Tabei, H. de Lencastre, and 
A. Tomasz. 2003. Normally functioning murF is essential for the optimal 
expression of methicillin resistance in Staphylococcus aureus. Microb. Drug 
Resist. 9:231-241. 
251. Chopra, I., A. J. O'Neill, and K. Miller. 2003. The role of mutators in the 
emergence of antibiotic-resistant bacteria. Drug Resist. Updat. 6:137-145. 
223 
References 
252. Marcusson, L. L., N. Frimodt-Moller, and D. Hughes. 2009. Interplay in the 
selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog 
5:e1000541. 
253. Hillemann, D., S. Rusch-Gerdes, and E. Richter. 2008. In vitro-selected 
linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob. Agents 
Chemother. 52:800-801. 
254. Fais, S., A. de Milito, H. You, and W. Qin. 2007. Targeting vacuolar H+-
ATPases as a new strategy against cancer. Cancer Res. 67:10627-10630. 
255. Versantvoort, C. H. M., H. J. Broxterman, H. M. Pinedo, E. G. E. de Vries, 
N. Feller, C. M. Kuiper, and J. Lankelma. 1992. Energy-dependent processes 
involved in reduced drug accumulation in multidrug-resistant human lung cancer 
cell lines without P-Glycoprotein expression. Cancer Res. 52:17-23. 
256. Davies, J. and G. D. Wright. 1997. Bacterial resistance to aminoglycoside 
antibiotics. Trends Microbiol. 5:234-240. 
257. Saier Jr., M. H. 1977. Bacterial Phosphoenolpyruvate: sugar 
phosphotransferase systems: structural, functional and evolutionary 
interrelationships. Bacteriol. Rev. 41:856-871. 
258. Pereira, M. B. P., R. Tisi, L. G. Fietto, A.  Cardoso, M. M. França, F. M. 
Carvalho, M. J. Trópia, E. Martegani, I. M. Castro, and R. L. Brandão. 
2008. Carbonyl cyanide m-chlorophenylhydrazone induced calcium signaling 
and activation of plasma membrane H+-ATPase in the yeast Saccharomyces 
cerevisiae. FEMS Yeast Res. 8:622-630. 
259. Krulwich, T. A., M. Ito, R. Gilmour, M. G. Sturr, A. A. Guffanti, and D. B. 
Hicks. 1996. Energetic problems of extremely alkaliphilic aerobes. Biochim. 
Biophys. Acta - Bioenergetics 1275:21-26. 
260. Guffanti, A. A., M. Mann, T. L. Sherman, and T. A. Krulwich. 1984. 
Patterns of electrochemical proton gradient formation by membrane vesicles 
from an obligately acidophilic bacterium. J. Bacteriol. 159:448-452. 
224 
References 
261. Lewinson, O., J. Adler, N. Sigal, and E. Bibi. 2006. Promiscuity in multidrug 
recognition and transport: the bacterial MFS Mdr transporters. Molecular 
Microbiology 61:277-284. 
262. Rosenberg, E. Y., D. Bertenthal, M. L. Nilles, K. P. Bertrand, and H. 
Nikaido. 2003. Bile salts and fatty acids induce the expression of Escherichia 
coli AcrAB multidrug efflux pump through their interaction with Rob regulatory 
protein. Mol. Microbiol. 48:1609-1619. 
263. Lin, J., C. Cagliero, B. Guo, Y. W. Barton, M. C. Maurel, S. Payot, and Q. 
Zhang. 2005. Bile salts modulate expression of the CmeABC multidrug efflux 
pump in Campylobacter jejuni. J. Bacteriol. 187:7417-7424. 
264. Pos, K. M. 2009. Drug transport mechanism of the AcrB efflux pump. Biochim. 
Biophys. Acta 1794:782-793. 
265. Huet, A. A., J. L. Raygada, K. Mendiratta, S. M. Seo, and G. W. Kaatz. 
2008. Multidrug efflux pump overexpression in Staphylococcus aureus after 
single and multiple in vitro exposures to biocides and dyes. Microbiology 
154:3144-3153. 
266. Perez, J. C. and E. A. Groisman. 2007. Acid pH activation of the PmrA/PmrB 
two component regulatory system of Salmonella enterica. Mol. Microbiol. 
63:283-293. 
267. Spengler, G., and L. Amaral. 2009. Effect of TZ on growth curves of 
Salmonella strains. Personal communication. 
268. Tucker, D. L., N. Tucker, and T. Conway. 2002. Gene expression profiling of 
the pH response in Escherichia coli. J. Bacteriol. 184:6551-6558. 
269. Seeger, M. A., K. Diederichs, T. Eicher, L. Brandstatter, A. Schiefner, F. 
Verrey, and K. M. Pos. 2008. The AcrB efflux pump: conformational cycling 
and peristalsis lead to multidrug resistance. Curr. Drug Targets 9:729-749. 
270. Ponte-Sucre, A. 2007. Availability and applications of ATP-binding cassette 
(ABC) transporter blockers. Appl. Microbiol. Biotechnol. 76:279-286. 
225 
References 
271. Feniouk, B. A., T. Suzuki, and M. Yoshida. 2006. The role of subunit epsilon 
in the catalysis and regulation of F0F1-ATP synthase. Biochim. Biophys. Acta - 
Bioenergetics 1757:326-338. 
272. Davidson, A. L. and J. Chen. 2004. ATP-binding cassette transporters in 
bacteria. Annu. Rev. Biochem. 73:241-268. 
273. Altendorf, K., W. Stalz, J. Greie, and G. Deckers-Hebestreit. 2000. Structure 
and function of the F(o) complex of the ATP synthase from Escherichia coli. J 
Exp Biol 203:19-28. 
274. Mitchell, P. 1966. Chemiosmotic coupling in oxidative and photosynthetic 
phosphorylation. Physiol. Rev. 41:445-502.  
275. Hayes, E., J. Wilks, P. Sanfilippo, E. Yohannes, D. Tate, B. Jones, M. 
Radmacher, S. BonDurant, and J. Slonczewski. 2006. Oxygen limitation 
modulates pH regulation of catabolism and hydrogenases, multidrug 
transporters, and envelope composition in Escherichia coli K-12. BMC 
Microbiol. 6:89.  
276. Leonard, G. D., T. Fojo, and S. E. Bates. 2003. The role of ABC transporters 
in clinical practice. Oncologist 8:411-424. 
277. Lee, E. W., M. N. Huda, T. Kuroda, T. Mizushima, and T. Tsuchiya. 2003. 
EfrAB, an ABC multidrug efflux pump in Enterococcus faecalis. Antimicrob. 
Agents Chemother. 47:3733-3738. 
278. Lee, E. W., J. Chen, M. Huda, T. Kuroda, T. Mizushima, and T. Tsuchiya. 
2003. Functional cloning and expression of emeA, and characterization of 
EmeA, a multidrug efflux pump from Enterococcus faecalis. Biol. Pharm. Bull. 
26:266-270. 
279. Simon, J., R. J. M. van Spanning, and D. J. Richardson. 2008. The 
organisation of proton motive and non-proton motive redox loops in prokaryotic 
respiratory systems. Biochim. Biophys. Acta - Bioenergetics 1777:1480-1490. 
280. Blair, J.M.A., and L.J.V. Piddock. 2009. Structure, function and inhibition of 
RND efflux pumps in Gram-negative bacteria: an update. Curr. Opin. Microbiol. 
12:1-8. 
226 
References 
281. Pietras, Z., V. N. Bavro, N. Furnham, M. Pellegrini-Calace, E. J. Milner-
White, and B. F. Luisi. 2008. Structure and mechanism of drug efflux 
machinery in Gram-negative bacteria. Curr. Drug Targets 9:719-728. 
282. Sperandeo, P., F. K. Lau, A. Carpentieri, C. De Castro, A. Molinaro, G. 
Deho, T. J. Silhavy, and A. Polissi. 2008. Functional analysis of the protein 
machinery required for transport of lipopolysaccharide to the outer membrane of 
Escherichia coli. J. Bacteriol. 190:4460-4469. 
283. Sperandeo, P., G. Deho, and A. Polissi. 2009. The lipopolysaccharide transport 
system of Gram-negative bacteria. Biochem. Biophys. Acta 1791:594-602. 
284. Maity, P., K. Biswas, I. Chattopadhyay, R. K. Banerjee, and U. 
Bandyopadhyay. 2009. The use of neem for controlling gastric hyperacidity 
and ulcer. Phytother. Res. 23:747-755. 
285. Korish, A. A. and M. M. Arafah. 2008. Catechin combined with vitamins C 
and E ameliorates insulin resistance (IR) and atherosclerotic changes in aged rats 
with chronic renal failure (CRF). Arch. Gerontol. Geriatr. 46:25-39. 
286. Kawai, Y., H. Tanaka, K. Murota, M. Naito, and J. Terao. 2008. (-)-
Epicatechin gallate accumulates in foamy macrophages in human atherosclerotic 
aorta: Implication in the anti-atherosclerotic actions of tea catechins. Biochem. 
Biophys. Res. Commun. 374:527-532. 
287. Howells, L. M., E. P. Moiseeva, C. P. Neal, B. E. Foreman, C. K. Andreadi, 
Y. Y. Sun, E. A. Hudson, and M. M. Manson. 2007. Predicting the 
physiological relevance of in vitro cancer preventive activities of 
phytochemicals. Acta Pharmacol. Sin. 28:1274-1304. 
288. Zessner, H., L. Pan, F. Will, K. Klimo, J. Knauft, R. Niewöhner, W. 
Hümmer, R. Owen, E. Richling, N. Frank, P. Schreier, H. Becker, and C. 
Gerhauser. 2008. Fractionation of polyphenol-enriched apple juice extracts to 
identify constituents with cancer chemopreventive potential. Mol. Nutr. Food 
Res. 52:S28-S44. 
289. Souccar, C., R. M. Cysneiros, M. M. Tanae, L. M. B. Torres, M. T. R. 
Lima-Landman, and A. J. Lapa. 2008. Inhibition of gastric acid secretion by a 
227 
References 
standardized aqueous extract of Cecropia glaziovii sneth and underlying 
mechanism. Phytomedicine 15:462-469. 
290. Kitagawa, S., T. Nabekura, and S. Kamiyama. 2004. Inhibition of P-
glycoprotein function by tea catechins in KB-C2 cells. J. Pharm. Pharmacol. 
56:1001-1005. 
291. He, S., G. Sun, and D. Pan. 2008. Red wine polyphenols for cancer prevention. 
Int. J. Mol. Sci. 9:842-853. 
292. Cowan, M. M. 1999. Plant products as antimicrobial agents. Clin. Microbiol. 
Rev. 12:564-582. 
293. Kuete, V., R. Metuno, B. Ngameni, A. T. Mbaveng, F. Ngandeu, M. 
Bezabih, F. X. Etoa, B. T. Ngadjui, B. M. Abegaz, and V. P. Beng. 2008. 
Antimicrobial activity of the methanolic extracts and compounds from Treculia 
africana and Treculia acuminata (Moraceae). South African Journal of Botany 
74:111-115. 
294. Woldemichael, G. M., S. G. Franzblau, F. Zhang, Y. Wang, and B. N. 
Timmermann. 2003. Inhibitory effect of sterols from Ruprechtia triflora and 
diterpenes from Calceolaria pinnifolia on the growth of Mycobacterium 
tuberculosis. Planta Med. 69:628-631. 
295. Gu, J. Q., Y. Wang, S. G. Franzblau, G. Montenegro, D. Yang, and B. N. 
Timmermann. 2004. Antitubercular constituents of Valeriana laxiflora. Planta 
Med. 70:509-514. 
296. Woldemichael, G. M., G. Wachter, M. P. Singh, W. M. Maiese, and B. N. 
Timmermann. 2003. Antibacterial diterpenes from Calceolaria pinifolia. J. 
Nat. Prod. 66:242-246. 
297. Jimenez-Arellanes, A., M. Meckes, J. Torres, and J. Luna-Herrera. 2007. 
Antimycobacterial triterpenoids from Lantana hispida (Verbenaceae). J. 
Ethnopharmacol. 111:202-205. 
298. Farina, C., M. Pinza, and G. Pifferi. 1998. Synthesis and anti-ulcer activity of 
new derivatives of glycyrrhetic, oleanolic and ursolic acids. Farmaco. 53:22-32. 
228 
References 
229 
299. Juan, M. E., J. M. Planas, V. Ruiz-Gutierrez, H. Daniel, and U. Wenzel. 
2008. Antiproliferative and apoptosis-inducing effects of maslinic and oleanolic 
acids, two pentacyclic triterpenes from olives, on HT-29 colon cancer cells. Br. 
J. Nutr. 100:36-43. 
300. Liu, J. 1995. Pharmacology of oleanolic acid and ursolic acid. J. 
Ethnopharmacol. 49:57-68. 
301. Bruno, A., C. Rossi, G. Marcolongo, A. Di Lena, A. Venzo, C. P. Berrie, and 
D. Corda. 2005. Selective in vivo anti-inflammatory action of the galactolipid 
monogalactosyldiacylglycerol. Eur. J. Pharmacol. 524:159-168. 
 
